Enhancement of Bioavailability and Determination of Some Fluoroquinolones Antibiotics; Application to U A E Market by Sultan Al-Zaabie, Moza Rashed
United Arab Emirates University
Scholarworks@UAEU
Theses Electronic Theses and Dissertations
5-2002
Enhancement of Bioavailability and Determination
of Some Fluoroquinolones Antibiotics; Application
to U A E Market
Moza Rashed Sultan Al-Zaabie
Follow this and additional works at: https://scholarworks.uaeu.ac.ae/all_theses
Part of the Environmental Sciences Commons
This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at Scholarworks@UAEU. It has been accepted for
inclusion in Theses by an authorized administrator of Scholarworks@UAEU. For more information, please contact fadl.musa@uaeu.ac.ae.
Recommended Citation
Sultan Al-Zaabie, Moza Rashed, "Enhancement of Bioavailability and Determination of Some Fluoroquinolones Antibiotics;
Application to U A E Market" (2002). Theses. 430.
https://scholarworks.uaeu.ac.ae/all_theses/430

��========================================d,� 
I! 
United Arab Emirates University 
Deanship of Graduate Studies 
M. Sc. Program 
In 
Environmental Sciences 
Enhancement of Bioavailability and 
Determination of Some Fluoroquinolones 
Antibiotics; Application to UAE Market 
A Thesis 
Submitted in partial fulfillment for the requirements of the 
Degree of Master of Science in Environmental Science 
By 
Moza Rashed Sultan AI-Zaabie 
B. Sc. (Chemistry) 
Faculty of Science, U.A.E. University (1997) 
May - 2002 
Ii 
. II '1 Ii 
T h e  T h esis of Moza Rash ed S u l ta n  for the Degree of Master of Science in 
E n viro n m e n ta l  is approved. 
E xa m i n i n g  Com m i ttee Mem be r, D r. Ibra h i m  Saad S h e h a tta 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Gd·l.E······································· 
E xa m i n i n g  Com mittee Mem be r, Dr. Hazem A. Hassa n 
E x a m i n i n g  Com m i ttee Mem ber, D r. Saleh A. AI-Suwayeh 
Un ited A ra b  E m i ra tes Univers i ty 
200112002 
United A rab Emirates University 
Dean hip of G raduate Studies 
M. Sc. Program in Environmental Science 
Title Enhancement of Bioavailability and Determination of Some 
Fluoroquinolones Antibiotics; Application to UAE Market 
Name : Moza Rashed Sultan AI-Zaabie 
Supervisors 
Name Position 
Director of Central 
Laboratories Unit, and 
Dr. Ibrahim S. Shehatta Associate Professor of 
Physical Chemistry, 
Department of Chemistry, 
Faculty of Science, 
UAE University. 
Associate Professor of 
Dr. Mohammed S. Ibrahim Analytical Chemistry, 
Department of Chemistry, 
Faculty of Science, 
UAE University. 
Signature 
TABLE OF CONTENTS 
T ABEL OF CONTENTS 
ACKNOW LE DG M ENT . . . . . .. .. .. . . . . . . . . . . . . . . . ... . . . . . . . .. . . . . . .. . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .  i 
ABSTRACT . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i- i i i  
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i 
LI T OF FIG URES . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .. . . . . . . . . . .  ii - vi i 
CHAPTER I: INTR ODUCTION 
1 . 1 .  Overv iew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 
1 .2. Determination of Q uinolones Compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 
1 .3. Cyclodextrins and Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
1 .4. DNA and Drug Interactions . . . . . . . . . . . . . . . . ... . . .. . . . .. . .. . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .  2 1  
1 .5. Aim of the work ... . . . . . . . . . . . . . . .. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........ . 29 
CHAPTER I I: EX PERIMENT AL M ET HODS 
2.1. Chemicals and Reagents ........ . ................... . ....... . . . ....... ..................................... . .  30 
2.2. Instrum entation ..... ... . . .. .. ... ... . ..... ... ... . ....... ....... . . ... .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 
2.3. Optimiza tion of the Experimental and Instru mental Parameters . .. . .. . .. . . . .. . . . . .  35  
2.4. Solubility Measurements . .......... . ... ... . .. . . .. . . . . ... . .... . . .. . . . . . . . . . . . . . . . . . . . . .. . . . . . ... . . . . . .. . . . . . .  38  
2.5. Spectrophotometric Measu rements . . . ..... . ..... . . . . . . . . . . . . . . . . . . . . . ... ... . . . . . . . . . . . . . . . .... . . ... . 39 
CHAPTER I II: DET ERM INAT ION OF NAL ID IX I C  ACID AND ITS 
I NT ERACT ION W IT H  DNA AND CYCL ODEXT RINS 
3.1. Cyclic Voltammetric Behavior of Adsorbed NAL . .... . . . . . . . . .. . . . . . . . . . . . . . . . . . ...... . . . . . .  .40 
3.2. Differential Pulse Stripping Voltammetry (D PSV) of NAL .. . . . . . . . . . ...... . . . .. . . . ... . .40 
3.2. 1 .  Dependence of (DPSV) peak ofNAL on pH . . . . . . . . . . . . .. ... . . . . . . . . . . . ... .. . . . . . . . . . . . . . . . . . . . .  .40 
3.2.2. Effect of anions of the supporting electrolytes on the DPSV peak of NAL . . . . . .  .4 1  
3.2.3. Effect of operational parameters on the DPSV peak ofNAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .4 1  
( i) Effect of scan rate on the DPSV peak ofNAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .4 1  
( i i )  Effect of pre con cent arion potentials on the DPSV peak ofNAL . . . . . . . . . . . . . .  .42 
( i i i) Effect of pre concentration time on the DPSV peak ofNAL. . . . . . . . . . . . . . . . . . . . . . .  . 42 
(iv) Effect of pulse amplitude and other instrumental parameters on the 
DPSV peak ofNAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42 
3.2.4. Quantitative trace determination ofNAL in the model samples . . . . . . . . . . . . . . . . . . . . . . . . . .42 
3.2.5. Interference study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43 
3.3. Analytical Application . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .43 
3.3. 1 .  Analysis of pharmaceutical samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .43 
3.3.2. NAL determination in urine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .44 
3.3.3. NAL determination in serum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44 
3.4. Voltammetric Studies of the Interaction of N AL with DNA . . . . . . . . . . . . . . . . . . . . . . . . . . .  .45 
3.5. Binding of the N AL with Cyclodextri ns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46 
3.5 . 1 .  Solubility studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46 
3.5 .2. Spectroscopic studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .47 
3.5 .3. Voltammetric studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48 
(i) Cyclic voltammetry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .48 
(li) Differential pulse stripping voltammetry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50 
3. 5 .4. Binding mode and mechanism of the inclusion complex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 1  
CHAPTER IV: DETERM I NATION OF NORFLOXACIN AND ITS 
INTERACTION W ITH DNA AND CY CLODEXTRINS. 
4.1. Differential Pulse Stripping Voltam metry (DPSV) of NOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  84 
4 . 1 . 1 .  Dependence of (DP V) peak of NOR on pH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  84 
4 . 1 .2. Effect of anions of the supporting electrolytes on the DPSV peak of NOR . . . . . . . .  84 
4 .1.3 .  Effect of operational parameters on the DPSV peak ofNOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 
(i) Effect of scan rate on the DPSV peak ofNOR . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  85 
(ii) Effect of pre con cent arion potentials on the DPSV peak of NOR . . . . . . . . . . . . . 85 
(iii) Effect of pre concentration time on the DPSV peak ofNOR . . . . . . . . . . . . . . . . . . . . . .. . 85 
(iv) Effect of pulse amplitude and other instrumental parameters on the 
DPSV peak of NOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .  86 
4 .1 .4 .  Quantitative trace determination of NOR in the model samples . . . . . . . . .. . . . . . . . . . . . . ... . 86 
4 . 1 .5 .  Interference study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  86 
4. 1 .6. Quantitative determination of NOR in formulation sample . . . . . . . . . . . . . . . . . . . ... . .. . . . . . . . .  86 
4.2. VoItammetric Studies of the Interaction of NO R with DNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  87 
4.3. Voltammetric Studies of the Interaction of NO R with Cyclodextrins . . . . . . . . .  88 
4.4. Solubi lity Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  89 
CHA PTER V: DET ERM INAT IO N O F  CIPRO FLOXA C IN AND ITS 
INT E RACT ION W ITH D NA AND CYCLODEXT RINS 
5. 1 .  Cyclic Voltammetric Behavior of Adsorbed CIP . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .  1 14 
5.2. Differential Pulse Stripping Voltammetry (D PSV) of CIP . .. .. . . . . . . . . . .... . . . . . . . .... . 1 14 
5.2.1. Dependence of (DPSV) peak of CIP on pH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 1 1 4  
5 .2.2. Effect of anions of the supporting electrolytes on the DPSV peak of CIP . . . . . . . . .  115 
5 .2 .3 .  Effect of operational parameters on the DPSV peak of CIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 115 
(i) Effect of scan rate on the DPSV peak of CIP . . . . . . . .. . . . . . . . . . . . ... . .. . . . . . ... . . . . .. . . . . . .  115 
(ii) Effect of preconcentarion potentials on the DPSV peak of CIP . . . . . . . . . . . . . . 1 1 5 
( iii) Effect of preconcentration time on the DPSV peak of CIP . . . . . . . . . . . . . . . . . . . . . . . .  1 1 5 
(iv) Effect of pulse amplitude and other instrumental parameters 
on th DP V peak of CIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 6 
5 .2.4. Quantitative trace determination of CIP in the model samples . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 6 
5.2.5. Interference tudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 6 
5 .2.6. Quantitative determination ofCIP in pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 7 
5.3. Voltammetric Studies of the Interaction of CIP with DNA . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 7 
5.4. Voltamm etric Studies of the Interaction of CIP with 
cyclodextrins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1 8 
CHAPTER VI: CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 42 
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 44 
APPENDIX 
ARAB I C  SUMM ARY 
A bbreviations 
CV : Cyclic Voltammetry 
HMDE : H anging Mercury Drop Electrode 
M : Molar concentration (mollL) 
DP V : Differential PuJ e tripping Voltammetry 
NAL : Nalidixic acid 
NOR : Norfloxacin 
CIP : Ciprofloxacin 
CD : Cyclodextrin 
DNA : Deoxyribonucleic acid 
BR : Britton- Robinson buffer 
ACKNOWLEDGEMENT 
Acknowledgement 
Thi stud is the result of dedicated effort of many individuals, several of whom 
des rve pecial mention: I thank Prof. Dr. Abdul Rahman S. AI-Sharhan, Dean of the 
Faculty of Science, UAE University, for offering the chance to join the Environmental 
cience Master Program. I greatly appreciate my supervisors Dr. Ibrahim S. Shehatta and 
Dr. Mohammed S. Ibrahim, Chemistry Department, Faculty of Science, UAE University 
for their suggestion, continuous guidance supervision and patient through out the study, 
and their effort in the completion of this study. I thank my colleagues in Chemistry labs, 
Faculty of Science, UAE University for their valuable cooperation. 
I thank my family especially my husband for his understanding, support, and 
encouragement. 
Finally, I extend my thanks to everyone who gave me the help and advice during 
the preparation of this work. 
Moza R. S. A lzaa bie 
ABSTRACT 
A bstract 
Chapter 1 of this thesis includes the importance of fl uroq uinolone as one of the 
mo t inlpressive antibacterial drugs. Also, a compl ete picture about the selective 
molecules named cy clodextrins (CDs) is drawn. Such molecules are able to form 
inclusion complexes with a wide variety of lipophilic drugs. That is why CDs act as 
drug carriers through an aq ueous media to the lipophilic cell membrane and delivers 
them to cell. Which results in enhancing the bioavailability of drug with low aq ueous 
solubility. M oreover, an explanation of the DNA/drug interactions is proposed. These 
are extremely useful in understand.ing the DNA seq uence recognition by drugs as well 
as by proteins. Finally, the objective of the present work is incl uded. 
Chapter 2 explains in detail the experimental part. It includes the chemicals and 
the material s used, the methods of preparation of the various solutions such as DNA 
cycl odextrins, drugs, buffers and metal salt. Also, the instruments used such as 
voltamm etric and spectrophotometric techniq ues were incl uded. The general procedures 
for all the measurements were described in detail. 
T he resul ts and discussion are presented in chapters 3, 4 and 5. In chapter 3 the 
quantitative determination of nalidix ic acid in pharmaceutica l samples, human urine and 
serum are described. The quinolone antibacterial agent nalidixic acid (NAL) was studied 
by cyclic voltammetry (CV) and differential pulse stripping voltammetry (DPSV). A 
sensitive method is described for the determination of NAL in its pure form, dosage 
forms and biological fluids. Control led adsorptive accumulation ofNAL on a hanging 
mercury drop electrode provides the basis for the direct stripping m easurement of that 
drug in the nanomolar concentration level. Different variables were studied and 
optimized. T he proposed method depends upon the voltammetric activity ofNAL in 
Britton-Robinson buffer, whereby a well -defined cathodic peak is produced at pH 5 .0 in 
presence of N03-. T he cal ibration graph to determine NAL was l inear in the range 2.9 
xlO-8 to 2.5 xlO-5 M by DPSV with detection l im it (sln=3 ) of 0.766 ng mI-1 (3.3xlO-9 M). 
The relative standard deviation (n=5) was 5.2% at concentration level of I.Ox! 0-7 M 
NAL. T he degree of interference from coexisting m etal ions on the DPSV signal for 
NAL was evaluated. The method was applied to two different commercia l 
pharmaceutica l products (Negram tablets and suspension) with very good recoveries. It 
was a lso shown that the method was successfully applied to the determination ofNAL in 
human llrme and blood serum. Mean recoveries were 98 .8±O.3% and 98 .9±O.41 %, 
respective I . Also, the inclusion of the antibacterial drug, nalidixic acid (NAL), in a-, 
and j3-cyclodextrins (CDs) cavities is studied using UV -Vis absorption and the 
voltammetric methods. It was corroborated that the UV absorption bands ofNAL are 
intensified in the presence of a- and j3-CDs. Also, a pronounced decrease in the peak 
currents of NAL was noticed upon the addition of a-, and j3-CDs. From the changes in 
the peak currents, it was concluded that NAL form 1: 1 inclusion complex with the 
various hosts, which is revealed from the phase solubility profile ofNAL-j3-CD system, 
a a representative example. Furthermore, from voltammetric data, the logarithm of the 
binding constants were calculated to be 2.60 and 3.20 for a-, and j3-CDs, respectively. 
The magnitude of the formation constants as well as the Gibbs free energies, for NAL 
with a-, and j3-CDs shows a trend that NAL is bound more strongly to j3-CD, with more 
apolar cavity than a-CD. These observations suggest that the hydrophobic interaction is 
the most important recognition element in the binding process. With the purpose of 
characterizing the inclusion complex ofNAL with CD, aU orientations of entering NAL 
into the cavity are proposed. Combining the experimental results and molecular 
modeling and energy calculations on the inclusion complexes yield a more detailed 
picture of the solution structure of the complex formed between NAL and either a-CD or 
I3-CD. It was inferred that the inclusion process can occur through 2-methyl-pyridine 
side. Also, an additional hydrogen bond was found to be formed between the carboxyl 
group of NAL, that remain outside the I3-CD cavity, and the secondary hydroxyl group of 
I3-CD. Therefore, this hydrogen bond should be operating as an important second 
recognition element in case of NAL-I3-CD system. Furthermore, the interaction on NAL 
with D NA was investigated by cyclic voltammetry and differential pulse stripping 
voltamrnetry. It was found that the stoichiometry of the NAL-DNA is 1 : 1  and the 
binding constant was calculated to be 1 .84 x 1 05 M-1, revealing the strong binding 
affinity ofNAL to DNA. 
In chapter 4 the determination of norfloxacin (NOR) and its interaction with 
DNA and CDs are reported. The dependence of differential pulse stripping peak of NOR 
on different variables are studied in order to choose the optimum conditions for the 
analytical determinations by D PSV at HMDE. Under the optimum coditions (phosphate 
buffer, pH = 1 1  in presence of CI04-, 1 00 mV pulse amplitude, 20 mVs-J scan rate, 30 s 
accumulation time and -0.6 V accumulation potential) the NOR can be accurately 
ii 
determined over the range from 1 .47 xlO-7 M to 2.3 xlO� M NOR. The detction limit, the 
percentage relative error and percentage relative standard deviation are 5 x 1 0-9 M, 3. 1 % 
and 4.2%, re pectively. According to this proposed method the NOR in Noroxin tablets 
was uccefully determined with excellent spike recovery (close to 1 00%) and high 
preci ion (% R D � 3.5).  
Finally, in chapter 5 the determination of ciprofloxacin (CIP) and its interaction 
with DNA and CDs are reported and discussed. The optimum conditions for the 
voltammetric determination of CIP were evaluated from comprehensive study on the 
factors affecting the electrochemical behavior of CIP such as pH, anions of the 
supporting electrolyes scan rate, adsorption potential, pulse amplitude and adsorption 
time. Thus, quantitative trace determination of CIP in model samples as well  as in 
pharmaceutical formulations was succesfully done using the following optimum 
conditions: phosphate buffer (PH = 7) in presence ofN03-, 1 00 mV pulse amplitude, 20 
mVs-1 scan rate, 60 s accumulation time and -0.4 V accumulation potential. Under these 
conditions the CIP concentration is linear over the range 1 .5 x 1 0-8 M - 1 .2 x l  0-7 M CIP 
with regresion coefficient equal 0.996. The detection limit, percent relative error and 
%RSD are 6 x 1 0-9 M, 3. 1 %  and 4.2%, respectively. Also, the proposed method was 
succesful ly applied for the determination of CIP in Bactiflox-250 tablets with high 
accurately and precesion (average recovery 1 05% and % RSD = 3.2%). Moreover, the 
interaction of elP with both DNA and CDs are studied. It was inferred that the binding 
complex of CIP molecule with either DNA or CD was 1 :  1 association complex. The 
binding constant for these complexes were calculated and indicated that the CIP 
mo lecule has a high affinity for DNA. 
iii 
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CHAPTER I 
Introduction 
INTRODUCTION 
1 . 1 .  Overview 
The Quinolones are one of the most important bactericidal drugs that are used 
extensi ely for treatment of a broad range of clinical infections. Quinolones are 
carbox lic acids that contain a quinolone ring. Because they are effective in treatment of 
infections, de eloping new quinolones came by the introduction of a fluorine atom at the 
C-6 position on the parent nuclei which became known as fluoroquinolones (De sarro et 
ai., 1 999). Fluoroquinolones have impressive antibacterial activity and good 
pharmacological properties with fewer adverse effects than the older quinolones and they 
are well absorbed orally, with bioavailability of usually greater than 70%. 
Fluoroquinolone contain protonated nitro gens therefore they can exist as zwitterions. So 
their activities depend on the pH of the solution. Quinolones work involves two phases. In 
the first phase the quinolone is inhibiting bacterial DNA gyrase, this enzyme is an 
essential bacterial enzyme that needed for DNA replication (Nelson, 1 988). DNA gyrase 
is the basic drug target and is more sensitive in gram-negative bacteria, while in the 
second phase they interact with topoisomerase IV which is more sensitive in gram­
positive bacteria. Therefore, the more sensitive enzyme will become the primary drug 
target for a given organism. In addition, the dual quinolone targets play an important role 
in development of resistance so that if the primary target enzyme is resisting the 
mutations, the second target enzyme can become the more sensitive enzyme (Hooper, 
1 999). For that, fluoroquinolones are used to treat a wide variety of infections such as 
infections of bone, joints, skin and respiratory tract. Also, they have great useful effect in 
treating urinary tract infections caused by multiple resistant pathogens, prostatitis, 
gastrointestinal pathogens, osteomylitis, gram-negative pneumonia, sexually transmitted 
diseases and zoonotic bacteria transmitted to humans via the food chain (Nelson, 1 988). 
Cyclodextrins are series of oligosaccharides produced by the degradation and 
cyclisation of starch by an enzyme produced by bacillus rnacerans (Marques, 1 994). 
They consist of six to twelve (a-l,4) linked D-glucose units so they are have doughnut 
shaped. Therefore, it has a cavity and the size of the central cavity increases as the 
number of glucose units increases. 
a - c y c l o d e x t rl n  t3 - c y c l o d e x t r l n  'Y - c y c l o d e x t r l n  
Fig. 1 . 1 :  tructures o f  cyc lodextrins 
The most corrunon cyclodextrins are composed of six, seven and e ight glucose units with 
approximate ly 0 .6, 0 .8  and 1 .0 nm in diameter which became knwon as u, � and y­
cyclodextrins, respect ive ly ( Fig. 1 . 1 ) ( Lindoy, 1 990). The yield of producing 
c c lodextrins is in the rank order � > u > y-cyc lodextrins, which is reflected in their 
relat ive prices (Jones et a/. ,  1 984). Because they have doughnut shapes, this results in a 
variety of interest ing features of cyc lodextrins, the cavit ies of  cyc lodextrin are sl ight ly V 
shaped in which the secondary hydroxyl groups on the C-2 and C-3 atoms are located on 
the more open side and they can not rotate. Whi le the primary hydroxyl groups on the C-6 
are located on the opposite side (the narrower) and they have abi l ity to rotate as to 
partia l ly b lock the cavity and reduce the effective d iameter of the cavity. The secondary 
hydroxyl groups are hydrogen bonded with the secondary hydroxy l  groups of the 
contiguous g lucose units. This intramo lecular hydrogen bonding is so strong as a result to 
the l imited rotation of g lucose units in these cycl ic molecules ( Bender and Komiyama, 
1 978). The effect of this intramolecular hydrogen bond is c lear in �-cyclodextrins where a 
complete secondary be lt is formed by these hydrogen bonds. Therefore, �-cyclodextrin is 
a rather rigid structure. Which is responsible for the lowest solubi l ity of�-cyclodextrin 
than a l l  others cyclodextrins. The hydroxyl groups on C-2, C-3 and C-6 are avai lable as 
points of structural modification without danger of e liminating the central void. The 
hydroxy I groups on C-6 are the most reactive than the others. On the other hand the 
interior of the tours consists only ofa  ring o f C-H in which the H-3 and H-5 atoms are 
directed toward the interior of the cavity but H- l ,  H-2 and H -4 atoms are located on the 
exterior of the cavity (Marques, 1 994) .  So the cavity is l ined by the hydrogen atoms and 
the glycosidic oxygen bridges. The nonbonding e lectron pairs of  the g lycosidic oxygen 
bridges are directed toward the inside of the cavity producing a high e lectron density and 
lending it some Lewis-base character. As a result of  this arrangement of the functional 
2 
group , the cavity i re latively hydrophobic compared to water while the external face 
are hydrophi l ic (Li and Purdy, 1992). Thi amphipathic property give cyc10dextrin 
abI l ity to form oluble and reversible inclu ion complexes with water- in oluble 
compound . Thi can lead to the alterat ion of physical , chemical and biological properties 
of the e compounds (Marques, 1 994). This remarkable abi l ity of cyclodextrins to form 
incIu Ion complexe with great variety of molecule especial ly with organic molecule In 
b lh  olut ion and cry lal l i ne tate is one of the most important characteristIcs of 
cycl dextrI n (Bender and Komiyama, 1978) .  These complexe exhibit  a I :  I 
toichlOmetry i n  many cases with association constants (K) which are moderate ly  high 
( 1 02_ 1 04 M- I ) (Lindoy, 1990). The binding forces invol ved in  the complexation are: (Li 
and Purdy, 1992 ;  Jones et al., 1984). 
1 .  an der waals in teraction between the hydrophobic moiety of the 
gue t molecules and the cyc10dextrin cavity. 
2. Hydrogen bonding between the polar functional groups of guest molecules and the 
hydroxyl groups of cycIodextrin .  
3 .  Release of h igh  energy water molecules from the cavi ty in  the complex formation 
process.  
4. Release of strain energy i n  the ring frame system of the cyclodextrin .  
5. The abi l i ty of the guest molecule of suitable shape and size t o  be physical ly 
accommodated in  the cyclodextrin cavity. 
The stabi l ity of  an inclusion complex depends on many factors and these are: (Li and 
Purdy 1992). 
1. The polarity of the guest molecules, the highly hydrophil ic molecule complex is  very 
weak or not at a l l  famed. 
2 .  The nature of  the medium used for complexation, the complexation is very weak in  an 
organic solvent.  
3. The temperature ,  the stabi l i ty of inclusion complex decreases with increas ing 
temperature . 
Cyclodextrins and their derivatives are widely used i n  drugs ei ther for complexation, 
di l luents, or tablet ingredients to improve the physical and chemical properties of drug 
(Szejtli, 1998). These many uses result from their captivating properties, some of these 
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propert ie are Ii ted i n  the fol lowing: (Bender et ai., 1 978; Uekama et ai. ,  1 998; Szejt l i ,  
1 99 1 ; Marques, 1 994) 
I .  The a a i labi l ity of cylodextrin of different internal cav ity lze for each 
cyclodextrin Ca,  P and y), which re ult  in  di fferent degree of inclusion complex 
formation.  
2 .  Low toxici ty and low pharmacological act iv ity, because they are metabol ized and 
ab orbed in the same way as starch and final ly excreted as CO2 and H20. Howe er, 
a l l  tox icity test have hown that oral ly admin i  tered cyclodextrins are harmless . 
3 .  Cyclodextrin have wel l -defined chemical structure and they have many start ing 
points for structural modifications, and various functional group can be introduced 
to alter the phy ical , chemical propert ies and inc lusion abi l i ty of the original 
cyclodextrin molecule.  
4 .  Cyclodextrins have the abi l i ty to protect the included o r  conjugated drugs from 
biodegradat ion .  So there are many efforts to use cyclodextrins for reducing the loss 
in enzyme act iv i ty caused by storage , freeze-drying, heat ing and oxidizing or 
dehydrating  agents .  
5 .  Cyclodextrins  i ncrease the solubi l i ty o f  a drug with low aqueous solubi l i ty. 
6 .  Final l y  us ing of cyclodextrin is cheaper and s impler than most other methods of 
encapsulat ion .  
I t  i s  expected that with increasing production, broadening research,  and decreasing 
prices of cyclodextrins ,  the appl ication of them and their derivatives wi l l  rapidly increase 
in a wide variety of i ndustries. S uch as food industries that use cyclodextrin for 
stabil ization of  flavors, fragrances, e l iminat ion of undesired tastes, microbiological 
contamination and other undesired components.  Also, they are used i n  chemical i ndustry 
as catalysts to i mprove the selectivity of reaction, separation and purification of 
i ndustrial-scale products (Li and Purdy, 1992). 
M uch attention was paid in  the l ast decades to the binding of smal l molecules with 
deoxyribonucleic acid (DNA). DNA binding studies are important for the rational design 
and construction of new and more efficient drugs targeted to DNA (Waring and 
Roberts, 1 977). A variety of smal l molecules interact revers ib ly with double-stranded 
DNA, primari l y  through three modes: 
1. Electrostatic interactions with the negative-charged nucleic sugar-phosphate, which 
are along the external DNA double hel ix  and do not possess selectivity. 
2. Binding i nteractions with two grooves of DNA double hel i x .  
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· Intercalation between the tacked base pair of nat ive DNA. 
Heterocycl i c  dye , uch a ethidium, anthracycline , phenothiazine and acridine 
dcri at ive in teract through intercalation with the planar, aromatic group stacked between 
ba e pai r . The interactions of DNA with nucleic-acid-binding molecules have been 
exten I vely tudied over the pa t year using variou techniques, inc luding peclroscoPlc 
and X-ra crystal lograph ic methods. In the recent year , electrochemical investIgat ion of 
nucleic-acid-b inding molecules and DNA interactions (Chu et ai., 1998; Ibrahim, 200 1 ;  
Shehatta and Ibrahim, 200 1 )  can provide a useful complement to the previously used 
method of investigation such as spectroscopic methods. e .g .  for nonabsorbing spec ies, 
and yield i n format ion about the mechanism of intercalat ion and the conformat ion of 
adduct . 
D A gyrase i s  the bacterial enzyme that e sential for cel l  surv ival which 
upercoi l DNA. I t  i s  a member of the topoisomerases, a group of enzymes that play a 
cruc ial role i n  control topological interconversions necessary for DNA repl ication, 
transcription , recombination, repair and chromosome partit ioning during cel l  d ivision 
(Shen et al., 1989).  These cellular functions require conformational and topological 
changes of the DNA structure such as rel axation, supercoi l ing,  knott ing/ unknotting and 
catenation! decatenation (Kwok et ai., 1 999). Topoisomerases are able to catalyze DNA 
relaxation, that is, to remove supercoi l s  from DNA; gyrase is unique i n  that i t  is  the only 
enzyme able to catalyze the introduction of negative supercoi ls .  This reaction is  ATP­
dependent and is thought to be the principle function of gyrase i n  t he bacterial cel l  
(Heddle e t  al., 2000) . 
DNA gyrase i s  the target of a number of therapeutical ly  useful antibacterial agents 
such as qu inolone drugs . In which the act ivity of quinolone is correlated with their  abi l ity 
to inh ibit  DNA gyrase. B ecause quinolone groups are leaned to reduction in  many 
biological systems that leads to redox cycl ing wi th oxygen .  So,  in  many cases this leads 
to the formation of oxygen free radicals and the corresponding drug somiquinolone. Both 
of these products cause damage in DNA leading to cel l death (Thomas et al., 1 990). 
On the other hand there is  a new viewpoint about the action of quinolones which 
concluded that the potency of quinolones not only come from their abi l i ty to inhibit DNA 
gyrase but also from their abi l ity to bind to DNA itself (Yeo et at., 2000) .  
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1 .2. Determination of Quinolones compounds 
The polarographic and voltammetric behav ior of otloxacin wa studied (Zhou 
and Pan, 1 995) by variou electrochemical method . A well -defined l i near-sweep 
voltammetric peak was obtained at - 1 . 343V (vs. saturated calomel e lectrode) in Britton­
Robin on buffer (pH 4 .00) . The characteristic of the peak has been examined in  detai l .  
The e peri mental resu l t  prove that the reduction o f  otloxac in  i i rrevers ible and that the 
pea"- ha. ad orpt ion characteristics. A mechan ism is proposed for the reduction of the 
ample . The peak current (ip) i proport ional to the concentrat ion over the range 8 x 1 0'4 _ 
2 1 0's m01lL and the l imit of detection is 4 x 1 0-6 molfL.  A single-sweep 
o c i l lopolargraphic method was developed for the determination of otloxacin in  
pharmaceutical formulation . The mean recovery of otloxac in  was 1 0 1 .0% with a relat ive 
tandard dev iation of 2 .2%.  
The in teraction of biological ly act ive metal ions: CoCIl), CrOll), FeCill), MnCIl)  
and Cu(m wi th  nortloxac in  (NOR) has been studied (Nanda et al. ) 1 999) using cycl ic 
voltammetric technique, i n  the potent ial range + 1 . 5 to - 1 .0 V with DMF and NaCI04 as 
support ing medium and platinum as working electrode . The voltammetric pattern shows 
characteristic peaks wi th  NOR, however, the peaks of the free metal ions are infl uenced 
by the presence of NOR indicating complexation with the metal ions.  The results show 
that NOR forms complexes with metal ions (M-NOR) in 1 :2 ratio. The values of stabi l ity 
constant (Kc) and thermodynamic parameters �Go, �Ir and �So for complex formation 
are evaluated. These findings reveal the possible use of various metal ions for analytical 
and chemotherapeutic i nvestigation with NOR. 
In 0.05 molfL N1-4Cl solution, a sensitive reduction wave of norfloxacin is  
obtained eLi et ai., 1 996) by s ingle-sweep osci l lopolarography. The peak potential is -
1 .44 V (vs. SCE). The peak height is proportional to the concentration of norfloxacin over 
the range of 1 .0 x 1 0-7_ 4 .0 X 1 0-6 molfL. The detection l imi t  is 5 .0  x 1 0.8 molfL. The 
method has been appl ied to the determination of norfloxacin .  The adsorptive 
characteristics of the system has been studied by means of l i near sweep and cyc l ic 
vol tammetry, NPP, etc . .  The electrode reduction process is i rreversible with adsorptive 
characteristics. 
The voltammetric behavior of Ni(ll) complex of three 3-quinolone antibacterials, 
namely:  norfloxacin (NOR), ciprofloxacin (CIP) and sparfloxacin (SFX) was studied 
(Rizk et ai., 2000) using direct current (DCt) differential pulse (DPP) and al ternating 
current polarography (ACt). The different experimental parameters affect ing the cathodic 
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wave were carefu l ly  invest igated, then a imple and sensit ive method for the analysis of 
the e compound wa deve loped.  The proposed method depend upon the polarographic 
acti V i ty of Ni ( II )-4-quinolone complexes in Britton-Robinson buffer over the pH range 
(4.0- .0) .  \ el l -defined cathodic wave wa created at pH 6.0, 5 . 5  and 6.5 for NOR, CIP 
and F , re pecti  ely.  The wave were characterized as being irreversible ,  di ffu ion­
contro l led wi th  l im i ted ad orption properties . The current-concentration re lationsh ip was 
found to be l i near over the range 2 .0 - 6.4 X 1 0-5 M ,  0 .8  - 3 .2  x 1 0-5 M,  for NOR 2 .0 - 6.4 
1 0-5 M, O.  - 5 . 6  1 0-5 M for CIP and 2 .0 - 7 .2  X 1 0-5 M ,  0 .8  - 4.8 x 1 0-5 M for SFX 
u ing DCI and DPP modes, respect ively, with minimum detectabil i ty (SIN = 2)  of about 2 
1 0-7 M for al l t he studied compound . The method described was succes ful ly appl ied 
to the determination of NOR,  CIP and S FX in bulk and tablet formulat ions. The average 
% recoverie for the studied compounds were 99.58 ± 0.72 to 1 00.50 ± 0.79 and 99 .50 ± 
0_7 1 to 1 00. 1 7  ± 0.29 u ing DCI and DPP, respectively. 
A i mple and rapid method for the determinat ion of the ant ib iotic ciprofloxacin by 
d ifferential pulse polarography (DPP) has been developed (O'Dea et aI., 1 990) . The 
changes in the vol tammetrk behavior of this drug compound with pH was studied, and 
the most sui table pH for analytical purposes was found to be pH 8 . 5 .  The DPP behavior 
of this compound at this pH exhibi ted two reduct ion waves at - 1 .44 and - 1 . 64 V. The 
former wave could be used to determine ciprofloxacin between 5 x 1 0-7 and 3 x 1 0-6 M .  
The method was appl ied t o  the determination o f  ciprofloxacin i n  formulated tablets with a 
relat ive standard deviation of less than 0.4%. 
O 'Dea et at., 199 1, compared hanging mercury drop e lectrode (HMDEs) and 
carbon paste e lectrodes (CPEs)  for the determination by adsorptive stripping voltammetry 
(AdSV) of the antibiotic c iprofloxacin in urine. The antibiotic compound could be 
preconcentrated at both e lectrode surfaces, with carbon paste electrodes yielding a better 
performance. These electrodes could be used to determine between 6 x 1 0-7 and 4 x 1 0-6 
M c iprofloxacin in urine. A c leanup procedure (with 8 1  % recovery), u t i l izing a CI S Sep 
Pak cartridge, was required to separate ciproflxacin from the biological matrix prior to 
adsorptive stripping analysis .  The method was appl ied to the determination of 
ciprofloxacin  in spiked urine samples with a relat ive standard deviat ion of 4 . 1 %. 
The quinolone antibacterial agent cinoxacin was studied (Gratteri et at., 1995) by 
adsorptive stripping voltammetry making use of i ts control led interfacial accumulation on 
a static mercury drop electrode. Measurements were obtained in differential pulse mode 
and optimized by experimental design . The chemometric approach al lowed the 
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ident I ficat ion of a strong interaction between pH and pulse ampl i tude. The dynamic l inear 
range of calibrat ion was extended from 0.4 to 9 x 1 0'8 M .  Analyse of cinoxacin capsule 
and pi ked human urine ample were carried out wi thout the need of previous extraction 
or fi l trat ion .  cleanup procedure wa required to eparate c i noxacin from the human 
pIa rna matrix prior to adsorptive tripping analy i . 
DI rect current polarography and cyclic vol tammetry were u ed (Maigorzata et 
al. , 1 995) to tudy quinolone ant ibiotic ciprofloxac in ,  enoxac in ,  norfloxac in ,  ofloxacin 
and perflo ac in on a mercury and carbon electrode. The dependence of l imit ing currents 
and half-wave potential on the pH of the solution, mercury head, temperature, ionic 
trength of the solution, methyl cel lulo e concentrat ion,  scan rate and quinolone 
concentrat ion was tudied. The optimal parameters and background solutions have been 
cho en . It was concluded that on mercury electrode quinolone are reduced in two one­
electron \ a e and the proces of the reduction is accompan ied by an acid-base 
equi l ibrium. An anodic peak observed on graphite electrode i probably caused by the 
ox idation of piperazine ring in the molecule. 
The f1uoroquinolone antibacterial agent  ofloxacin was studied (Tamer, 1 990) by 
adsorpt ive stripping vol tammetry. Control led interfecial accumulation of ofloxaicn on a 
tatic mercury drop electrode in the hanging mercury drop mode provides high 
sensit ivi ty .  The l inear concentration range was 0.079 - 1 97 .5 �g mr l when using a 60 s 
preconcentration at - 1 .00 V vs. AgI AgCl in  Britton-Robinson buffer of pH 6.00. The 
detection l imit  of ofloxacin was 1 .00 ng mr! . The precision is excel lent wi th a relat ive 
standard deviation of ca. 0.75% at a concentration of 0.848 � g  mr l . 
Cycl ic voltammetric investigations have been performed (Jaber and Lounici, 
1994) which showed that norfloxacin exhibits an adsorptive process at the HMDE surface 
in  various base e lectrolytes of pH < 9 but not in  strongly acidic media. The combination 
of the adsorptive behavior and differential-pulse stripping operation had led to a peak 
current enhancement and consequently to a lower l imi t  of detect ion for norfloxacin .  The 
AdSV peak currents showed various l inear segments wi th concentration within ranges 
extending from 0 .32  ng L· I to > 900 �g L' I with a leve l l ing-off region between ng L' I and 
� g  L' I concentration levels .  The standard addition method can be used successful ly for 
the determination of ultratraces of norfloxacin in  the commercial norfloxac in  tablets 
without interference from the drug matrix .  
Aqueous solution of c iprofloxacin and i ts metal complexes with Mg, Cu,  B i  and 
Fe were investigated (Kmetec et al., 1999) with the aim to characterize their retention 
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and permeabi l ity properties with consequent complex stabi l ity evaluation. For this 
purpo e HPLC c upled with UV detector for ciprofloxacin and with atomic absorption 
spectrometer for metal ions detection was used. Determinat ion of l ipid barrier 
permeabi l ity wa carried out u ing a artorius absorption apparatus with the lipid-type of 
membrane. Under the app lied experinlental cond it ions, no significant differences in 
retent ion and permeabi l ity properties were found, indicating the low stabil ity of studied 
ciproflo acin complexes in aqueous soutions. 
A method for the determinat ion of trace amounts of ciprofloxacin has been 
developed (Naval6n et aL, 2000), based on so lid-phase spectrofluorimetry. The relative 
fluorescence intensity of ciprofloxac in fixed on Sephadex SP C-25 gel was measured 
direct ly after packing the gel beads in a I -mm si l ica cel l, using a solid-phase attachment. 
The wavelengths of exc itation and emission were 272 and 448 nm, respectively. Using a 
sample o lume of 1 000 ml, the l inear concentration range of appl icat ion was 0.3 - 1 0 .0 ng 
mr l  of c ipro floxacin, with a R.S .D. of 1 .2% (for a level of 4.0 ng ml- I )  and a detection 
l imit of 0. 1 ng ml- I .  The method was appl ied for the determination of ciprofloxacin in 
human urine and serum samples. It was validated applying the standard addition 
methodology and using HPLC as a reference method. Recovery level of the method 
reached 1 00% in al l  cases_ 
A spectrofluorimetric method to determine levofloxacin is proposed (Gonzalez et 
aL, 2000) and applied for the determination of the substance in tablets and spiked human 
urine and serum The fluorinletric method allows the determination of 20-3000 ng mrl of 
levofloxacin in aqueous solution containing acetic acid-sodium acetate buffer (PH 4) with 
Aexc = 292 and "-em = 494 nm., respect ively. M icel le enhanced fluorescence improves the 
sensibi l ity and a l lows levofloxacin d irect measurement in spiked Human serum (5 J.l.g ml­
I) and urine (420 J.l.g rnI- I ), in 8 mM sodium dodecyl sulphate solut ion at pH 5 .  
Spectrophotometric and spectrofluorimetric methods for the determination of two 
broad-spectrum fluoroquino lone ant ibacterials (ciprofloxacin and norfloxacin), e ither in 
pure form or in tablets are described (EI Walily et al. , 1 996). Both methods are based on 
the formulat ion of a ternary complex between palladium ( I I) ,  eosin and the 
fluoroquino lone in the presence of methyl cel lulose, as surfactant. Spectrophotometrically, 
under the optimum condit ions, the ternary complexes showed an absorption maximum at 
545 nm., with apparent molar absorptivities of 3 .4 and 2.7 x 1 04 1 mor l  cm- I  and 
Sandel l 's  sensit ivit ies of 1 .0 1  x 1 0-2 and 1 . 1 2  x 1 0-2 J.l.g cm-2 for ciprofloxacin and 
norfloxacin, respectively. The solution of the ternary complex obeyed Beer's law in the 
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concentration range 3- 1 0  I1 g ml - I for both quinolones. The proposed method wa appl ied 
for the determination of the two drug in  pharmaceutical tablet . A fluore cence 
quenching method for the determination of both quinolone by forming thi ternary 
comple wa al o i n e t igated for the purpo e of enhancing the en i t iv i ty of the 
determmation . The re ult obtained by the appl ication of both procedure and the USP 
X X I I I  method were In  good agreement and stat ist ical compari on by mean of Studen t ' s  
{-test and the variance relation F-test howed no  ignificant di fferences between the three 
method . 
A equential i njection spectrophotometric method for toichiometric studie , 
opt imizat ion and quanti tat ive determinat ion of c iprofioxacin and norfloxacin was 
developed by (Su l iman and S ultan, 1 996). The work is based on the complexation 
reaction of c iprofloxacin and norfloxacin with i ron(III) in sul furic acid media and a 
pectrophotometric measurement of absorbances of the corresponding complexes at 447 
and 430 nm, re pect ive1y .  The stoichiometries and formation constants were determined. 
A 1 : 2 i ron (III) to drug rat io was found to give the most predominant  complexes for both 
drugs with 5 .00 x 1 0-3 M H 2S04 and at 0.20 M ionic strength uti l iz ing job ' s  method and 
the molar ratio method. A numerical method was ut i l ized for the calculation of the 
formation constants, the logari thms of which were found to be 7 .756 ± 0. 1 2 1  and 7 .839 ± 
0.056, for c iprofl oxacin and norfloxacin,  respectively. A factorial design together wi th the 
al l-model -search method was ut i l ized for the optimization of the concentration and 
aspiration volume of i ron(III) as these were the variables which most affected peak 
absorbance. Working dynamic ranges of 50 - 500 ppm and 50 - 400 ppm were obtained 
for c iprofloxac in  and norfloxacin,  respect ively. The method was found to be suitable for 
the determination of these compounds i n  pharmaceutical preparations. 
Achi ral and chiral HPLC methods were developed (Brodfuehrer et al., 1 998) for 
c l inafloxacin ,  a quinolone antimicrobial agent .  For achiral assay, analytes were isolated 
from plasma by precip i tat ing plasma proteins .  Separation was ach ieved on a C I 8 column 
using an isocratic eluent of ion pairing solution-acetoni tri le (80 :20, v/v) at 1 .0 mUmin 
with UV detect ion at 340 nm. The ion pairing solution was 0.05 M c i tric acid ,  1 . 1 5  mM 
tetrabutylammonium hydroxide and 0 . 1 % ammonium perchlorate. Inter-assay accuracy 
was with in 4 .9% an inter-assay precis ion of 3 .7% over a quantitation range of 0.025 to 
1 0.0 l1g1ml .  For chiral  assay, analytes were isolated from plasma by solid-phase 
extraction. Separation was achieved on a Crownpak CR(+) column using an isocratic 
e luent of water-methanol (88 : 12, v/v) contain ing 0. 1 mM decylamine at 1 .0 mllmin with 
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UV detection at 340 nm. Perchloric acid wa added to adjust pH to 2. Inter-a ay 
accuracy wa with in 3 .5% with a inter-a say prec is ion of 5 .4% over a quanti tation range 
of 0.040 to 2 .5  Jl g/ml .  
A imple, en  i t ive isocrat ic method for the detection and quantification of  
c iproOoxacin in  pia rna and urine ha  been developed (Karnberi et  al. ,  1 998). The assay 
con i ted of rever ed-pba e HPLC with ul traviolet detection. Plasma proteins were 
removed by a fa t and efficient procedure. For the urine ample , the only required 
ample preparat ion wa d i lut ion. Separat ion was achieved on a C I 8  reversed-phase 
col umn. The quanti fication l imit was 0.0 I mglL in plasma and 0.5 mglL in  urine. Thi 
method wa ufficiently ensit ive for pharmacokinetic studies. 
Two imple and sensi t ive extract i ve spectrophotometric methods for the 
determinat ion of some fluoroquinolone derivatives (norfloxacin ,  NOR; ciprofloxacin ,  
C IP ;  ofloxac in ,  OFL' and enrofloxac in ,  ERF) with Supracene Violet 3B (SV 3B ,  method 
A) and tropaeol i n  000 (TP 000, method B) are described (Sastry et al., 1 995). The 
method i ba ed on the formation of ion-association complexes of fluoroquinolones with 
these dyes, which are extracted i nto chloroform and have absorption max imum at 575 nm 
(SV 3B)  and 485 nm (TP 000). The methods obeys Beer' s law and the precision and 
accuracy of the methods were checked by UV reference methods. The detection l imits 
were 5 .0  Jlglml for NOR and 2 .5  Jlglml for CIP in method A and 2 .5  Jl glml for OFL and 
ERF in methods A and B .  
A s imple, accurate, precIse, and versat i le  high-performance l iquid 
chromatographic  (HPLC) method was developed and val idated for the determination of 
three qu inolone anti biotics in Muel ler-Hinton broth. The fluoroquinolone agents studied 
were c iprofloxac in ,  ofloxac in ,  and sparfloxacin ;  other quinolone agents have been 
ident i fied us ing th is  method but not val idated in this matrix ( levofloxacin ,  c l inafloxacin ,  
temafloxac in ,  and trovafloxac in) .  In  addit ion,  several other biological growth medium 
have been i nvesti gated (human serum, human urine, Todd-Hewitt growth media, Ensure 
enteral feeding solution, and Haemophilus growth media) .  This method uses UV 
detect ion (280 nm), a s imple, one-step protei n  precipi tat ion extraction, and separation 
using a C I 8 column with an i socratic, ion-pairing mobi le phase. An appropriate internal 
standard was obtained by using another quinolone ant ibiotic of differing retention t ime. 
The calibration curves were l inear (� � 0.999) over a concentration range of 0.0625-20.0 
1 1  
J.l g/ml with a lower l imi t  of quant ificat ion of 0. 1 J.l g/ml .  The intra-day and inter-day 
coefficient of variation were less than 1 5% (Wright et al. ,  1 998). 
A high-performance l iquid chromatographic method for the determination of a 
nev tluoroqui nolone ant imicrobial agent, (S)- 1 O- [ (S )-(8-amino-6-azaspiro[3 ,4 ]octan-6-
yl) ] -9-tluoro-2 ,3-di hydro-3-methyl-7 -oxo- 7H-pyrido[ 1 ,2 ,3-de] [ 1 ,4 ]benzoxazine-6-
carbo ylic ac id hemi hydrate (DV-775 J a, I) in human erum and urine ha been 
de eloped (Tanaka et ai. , 1 995). Compound I and the internal standard were extracted 
from erum and uri ne by means of Bond Elut C8 LRC column . The extract were 
chromatographed on a rever ed-phase Inerts i l  ODS-2 column using tetrahydrofuran-50 
mM KH2P04 (pH 2)- 1 M ammonium acetate ( 1 9 : 8 1 :  1 ,  v/v) as the mobi le phase at a tlow­
rate of 1 .0 mllm in .  Fluorescence detection at an exci tation wavelength of 305 nm and an 
emi ion wavelength of 530 nm resulted in  a l imit  of quant i tation of 0.0098 )lg/ml for 
erum and 0.098 )lg/ml for urine. The method showed sat isfactory sens i t iv i ty, precis ion, 
accuracy, recovery and select i v ity. Stabi l i ty studies showed that I was stable in  serum and 
urine for at least 1 month at -20°C and for at least 48 h at room temperature .  
A s imple and quanti tat i ve method for the preparation and h igh performance l iquid 
chromatography (HPLC) of N-acylated fluoroquinolones has been developed (Morley 
and Elrod, 1 993). The acylat ion procedure was performed with four d i fferent acid 
anhydrides and found to be app l icable to several fluoroquinolones. The acylated 
derivatives were chromatographed directly on a Nucleosil C I 8  column w ithout the 
necessity of further sample manipulation. Detector response for the N-acetyl derivatives 
of norfloxacin ,  c iprofloxacin ,  sarafloxacin and temafloxac in  was l inear to at least 50 
)lg/ml .  The retention behavior of the N-acyl derivatives can be predicted by the length of 
the carbon chain of the amide. 
Protonated and uncharged forms of nal id ix ic acid ( l -ethyl - l ,4-dihydro-7-methyl-
4-oxo- I ,8-naphthyrid ine-3-carboxylic acid) and i ts 7-hydroxymethyl derivative are 
reduced at the droppi ng mercury electrode in two one-electron waves, whereas the i r  
anions are reduced i n  a s ingle one-electron wave. Reduction of nal id ix ic acid resul ts in  
hydrogenation of the ethylen ic bond i n  the azinone ring. Protonated and uncharged forms 
of the propyl ester of the nal idi x ic acid are reduced i n  a s ingle one-electron wave. In 
acidic media, t he C-O bond in  the 7-hydroxymethyl nal id ix ic  acid is also reduced. 
Structural effects on the properties of the acid-base equi l ibria are discussed. Based on 
these studies, a differential pulse polarographic method for the determination of 1 0.5 - 1 0-6 
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M nal idix ic acid and i ts metabol ite, the 7-hydroxymethyl derivat ive, In  unne was 
de eloped; on ly  a simple extract ion i needed (Van Oort et al., 1 983). 
A comprehen ive rev iew with 270 reference for the analysis of the members of 
an important cla of drug , 4-quinolone ant ibacterial , is pre ented (Belal et al., 1 999). 
The re iew cover mo t of the methods de cribed for the analy is of these drug either in 
do age form or in  biological fluid . 
1 .3.  Cyclodexterins and Dru g  I nteractions 
The re olut ion of binary mixtures of nal idix ic acid (NAL) and 7-
hydroxymethylnal id ix ic acid (OH- AL) ha been accompl i hed by partial lea t squares 
(PLS )  and principal component regression (PCR) multivariate cal ibrat ion. The method of 
determination i ba ed on the fluorescence emis ion of these compounds in the presence 
of y-cyc lodextrin (y-CD).  The formation of the inclusion compounds gi ves rise to an 
increa e of the fl uore cence emission compared to aqueous solution. The total 
luminescence information of the compound ha been used to opt imize the spectral data 
et to perform the calibrat ion . A comparison between the predictive abi l i ty of three 
mult ivariate cal ibration methods, PLS- l ,  PLS-2 and PCR, on three spectral data set , 
excitat ion, emission and synchronous spectra has been performed. The PLS- l method, 
appl ied to the emission spectra, has been selected as optimum. The proposed method has 
been appl ied to the s imultaneous determination of NAL and OH-NAL in urine. Recovery 
values from urine samples containing (NAL) and (OH-NAL) range from 9 1  to 1 03% 
(mean 97%),  and from 92 to 1 05% (mean 99%), respectively (Duran-Meras et  al., 
1998). 
Interaction of nal idixic acid (NAL) with y-cyclodextrin in  aqueous solut ion and in 
the sol id  state was confi rmed (Celebi et ai., 1987) by the solubi l i ty method, powder x-ray 
di ffractometry, differential scanning calorimetry (DSC) and IR spectroscopy. The 
solubil i ties of NAL in the presence of a, � and y-cyclodextrins in aqueous solution were 
studied. The solubi l i ty diagram was obtained with y-cyclodextrin. The apparent stabi l i ty 
constant ,  Kc ,  was calculated from the slope and intercept of the straight l ine of the all 
type solubi l i ty d iagram. A solid complex of NAL with y-cyclodextrin in 1 :  1 molar ratio 
was prepared by freeze-drying method. Also ground mixture of NAL with y- cyclodextrin 
and potato starch in  1 :  1 molar ratio was prepared. The dissolution rate of the powder was 
determined by the d ispersed amount method in buffer solution (pH 1 .2), no significant 
enhancement was observed in the dissolution rate of the solid complex with y-
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cyc lodextrin. On the other hand the disso lution rate of NAL from the ground mixture was 
found t be greater than tho e of the physical mixture and pure NAL powder. 
A method for nalidixic acid (NAL) determinat ion by transmitted room­
temperature phosphore cence is proposed (Capitan et ai , 1 998). The ant ibacterial agent 
L in ac idic o lution shows nat ive fluorescence, when NAL is spotted on a fi lter paper 
precoated with �- cyclodextrin and lead ( I I )  acetate and dried for 5 min, phosphorescence 
resu lts. The transmitted phosphorescence was measured directly with the use of a 
homemade ample holder, the excitation and emission wavelengths were 330 and 4 1 7 run, 
respectively. The appl icable concentration range was between 0.06 and 4.50 �g/rnL with 
a relative standard deviat ion of 2 .8% and a detection limit of 0.02 �g/rnL. The method 
was applied to the determinat ion of NAL in human urine and pharmaceut icals, with 
recoveries from 97.5 to 1 05.5%. 
A fluorimetric study on the spectral characteristics and ac id-base behavior of7-
hydroxymethylnalidixic acid has been performed. The host-guest complexation process 
between y-cyc lodextrin and 7-hydroxymethyl nalidixic acid has also been invest igated by 
fluorescence spectroscopy (Duran-Meras et al., 1 997).  Scatchard and Benesi-Hi ldebrand 
methods have been appl ied to determine the stoichiometry of the complex, and a 1 :  1 
stoichiometric ratio has been establ ished. A K- 1 = 1 1 8  ± 25 M-1 format ion constant has 
been calculated for the inclusion complex, by using the changes produced on the 
fluorescence of 7-hydroxymethyl nal idixic ac id, when it is included on the hydrophobic 
cyc lodextrin cavity. A fluorimetric method of determinat ion of 7-hydroxy­
methylnalidixic acid, ill y-cyclodextrin aqueous solution, has been proposed. The 
analyt ical parameters and detection and quantification l imits of the method 
have been determined. 
The improvement of the d issolution rate and efficiency and bioavai labi l ity of 
nal idix ic acid (NAL) were reported to evaluate three modified starches namely dextrin 
CD) �-cyclodextrin (�-CD) and hydroxyethyl starch ( HES) as carriers for solid 
d ispersions. Solid d ispersions of NAL in D, �-CD and HES were prepared by common 
solvent method and the dispersions were evaluated by TLC, I R, DTA, X-ray diffraction, 
moisture absorption, disso lution rate and bioavailabi l ity studies. The three modified 
starches were found to be non-hygroscopic, non-interacting carriers giving so lid 
d ispersions and effect ive in increasing the d isso lut ion rate efficiency and absorption rate 
of NAL marked reduction in the crystal l in ity and crystal size o f NAL in the dispersions 
was observed (Chowdary and Rao, 1 994). 
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The characteristic of host-gue t complexation between y- cyclodextrin and 
nai id l  ic ac id were investigated (Duran-Meras et ai. ,  1 994) by fluorescence 
pectrometry. A I :  I toichiometry of the complex was establ ished and an a sociation 
con tant of 292 L mor l wa calcu lated by using the changes in the fluore cence of 
nal id I x ic acid  that occurred when it wa included in the hydrophobic cyclodextrin cavity. 
A spectrofluori metric method for the determi nation of nal idixic ac id wa developed, with 
a range of appl ication between 0. 1 and 2 �g mr l . The method was appl ied at i factori ly 
the determinat ion of nal id ix ic ac id in a pharmaceutical preparat ion and in urine.  
Chowdary and Rao, 1 992, studied the use of the modified tarche dextrin ,  
cyclode tr in  and heta tarch (hydroxyethyl starch) as carriers for sol id di spersions of  the 
model drug phenylbutazone and nal idix ic ac id .  Analytical studies showed no interaction 
between the drug and the carriers. Marked i ncrease in the dissolution rate and efficiency 
wa ob erved with solid dispersion of the drugs. A marked reduction in the crystal l i n i ty 
and crystal s ize of the drug di spersed was observed . It wa concluded that modified 
tarches were successful  in i ncreas ing the di solution rate and effic iency of poorly soluble 
drugs in sol id dispersions.  
Panosyl-a-cyclodextrin was synthes ized from a-cyclodextrin and panose through 
the reverse action of Baci l lus acidopul lu lyticus pul lulanase and purified using high­
performance l iquid chromatography on ODS and amino columns. The physicochemical 
and biological properties and solubil ization capabil ity of panosyl-a-cyclodextrin were 
compared with those of conventional a-cyclodextrin and branched a-cyclodextrins. The 
hemolytic act iv i ty of panosyl-a-cyclodextrin was lower than those of a-cyclodextrin and 
glucosyl-a-cyclodextri n .  Panosyl-a-cyclodextrin was found to be sl ightly unstable in an 
acid  solut ion,  with stabi l i ty s imi lar to that of maltosyl-a-cyclodextrin .  The solubi l ization 
of panosyl -a-cyclodextrin for drugs slightly soluble or insoluble in water was greater than 
that of a-cyclodextrin ,  but the same as that of conventional branched a-cyclodextrin .  The 
suppressive effects on the photolysis of mecobalamine in the presence of a-cyclodextrins 
were in  the fol lowing order: panosyl-a-cyclodextrin > maltosyl -a-cyclodextrin > 
glucosyl -a-cyclodextrin > a-cyclodextrin (Kimura et ai., 2000). 
A comparative bioavai l abi l ity study was carried out (Fawaz et ai., 1996) in 
rabbits on pure powder of norfloxacin and i ts formulations, aqueous solution , 
polyethyleneglycol 6000 solid dispersions (PEG 6000 SD),  p-cyclodextrin (P-CD) and 
hydroxypropyl-P- cyclodextrin (HP-P-CD) complexes. Norfloxacin plasma 
concentrations were measured by HPLC method with a fluorimetric detection. Estimation 
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of t l/2 and k-e proved that PEG 6000 S D  and CD complexes did not modify the 
e l iminat ion characteristic of norfloxacin .  Data from plasma concentration profi le 
indicated that ab orption of norfloxacin from SD and i nclusion complexe was markedly 
accelerated when compared with powder of pure drug. The extent of ab orption wa 
ign i ficantly mai ler with powder of norfloxacin than with its formulations .  
B ioavai labi l i ty wa improved and sign ificantly higher with CD and complexes SD than 
with powder, but the improvement was lower than expected . 
In  rea e in  the poor water solubi l i ty and di solution rate of norfloxacin was 
tudied (Guyot et al., 1 995).  Two systems were used: sol id dispersion with PEG 6000 
prepared u ing the fu ion method and inclusion complexes with cyclodextrins W­
cyclodextrin and H P-p-cyclodextrin) obtained by freeze-drying .  IR spectrophotometry, X­
ray diffractometry, and di fferential scanning calori metry showed di fferences between 
norfloxacin /cyc lodextrin complexes and their corresponding phy ical mixtures , but not 
between norfloxacin !PEG 6000 sol id dispersions and their corresponding physical 
mixture . The solubi l i ty and dissolution rate of norfloxac in  were sign i ficantly increased 
with PEG sol id dispersions and cyclodextrin complexes as wel l  as with norfloxacin-CD 
physical mixtures. H owever, enhancement was not stati stical ly di fferent e i ther among 
various cyc10dextrin complexes, or between sol id dispersion and cyclodextrin complexes. 
The norfloxacin-p-cyc1odextrin complex prepared by neutral ization method was 
confirmed by differential scanning calorimetry (WU et al., 1 994). The dissolution rate and 
the relative bioavai l abil i ty of the complex were improved significant ly in comparison 
with marketed capsules.  The resul ts indicated that p-cyc lodextrin could be a useful  
addit ive to sol id norfloxacin formulations. 
Interaction between norfloxacin and p-cyclodextrin W-CD) in  solution was 
characterized by i mmersion calorimetry studies and nuc lear magnetic resonance (Torres 
et ai., 1998). l H-NMR studies suggest that the piperaz ine group of norfloxacin is  the part 
of the molecule bound inside the P-CD cavity. Sol id inclusion complexes of norfloxacin 
with P-cyc lodextrin were prepared by freeze-drying in two d ifferent molar ratios, I :  1 and 
1 : 2, and characterized by X-ray diffractometry, and differential scanning calorimetry. 
Drug dissolution rate was improved by inclusion complexation and norfloxacin 
incompatib i l ity wi th metal cations (Mg2+, Ae+) was reduced. 
The freeze-dried ternary formulations of mecl izine (MZ, an anti-motion sickness 
drug), prednisolone (PRED, an anti-inflammatory drug) and norfloxacin (NFLX, an anti­
microbial drug) which are poorly water-soluble and are low bioavai l abi l i ty drugs, were 
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prepared usmg egg albumin and o l ive oi l .  The powder X-ray diffract ions, the disso lution 
rate and the bioavailabi l it ies of these formulat ions were tud ied in comparison with each 
drug alone. By forming ternary formulat ions of these drugs, the disso lution rates of the 
drug from the formulat ions were significant ly improved compared with each drug alone. 
The re ults of th ir powder X-ray diffract ion measurements showed that these drugs in 
the ternary formulat ions pr sented in an amorphous form, ind icating increased disso lution 
rates. On the other hand, the plasma concentrations of these drugs increased significant ly 
after oral admin istration in formulat ions to rats, except for the NFLX formulation, and the 
areas under the concentrat ion-t ime curves (AU C) of the ternary formulations of MZ, 
PRED and NFLX were 2. 1 ,  1 .6 and 1 . 3 t imes those of the drugs alone, respect ively. From 
the e resu lts, it was proven that formulat ions consist ing of egg albumin, o l ive oil  for 
poorly water-soluble drugs were useful preparat ions for improving the drug's 
disadvantageous pharmaceutical properties (Tsuj i et aL, 1 996). 
An attempt has been made (D'souza et aL, 1 997) to design suitable niosome­
encapsulated drug delivery system for ciprofloxacin and norfloxacin. Encapsulat ion of 
c iprofloxac in and norfloxacin in niosomes was invest igated and the nasal and intest inal 
absorption of the products studied. More than 80% of the drugs were successfully 
encapsulated to give products with sustained release characterist ics. Encapsulat ion in 
ruo so mes also improved the stability of the antibacterial compounds. Although the 
systemic availabi lity of these niosome-encapsulated antibacterial compounds was not 
increased after nasal administration, intestinal absorption was significantly higher in 
comparison with that of plain inclusion complexes. 
Formulat ions containing c iprofloxacin hydrochloride and norfloxacin for the 
treatment of ophthalmic and skin infections were made (Udupa and Lee, 1 992). The 
stability, bioavailabi l ity and therapeutic efficacy o f  the preparations were evaluated. 
These antibiotics were not systemically absorbed, when applied locally. Preparations 
were found more effect ive for the treatment of skin and eye infect ions. �-cyclodextrin 
improved the bioavailabi l ity o f  ant ibiot ics. 
The in vitro drug release patterns and stabil ity of biodegradable dental implants 
formulated usmg poly(epsi lon-caprolactone) and containing ciprofloxacin and 
norfloxacin complexed with betadex ( �-cyclodextrin ) were reported (Nagaraju and 
Udupa, 1998). In  vitro release studies showed a sustained release of the drug complexes 
throughout the study period of 40 days with sufficient antimicrobial drug concentrations. 
The degradation of the complexes was much less than pla in drugs. Degradation further 
1 7  
lowed when formulated i n  the polymer. It was concluded that the drug complexing 
proce e improved tabi l i ty .  
The di olut ion ,  d i ffusion, and tabi l i ty of norfloxac in  complexes with �­
cyc!ode tnn were inve t igated (Aithal and Udupa, 1 996) and implants prepared with 
the e complexe were incorporated into inert polymeric matrice and uti l ized a 
ophthalmic implant in  rabbit for local drug del ivery. The dis olut ion and diffusion of 
the In lu Ion complex in  buffer olution of pH 7 .2  and 1 . 2 were better compared to the 
plain drug. The promi ing uti l i ty of the complex over the plain drug in  local drug de l i very 
cou ld al 0 be substantiated due to the better stabi l i ty and i ncreased antibacterial acti vi ty 
of the complex compared to the plain drug. The better release of the complex wa 
e idenced from both i n  v i tro and i n  v ivo studies. It was concluded that the norfloxacin-�­
cyc!ode trin complex can be ucces fu l ly  used in  ocular implants for local drug del i very . 
Martin and Udupa, 1 995, improved the stabi l ity and the ocular delivery of ant i­
infect i ve drugs, inc lusion complexes of ciprofloxacin ,  norfl oxac in ,  and t in idazole with �­
cyclodextrin were prepared and i ncorporated into ocular implants,  the sustained release 
profi le wa evaluated i n  v i tro and fol lowing ocular admin istration to rabbits . The release 
rates of the drug from the implants contain ing drug alone and drug-p-cyclodextrin 
complex were almost identical in  the case of t in idazole.  However, in the case of 
norfloxacin and c iprofloxacin implants, the release of the drug from its p-cyclodextrin 
complex was much greater compared to that from the drug-on ly  implants. It was found 
that the stabi l ity of the drugs was improved after complexation. It was concluded that the 
ocu lar preparations may be very useful for treating ophthalmic ai l ments due to infection 
requiring chronic treatment  wi th  ant i- infective drugs. 
Dental implants of c iprofloxacin-p-cyclodextrin inc lusion complex were 
formulated using poly (eps i lon-caprolactone), a biodegradable polymer and evaluated 
(Nagaraju et at. , 1 999). Cl inical evaluation was carried out i n  ten patients with acute 
peridontit is .  Various c l in ical parameters, viz. gingival index , plaque score, attachment 
gain ,  reduction in pocket depth were evaluated at 1 0, 20, 30, 40 days of treatment and 
compared with placebo as contro l .  A sign ificant (P < 0.000 1 )  improvement in the heal ing 
of peridontal pockets treated with c iprofloxacin-�-cyclodextrin implant was observed in 
most of the c l in ical parameters. Estimation of gingival crevicular fluids (GCF) for the 
drug content revealed that drug levels above the minimum inhibi tory concentration ( 1 0.2 
Il glmg) for many of the periodontal pathogens were maintained throughout the period of 
study (40 days) .  This confirms the c l in ical efficacy of the dose and the duration of the 
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tudy. It wa found that biodegradable carrier wa better accepted than the non­
biodegradable carriers reported. 
The effect of variou phy ical parameter and P-cyc Iodextrin on the apparent rate 
of In  itu na al ab orption of ciprofloxacin hydrochloride wa studied (Salama and 
Udupa, 1 993) . The apparent rate con tant of the nasal absorption of ciprofloxacin HCl 
wa md pendent of the rate of perfu ion abo e a value of 2 ml/min . ,  molar concentration 
of nature of the olvent .  However, it decreased with an increa e in vi cosi ty. It increa ed 
when the perfu ate volume was decreased, with an increase in the temperature of 
perfu ion olut ion and with an appropriate concentrat ion of Tween 80 (0.5% v/v) and p­
cyclodextrin ( 1 .0% w/v ) .  
A chemical del ivery system for zidovudine (AZT-CDS ) has been shown 
( B rew ter et aI. , 1 995) to increase brain levels of the parent ant i retrovi ral agent while at 
the arne t ime reducing blood concentrations. Such select iv i ty may improve the 
therapeutic i ndex for AZT. Unfortunately, the AZT -CDS i s  l ipoph i l ic and labi le to 
oxidative and hydrolytic degradation thereby compl icat ing the development of a 
conven ient formulat ion.  The configuration of several potential ly acceptable parenteral 
dosage form using cyclodextrin-based systems are described here in .  A prototype 
formulation was developed using the AZT-CDS potassium salt in an aqueous matrix of 2-
hdroxypropyl -P-cyclodextrin (HP-P-CD) ( 1 5% w/v) and Na3P04 (0.005 M). While 
alkal ine, the formulation was associated with a low bufferi ng capacity and was not 
i rritating i n  a rat tai l model of extravasation. Systemic administration of this dosage form 
provided for, i n  addit ion to improved brain levels of AZT and an increased brain to blood 
ratio, improved bioavai l ab i l i ty 
compared to a d imethyl sulfoxide (DMSO) vehicle. 
AithaJ et aI., 1 995, studied the abi l i ty of ciprofloxacin to form an i nclusion 
complex w ith p-cyclodextrin .  In vitro antibacterial activity of c iprofloxacin on E ( 1 0) 
Col i and S taphylococcus aureus was found better on complexation . The complex was 
found very effective as a local ant ibacterial agent when used i n  dental implants. 
S ign ificant reduction in the gingival index, probing pocket depth and microbial growth 
coupled with gain in attachment at the test site compared to control on the 1 4th day was 
observed when the implants containing 2.0 mg of the complex equivalent to 0.4 mg of 
ciprofloxacin was used in c l in ical trials. 
The interaction between ciprofloxacin and P-cyclodextrin leading to the formation 
of an i nclusion complex was studied by (Shrinivas and Udupa, 1996) into phase-
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olubi l ity, X-ray d i ffractometry, di fferential scanning,  calorimetry d ifferential thermal 
analy i , UV,  infra red and NMR spectroscopy. Part ial inclusion of the drug mOIety 
with in the �-cyclodextrin cav ity along with an in teraction of the carbonyl funct ion of the 
arboxyl lc acid of c iprofloxacin with the hydroxyl function of �-cyclodextrin leav ing the 
pIperazine moiety hanging around the narrower rim of the cyclodextrin cavity was 
e.labl l shed . Change in  the cry tall in i ty coupled with improved stabi l i ty of the drug was 
al'o b erved on comple ation . For improved stabi l i ty, the complex may be used in pl ace 
of the drug alone. 
Shehatta, 1996, studied the inclu ion nature of a- and �-cyclodextrins with orne 
traight-chain a ,  w-alkaned iol and methyl orange in aqueous solution at 288. 1 5 , 298 . 1 5  
and 308. 1 5 K using the spectrophotometric technuque. The formation of inclu ion 
complexe between cyclodextrins and alkanediols i s  main ly  hydrophobically dri ven .  Its 
tabi l i ty increase wi th the i ncrease of Na2S04 concentration, the number of methylene 
group in the alkyl chain of the alkanediols the part i t ion coefficients of the guest 
ubstances and the decrease of cosolvent concentration (methanol ) .  Favourable 6Ji and 
unfavourable IJ.S values indicate that other interactions are s ignificant for the stabi l izat ion 
of the complex formed besides the hydrophobic effect. 
The interaction of the anti- inflammatory drug i ndomethacin (IMC) with a-, �­
cyclodextrins and calf thymus deoxyribonucleic acid  (ct-DNA) have been investigated 
(Shehatta and Ibrahim, 2001)  i n  Bri tton-Robinson buffer (pH = 7 .2) using solubi l i ty, 
spectroscopic and voltammetric methods. The measurements show that the IMC 
molecule, as an in tercalator, is inserted, from the p-chlorobenzoyl part, into the cavity of 
the cyclodextrins as wel l as into the base-stacking domain of the ct-DNA double hel i x .  
Adding �-cyc lodextrin in  buffer IMC solution , the solubi l i ty of IMC increases and the 
Gibbs free energies of transfer of the drug from aqueous solution to the cavity of �­
cyclodextrin are negative and decrease with increasing p-cyclodextrin concentration. The 
in teraction of IMC with cyclodextrins and ct-DNA causes a hypochromism and 
bathochromism in the absorption spectra and pronounced changes in the e lectrochemical 
behavior of the drug. The stoichiometry of complexes formed in solution is inferred to be 
1 :  1 .  The binding constants were calculated from the increase of the solubi l i ty, the strong 
hypochromism and the decrease in peak current of WC upon the addition of the host 
molecules. The WC has a h igher affinity for p-cyclodextrin than for a-cyclodextrin ,  as 
the IMC-p-cyclodextrin interaction is the most exergon ic.  B i nding is interpreted in terms 
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of the intercalat ive (hydrophobic) interactions with the ct-ONA hel i x  ( i .e . ,  the stacked 
ba e pai r ) or with in cyclodextrin CO cavity. 
1 .4. D A and Drug I n teractions 
The binding of pia mid 0 A to norfloxacin was in  e t igated (Palu et aI., 1 922) 
by fl uore cence ,  electrophoretic ON A unwinding, and affinity chromatography 
techn Iques . The amount of norfloxacin bound to D A wa modu lated by the 
concentration of Mg2+ . No interaction was evident in the absence of Mg2+ or in the 
pre ence of an exce s of Mg2+, whereas maximum binding was observed at a Mg2+ 
concentration of 1 -2 mM .  The experimental data can be fitted to the formation of three 
type of Mg adduct : a binary adduct with norfloxacin and Mg2+, a binary adduct with 
o A and Mg2+, and a ternary adduct wi th norfloxacin ,  plasmid, and Mg2+ . A model \Va 
propo ed for the ternary complex, in  which Mg2+ acts as a bridge between the phosphate 
group of the nucleic acid and the carbonyl and carboxyl moietie of norfloxac in .  
Addi t ional stab i l ization may arise from stacking i nteractions between the condensed rings 
of the drug and DNA bases (especial l y  guanine and adenine),  which may account for the 
preference exhibi ted by the drug for single-stranded and purine-rich regions of nucleic 
acids. Other possible biochemical pathways of drug action are suggested by the 
observation that norfloxacin binds Mg2+ under conditions that are close to physiological . 
The i nteraction of nogalamycin (NOM), an anthracyc1 ine antitumor drug, with 
calf thymus DNA has been studied (Ibrahim, 2001 )  by cycl ic voltammetry (CV) and 
differential pulse voltammetry (DPV). The variations in the cycl ic voltammetric behavior 
of NOM on addition of DNA have been carried out. The experimental results reveal that 
the reduced form (H2NOM)red, of NOM is bound more strongly to DNA than the 
oxidised form (NOM)ox . The cal ibration graph for the determination of DNA was 
obtained by the decrease in the DPV peak curren t  of NOM in the presence of DNA. 
Furthermore, the resul ts are compared wi th the s imi lar type of i nteraction behaviors of 
daunomycin (DAM), adriarnycin (ADM) and 4 '-deoxyadriamycin (DADM), mainly from 
the viewpoint of the i nfluence of chemical structure. B inding constants were determined 
from voltammetric data, i .e .  changes in l imit ing current with addition of DNA. In 
comparison w i th DAM, ADM and DADM, nogaJamycin displayed high binding affinity 
to DNA (K = 4.44 x 1 05 M- 1 ), and the binding affin ity increases i n  the sequence: DAM < 
DADM < ADM < NOM. The results show also that, a s l ight change in  chemical structure 
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i gn i ficant change In the binding affini ty to DNA and con equently in c l i nical 
propert ie . 
It ha been found that, contrary to prior bel ief, norfloxacin ,  a member of the 4-
qui nolone fami ly  of antibacterial drugs that speci fical ly inh ib i t  DNA gyra e, did not bind 
to the enzyme but i n  tead to DNA. (Tornaletti and pedrini, 1 988) have performed DNA 
unwinding experiment in order to dec ide whether b inding of norfloxacin to DNA 
introduce changes in  it  upercoi led conformation . They have found that :  1 .  Norfloxacin 
and nal id l ic  acid are capable of unwinding the double hel i x ,  thu confi rming the binding 
of the e antibiotic to DNA. 2 .  DNA unwinding can be observed only in the presence of 
Mg2+ and decrea es w i th increasing KCI concentrat ion. 3 .  The extent of unwinding varies 
in d i fferent DNA molecu le , suggesting a sequence preference of norfloxacin binding to 
D A.  
orfloxac in  ha been studied (Son et  at., 1 998) with respect to its binding to cal f 
thymu D A u ing fluore cence and l i near dichroism techniques and unwinding of 
upercoi led DNA. The fl uorescence of norfloxacin i s  strongly quenched in the presence 
of DNA and using this decrease i n  a fluorescence t i trat ion the equi l ibrium constant of the 
complex formation was establ ished to be 2 .8  x 1 03 M- 1 .  The electric transition moments 
of the norfloxacin chromophore have been analyzed using fluorescence anisotropy, 
magnetic c i rcul ar dichroism, and l inear dichroism in stretched poly(vinyl alcohol) film 
and INDO/S calculations. These data were then used to interpret flow l inear dichroism 
results for the norfloxacin-DNA complex. The transition moments for the long­
wavelength transitions are found to be oriented at about 6S.0-8S .0{  degree } with respect 
to the DNA hel i x  axis .  A near perpendicular orientation of the norfloxacin chromophore 
p lane makes it possible to exclude classical groove or surface binding modes. The 
possibi l ity of a c lassical intercalation binding mode also can be ruled out from unwinding 
experiments. However, i t  is shown that the molecular plane of norfloxacin i s  near 
perpendicular relative to the DNA hel i x  axis with a possibi l ity of bending of the DNA 
hel i x  at the binding site. 
Yeo et al., 1998, compared various spectroscopic properties of a norfloxacin­
single stranded DNA complex with those of norfloxacin-double stranded DNA complex. 
Norfloxacin binds to both double and single stranded DNA, and they observed the 
fol lowing spectroscopic changes for both complexes: hypochromism in the norfloxacin 
absorption region in the absorption spectrum, the characteristic induced CD spectrum 
consisting of a weak positive band at 323 nm and a strong positive band at 280-300 nm 
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fol lowed by a negat ive band in the 260 nm region, a strong decrease in the fluorescence 
tnten i ty and a red- hift in the fluorescence emis ion spectrum, and shorter fluorescence 
decay t ime . The e re ul ts indicate that the environments of the bound norfloxacin in both 
DNA are imi lar, although the equi l ibrium con tant of the norfloxacin- ingle stranded 
DNA wa twice a high a the norfloxacin-double stranded DNA complex . Both 
comple e were thennodynamical ly favored with imi lar negative 6G(0). Negat ive 6H-0 
term, contribute to these pontaneous reactions; 6S-0 term was unfavourable. 
The quinobenzoxazine compounds A-62 1 76 and A-85226 be long to a novel class 
of antineoplastic agents that are catalytic inhibitors of topoisomerase II and also structural 
analog of the antibacterial DNA gyrase inhibi tor norfloxac in .  In vi tro studies have 
hown that their  antineopla tic act iv i ty is dependent upon the presence of divalent metal 
Ion uch as Mg+2 and Mn+2, al though the precise role of these ions in the mechan ism of 
action i unknown. In this study (Fan et al., 1 995) have investigated the structures of the 
binary complex between the quinobenzoxazines and Mg+2 and the ternary complex 
between quinobenzoxazine-Mg+2 and DNA. The stoichiometry of the binary and ternary 
complexes and the biophysical studies suggest that a 2 :2 drug: Mg+2 complex fonns a 
'heterodimer complex' with respect to DNA in which one drug molecule is i ntercalated 
into DNA and the second drug molecule is externally  bound, held to the first molecule by 
two Mg+2 bridges, which themselves are chelated to phosphates on DNA. There is a 
cooperativ i ty i n  binding of the quinobenzoxazines to DNA, and a 4:4 drug: Mg+2 complex 
is proposed in which the two externally  bound molecules from two different 2 :2  dimers 
interact via Pi-Pi in teractions. The external ly  bound quinobenzoxazine molecules can be 
replaced by the quinolone antibacterial compound norfloxacin to fonn mixed- structure 
d imers on DNA. Based upon the proposed model for the 2 :2  quinobenzoxazine: Mg+2 
complex on DNA, a parallel model for the antibacterial quinolone-Mg+2-DNA gyrase, 
complex is proposed that rel ies upon the ATP-fueled unwinding of DNA by gyrase 
downstream of the c learable complex site. These models ,  which have analogies to leucine 
zippers, represent a new paradigm for the structure of drug-DNA complexes. In addit ion, 
these models have important impl ications for the design of new gyrase and topoisomerase 
II inhibi tors, in that optimization for structure- acti vity relationships should be carried out 
on two differen t  quinolone 
molecules rather than a single  molecule. 
The interaction between divalent cations and quinolones and the mechanism by 
which the fonner antagonizes the antimicrobial act ivit ies of the latter were investigated 
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(Mar hall  and Piddock, 1 994). In the presence of ei ther magne ium or calcium ch loride, 
the MIC of 1 8  quinolone for Gram-posit ive and Gram-negati ve bacteria increased . 
Accumulat ion of and inhib i t ion of DNA synthe is  by quinolones were decreased in the 
pre ence of magne ium ch loride whi le ,  in the pre ence of EDTA, there was no increa e in 
the concentrat ion of accumulated quinolone for any of the agents te ted . Only with 
na J id l ic ac id wa their  en hancement of the inhibi tion of DNA ynthe is .  Chelation of 
elected qui nolone by magnesium was demonstrated with a f1uore cence assay, which 
howed that the extent to which fluorescence (consi stent with chelation) was enhanced 
varied with the quinolone. Asse sment of the strength of the magnesium-quinolone 
comple es w ith the chelat ing agent EDT A demonstrated that some of the complexes 
could be broken .  Thin layer chromatography of quinolones and quinolone-Mg+2 
complexe provided evidence that the components of the complex were probably 
combined in  a rat io of 1 :  1 and that reduced intrace l lu lar accumulat ion of the quinolone 
i n  the pre ence of Mg+2 was unl ike ly to be due to a complex being too bulky to be taken 
through the porin channels .  In contrast with permeabi l izers which are known to uti l ize the 
e lf-promoted uptake pathway, none of the quinolones studied permeabi l ized Gram­
negat i ve bacteri a to l ysozyme, caused enhanced fluorescence to I -N-phenyl­
naphthylamine (NPN )  or i ncreased the leakage of peri plasmic p-lactamase in to the culture 
medium.  These data suggest that the quinolones do not use the sel f-promoted uptake 
pathway. The reduced activities of the quinolones in the presence of divalent cations may 
be the resul t  of the chelation of exogenous ions and, possibly, l ipopolysaccharide- or 
l ipoteichoic acid-associated Mg+2 , thereby result ing in less drug being avai lable to enter 
the bacterium.  Al ternatively, reduced act iv ity may be due to a fundamental effect on the 
in teraction between quinolones and their target DNA gyrase .  
The quinobenzoxazines, a group of structural analogues of the antibacterial 
f1uoroqu inolones, are topoisomerase II inhibitors that have demonstrated promising 
anticancer acti v i ty in  mice. It has been proposed (Yu et ai.,  2000) that found the 
quinobenzoxazines form a 2 :2  drug-Mg+2 self-assembly complex on DNA. The 
quinobenzoxazine (S)-A-62 1 76 is photochemical ly  unstable and undergoes a DNA -
accelerated photochemical reaction to afford a highly fluorescent photoproduct. Here they 
report that the irradiation of both supercoi led DNA and DNA ol igonucleotides in the 
presence of (S)-A-62 1 76 results in photochemical cleavage of the DNA. The (S)-A-
62 1 76-mediated DNA photocleavage reaction requires Mg +2. Photochemical cleavage of 
supercoi led DNA by (S)-A-62 1 76 is much more efficient than the DNA photocleavage 
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reactions of the fluoroquinolones norfloxacin, ciproflo xacin, and enoxacin. The 
photoclea age of supercoiled 0 A by ( S)-A-62 1 76 is unaffected by the presence of 
00. catalase, or other reactive oxygen scavengers, but is inhibited by deoxygenation. 
The photochemical clea age of upercoiled DNA is also inhibited by 1 rnM Kl . 
Photochemical cleavage of 0 A oligonucleotides by ( S)-A-62 1 76 occurs most 
e ten i ely at DNA ite bound by drug, as determined by DNase I footprinting, and 
e pecially at certain G and T residues. The nature of the DNA photoproducts, and 
inllibition studies, indicate that the photo cleavage reaction occurs by a free radical 
mechanism initiated by abstraction of the 4'- and I '-hydrogens from the DNA minor 
groove. These results lend further support for the proposed DNA binding model for the 
quinobenzoxazine 2 :2  drug-Mg+2 complex and serve to defme the position of this 
complex on the minor groove of DNA. 
As a means of gaining additional information on the topoisomerase-mediated 
cytoto icity induced by a variety of antibacterial and antitumor compounds, Shen et al., 
1 989 have examined. The interaction of the quinolone antibacterial agent, norfloxacin, 
with the bacterial topoisomerase, DNA gyrase. Membrane filtration and spincolurnn 
techniques were used to study the binding of (super 3 H )  norfloxacin to purified plasmid 
DNA, DNA gyrase and complexes formed by adding gyrase to different forms of 
plasmid DNA. These [mdings provide the first direct correlation of quinolone binding 
with inhibition of enzyme activity and induction of DNA breakage, and they suggest that 
the inhibition of DNA gyrase by norfloxacin occurs as a result of binding to a site which 
appears after the formation of a gyrase -DNA complex. 
A fluorescence probe, safranine T (ST), was proposed (Guo et 01., 1 998) for the 
investigation of DNA. ST is a fluorescent cationic dye, displayed high affmity for DNA. 
Its fluorescence intensity was lowered as a result of formation of a complex with DNA, 
which is less fluorescent than the free dye. Its fluorescence polarization or anisotropy 
increased due to the small molecules of dye binding to DNA macromolecules. Based on 
the interaction between ST and DNA, a procedure for DNA determination was proposed. 
Variation of the cyclic voltammetric behavior of pharmorubicin in an aqueous 
medium upon addition of DNA were studied (Chu et al., 1 999) and utilized for the 
determination of DNA. It was observed that the redox waves of pharmorubicin after 
binding to the large and slowly diffusing DNA almost disappeared. The anodic peak 
currents of pharmorubicin, when the concentrations were fixed at 2.0 x 1 0-5 and 2.0 x 1 0-4 
mol/L, decreased linearly in relation to the concentration of DNA added in the range of 
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0-30.7 and 0 - 260.3 Ilg/ml, with the detection l imit of 1 .2 and 20.8 Ilg/ml, respectively. 
The propo ed method exhibited good recovery and reproducibi l ity for the determinat ion 
of DNA. Furthermore, the binding constant and binding site size of the pharmorubicin­
DNA interaction were also calcu lated. 
Shea and H iasa, 1 999, studied the co ll isions between replicat ion forks and 
topei omerase-drug-DNA ternary complexes that result in the inhibition of DNA 
rep licat ion and the conversion of the normally reversible ternary complex to a 
nonreversible form. U lt imately, this can lead to the double strand break formation and 
sub equent cell death. To understand the molecular mechanisms of replication fork arrest 
by the ternary complexes, they have invest igated mo lecu lar events during coll isions 
between DNA hel icases and topeisomerase-DNA complexes. A strand displacement 
assay was employed to assess the effect oftopoisomerase I V  (Topo I V)-norfloxac in-DNA 
ternary complexes on the DnaB, T7 gene 4 protein. SV40 T-antigen, and UvrD DNA 
hel icases. The ternary complexes inhibited the strand displacement act ivit ies of these 
DNA hel icases. Unlike rep lication fork arrest, however, this general inhibit ion  of DNA 
hel icases by Topo I V-norfloxacin-DNA ternary complexes did not require the c leavage 
and reu nion act ivity o f  Topo IV.  They also examined the reversibi l ity o f  the ternary 
complexes after col lisions with these DNA hel icases. UvrD converted the ternary 
complex to a non reversible form, whereas DnaB, T7 gene 4 protein, and SV 40 T -antigen 
did not. These results suggest that the inhibition of DnaB translocation may be sufficient 
to arrest the replicat ion fork progression but it is not sufficient to generate cyctotoxic 
DNA lesion. 
Voltammetric methods have been used (Carter et ai., 1989) to probe the mode of 
interaction of M(phen)J3+12+ and M(bpY)33+12+ with DNA, where M = Co or Fe. Shifts in 
EO ' can be used to differentiate intercalative interactions, which involve hydrophobic 
interactions with the interior of the DNA molecule from electrostatic ones, which invo lve 
the outer anionic coat of DNA. Binding parameters for mult iple oxidation states can be 
obtained from the dependence of peak current on the ratio of nucleotide phosphate to 
metal from t itration experiments. Co(phen)33+ binds intercalatively to DNA, with the 
reduced (2+) form associat ing more strongly than the oxidized form. For Fe(phen)/+, no 
charge preference was found. Co(bpy)/+ and Fe(bpY)32+ bind via electrostatic interaction, 
where the oxidized (3+) form is bound more strongly. Fe(bpy)/+ displays a marked ionic 
strength dependence of its binding to DNA. No binding is observed in 50 mM NaCI, 
whereas Co(bpY)33+ binds moderately, under these conditions. 
26 
A group of 1 5  anthracy cl ine derivativ es has been compared (Berg et al., 
1 98 1 )  by p olarographic and coul om etric measurements in respect to the infl uence of their 
sugar residues. For the am ino sugar in position 10 of the D-ring (iremy cin) a reversibl e 
electron e change o f  the q uino ne gro up was found, whereas in position 7 (daunomy cin, 
adriamy cin) a reductiv e spl itting of the gly co idic bond tak es place (E .C .E .  mechanism) 
producing 7- d oxy-anthracy cl ino ne or the corresponding hy droq uinone. By this 
mechanism a v iolamy cin component (with sugars in position 7 and t o) is conv erted to 
iremy cin. Reoxidation of the hy droq uinones by oxy gen generates hy drogen peroxide, a 
reaction which is al so po sibl e in the organism. The binding affm ities to DNA hav e been 
compared from titration curves and binding isotherms, this is possibl e because the 
reduction of the q uino ne group intercalated between the bases is prev ented. Four groups 
can be roughly distinguished: 
(1) L ow binding: derivatives with neutral sugar (stefftmy cin) . 
(2 ) M edium binding: derivatives with one basic sugar (daunomy cin, adriamy cin, 
iremycin, carm inomy cin, I -deoxypyrromy cin). 
(3)  H igher binding: derivatives with one basic and one or more neutral sugars 
(aclacinomycin, macrel lomy cin) . 
(4) H ighest binding: derivatives with two basic sugars (violamy cines) . 
H owever, their cytostatic activ ities depend generally not only on the height of binding 
affinities but also on the influence of rates of dissociation of spl itting and of transport (to 
the DNA of the tumor), apart fr om l ow toxicity. 
The qu inobenzoxazine compounds deriv ed fr om antibacterial q uin ol ones, are 
active in vitro and in vivo against murine and hum an tum ors. In this contribu tion, (Kwok 
et af., 1 999) show that the relativ e  DNA binding affi nity of the q uinobenzoxazine 
compounds correlates with their cytotoxicity, their abil ity to inhibit gyrase-DNA compl ex 
formation and the decatenation of k inetoplast DNA by human topo isomerase I I .  DNA 
binding studies with the descarboxy-A-62176 anal ogue indicate that the �-keto acid 
moiety of the q uinobenzoxazine compounds play s an important rol e in their interaction 
with DNA. 
DNA gyrase supercoil s DNA in bacteria. The fact that it is essential in al l bacteria 
and absent fr om eukary otes makes it an ideal drug target. (Heddle et aI., 2000) discuss 
the action of coumar in and quinol one drugs on gyrase. In the case of coumarins, the drugs 
are known to be competitive inhibitors of the gyrase ATPase reaction. From a 
combination of structural and biochemical studies, the molecular details of the gyrase-
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coumarin complex are well established. In  the case of qu ino lones, the drugs are thought to 
act by stabi lising a c lea age comple between gyrase and DNA that arrests polymerases 
in vivo. The e act nature of the gyrase-quino lone-DNA complex is not known, they 
propo e a mode l for thi comple based on structural and biochemical data. 
Yeo et al., 2000, inve t igated the self-assoc iat ion and protonation state of 
norflo acm using el  ctric ab orption and potentiometric titrat ion. Both nitrogen at the 
piperazine ring and carboxylic acid were protonated at a low pH (cationic norfloxac in), 
and deprotonated at a h igh pH (anio nic norfloxac in). I n  the intermediate pH range, a 
neutral spec ies was dominant with the possibility of forming a zwitter ion. They also 
observed that norfloxac in mo lecu les can be stacked to form a d irner at an intermediate 
pH.  The equi l ibrium constant of the norfloxac in-DNA complex format ion, which was 
measured by Stem-Volmer method, increases as the pH of the system is lowered. This 
observat ion ind icates that it is the cat ionic norfloxacin t hat forms a complex with  DNA 
among various norfloxac in spec ies in aqueous solut ion. 
Thomas et al., 1 990, tried to determine whether 4-quinolone ant imicrobials were 
reduced under bio logical ly attainable redox conditions and whether they had any effect on 
DNA in the absence of the DNA gyrase enzyme. Electrochemical characterist ics of the 
drugs were invest igated using dc polarography, differential pulse polarography and cyc l ic 
vo ltammetry. The abi l ity o f  the drugs to interact with, and cause damage to naked DNA 
was invest igated by a <l>X 1 74 DNA double transfection essay. I nduction of DNA SOS 
repair was assessed using a strain of Escherichia coli in which the synthesis of p­
galactosidase was under t he contro l  of the su l A  gene. Growth studies were performed 
using a conductirnetric method in a Malthus system. Al l  five 4-quino lones examined had 
redox potentials lower (more negat ive) than - 1 .2V and thus were incapable of being 
reduced in biological systems, even under strict anaerobiosis. Exposure of all drugs to 
single-stranded <l>X 1 74 DNA for up to 50 h engenered no detectable damage. However, 
al l  the drugs induced DNA SOS repair, in the order ciprofloxacin > fleroxacin = 
pefloxacin > norfloxac in > nalidixic acid. This rank order corresponds approximately 
with antibacterial efficiency. The growth studies indicated that redoxyendonuc lease I I I  
and excision repair enzymes may be involved i n  t he fixat ion of quinolone-induced 
damage. 
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1 .5. Aim of the Pre eDt Work 
I mproving n w drug formulation is one of the most important subjects that human 
looked to it through his life. Whether by enhancement the drug stability and so lubi l ity or 
bioa ai labi l it . 
The abi l ity of cyc lodextrins to form inc lusion complexes with large variety of 
sub tances espec ially organic mo lecules in both solution and crystall ine state has 
promoted research to fmd appl icat ions for them in design of drug formulat ion. It has been 
found that cyclodextrin complexat ion improves the aqueous solubil ity, stability and 
consequent ly the bioavai labi l ity of many drugs that are poorly so luble in water. The 
bioavai labity of an orally administered drug is contro lled by its so lubi l ity and disso lution 
rate in the gastrointestinal fluid, and by the transfer rate of the dissolved drug through the 
absorption barrier into the blood. In addit ion, cyc lodextrin consists of glucose units so it 
has no harmful effects on human health. 
The fluorinated 4-quinolones are a group of orally act ive antimicrobials, which are 
active against a wide range o f  gram-negative organisms and gram-posit ive cocci. These 
compounds are essential ly zwitterions at physio logical pH and, therefore, in their lowest 
state of so lubil ity i .e .  they represent low solubi l ity in aqueous solut ions and, 
consequent ly, poor absorption from the intestinal tract. For that, the specific aims of this 
study are: 
1 - To propose new methods o f  analysis o f  Fluoroquinolones. 
2- To study their interactions with cyclodextrins. 
3- To study their interactions with DNA 
4- To study effect of CD complexation of their solubi l ity as a predictive measure of 
disso lution and bioavailabi l ity. 
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CHAPTER II 
Experimental 
E X P E R I M E NT A L  
2. 1 .  C hemica ls and Reage nts 
2. 1 . 1 .  Prepa ration of the inve t igated d rugs 
Nalid ixic Ac id (NAL) [ l -ethyl- l ,4-dihydro-7-methyl-4-oxo- l ,8- napht hyr id ine-
3 -carbox lie ac id) ,  c iprofloxac in (CI P) [ 1 -cyclopropyl-6- fluoro- l ,4-dihydro-4-oxo-7 -( 1 -
piperaziny 1)-3-quino l ine carboxy l ie ac id) and norfloxac in (NOR) [ 1 -ethyl-6-fluoro- l ,4-
dihydro-4-oxo-7-( I -piperazinyl)-3-quino l ine carboxylic ac id) were obtained from S igma 
and were used without further purification. The structures of the tested drugs are given in 
Fig. 2 . 1 .  Stock solut ion of NAL was prepared by disso lving an appropriate amount of 
NAL in 1 :  I ethanoVwater solution (or in methano l for interaction study), whi le stock 
so lut ions ofCIP  and NOR were prepared by d isso lving an appropriate amount of the drug 
in 1 O-3M HCl so lut ion. A series of standard solut ions of these compounds were prepared 
by di lut ing their stock solut ions. 
2. 1 .2. Preparation of DNA and Cyclodextrins solutions 
Calf thymus deoxyribonuc leic acid (ct-DNA), a-cyclodextrin and �-cyc lodextrin 
were obtained from S igma and were used without further purification. Stock solutions of 
DNA were prepared by d issolving an appropriate amount of the DNA in H20 and stored 
at 4°C. DNA concentration (per nucleotide phosphate, NP) was determined 
spectrophotometrical ly assuming £260 = 6600 M-1cm- 1 . Stock solutions of a- and �­
cyclodexterins were prepared by disso lving an appropriate amount of the cyclodextrin in 
water. 
2. 1 .3. B ritton-Robinson (BR) buffer solutions 
Britton-Robinson (BR) buffer (Britton, 1 952) is a universal buffer containing the 
pH range 2- 1 1  and used as supporting electrolyte. The BR buffer was prepared in the 
usual way by adding appropriate amount of 0.2 M sodium hydroxide to orthophosphoric 
acid, acetic acid and boric acid (0.04M in each). All  chemicals were reagent grade 
( Merck, Darmstadt). Twice-dist i l led water was used to prepare the solutions. The pH 
measurements were made by a Metrohm 632-pH meter accurate to ± 0.05 unit. 
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o 
N a l i d ixic Acid ( N AL ) 
C O O H  
o 
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C i p rofloxaci n  ( C I P )  
F ig . 2 . 1 .  Stru ctu res of the i n vestig ated co m pou nds 
3 1  
2 . 1 .4. Phosphate buffer solutions 
A serie of pho phate buffer covering the pH range 2- 1 1 was prepared in the usual 
way by adding appropriate amount of 1 .0 M orthophosphoric acid to 0. 1 25 M sodium 
phosphate (Bates, 1 954) .  
2. 1 .5. Acetate buffer olutions 
A seri s of acetate buffer covering the pH range 4-6 was prepared by disso lving a 
known amount of sodium acetate and acetic acid in a definite vo lume of twice dist i l led 
water. 
2. 1 .6. M etal salt solutions 
Stock solutions 1 x l  0-2 M of Co( I l )  Cu( I l )  Zn( I l ), Pb( I l ), Ni( I l ) ,  Cd(I I)  and Cr( I l l )  
were prepared from their analyt ical grade nitrate salts o r  chloride salts (BDH Chemicals) 
in twice dist i l led water. Diluted solutions of the above so lut ions were prepared by di lut ing 
the stock solut ion with double dist i l led water to the specific vo lume. 
2 . 1 .7. Tablet and suspension treatment for NAL 
Five tablets o f Negram, each containing 500 mg of NAL, were powdered and the 
amounts corresponding to 1 00 mg ofN AL were weighed and [ma l ly dissolved in ethano l 
for 1 5  min. The excipient was separated by fi ltration and the precipitate washed three 
times with ethano l .  The so lution and washing ethanol were transferred quantitatively into 
a calibrated flask and diluted to a final volume of 250-ml ( 1 :  1 ethanol/water mixture). An 
aliquot of 1 .0 ml of this solution was diluted to 1 0 .0 ml with ethano l to obtain the suitable 
[mal concentrat ion. An al iquot of this so lution was added to 1 0 .0 ml of BR buffer 
(PH=5 .0) and the vo ltarnmogram was recorded fol lowing the voltarnmetric procedure. 
On the other hand, 1 .0 ml of  Negram suspension, c laimed to contain 250 mg 
NAL per 5 . 0  ml suspension so lution, was dissolved in 1 00 ml 1 :  1 ethanol/water mixture. 
A smal l amount of nondisso lving excipients settled at the bottom of the flask. We 
transferred 1 .0 ml of  the c lear supernatant to a 1 0.0  ml  vo lumetric flask and di luted to 
mark with ethano l .  A 50 III portion was added to the vo ltarnmetric cel l  containing 
supporting e lectrolyte (BR buffer, pH 5 .0) and the voltammogram was recorded. The 
standard additions method was then appl ied, adding successive aliquots of 1 00 �l of 1 x 
1 0-4 M NAL solution. The concentrations of  the NAL in the investigated samples were 
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calculated from the mult i-step standard additions plots using the Kaleida Graph computer 
program version 3 .06. 
2 . 1 .8. Tablet treatment for CIP 
Fi  e tablet of Bacti flox-250, each containing 250 mg o f C I P, were powdered and 
the amount corresponding to 1 25 mg of CI P were weighed and fmal ly dissolved in 1 0-3 
M HCl during 1 5  min. The exc ipient was separated by filtration and the prec ipitate 
washed three times with 1 0-3 M HC!. The so lut ion and washing HCI  were transferred 
quant itat ively into a calibrated flask and di luted to fmal vo lume of 250 ml by 1 0-3 M HCl .  
An aliquot ( 1 .0 ml)  of this so lut ion was diluted to 1 0.0  ml with 1 0-3 M HCI to obtain the 
uitable fmal concentrat ion. An al iquot of trus so lut ion was added to 1 0 .0 ml of pbosphate 
buffer (pH =7.0) and the vo ltammogram was recorded fo llowing the vo ltammetric 
procedure. The standard additions method was then app l ied, adding successive aliquot of 
1 00 �l of 1 x 1 0-3 M crp so lution. The concentration of the crp in the investigated 
samples was calculated from the mult i-step standard addit ions p lots using the Kaleida 
Graph computer program. 
2 . 1 .9. Tablet treatment for NOR 
Five tablet ofNoroxin 400, each containing 400 mg of NOR, were powdered and 
the amounts corresponding to 400 mg of NOR were weighed and flllal ly disso lved in 1 0-3 
M Hel for 1 5  min. The excipient were separated by filtration and the precipitate washed 
three t imes with 1 0-3 M HC!. The so lution and washing HCI  were transferred 
quantitatively into a calibrated flask and diluted to final vo lume of 500 ml by 1 0-3 M HC!.  
We added 0.05 ml of  this solution to 1 0.0 ml of  phosphate buffer (PH = 1 1 .0) and the 
vo ltammogram was recorded fol lowing the vo ltammetric procedure. The standard 
additions method was then applied, adding successive aliquot of 1 00 �l of 1 x 1 0-5 M 
NOR solut ion. The concentration ofthe NOR in the investigated samples was calculated 
from the mult i-step standard additions p lots using the Kaleida Graph computer program 
2. 1 . 1 0. Urine and serum treatment 
Different vo lumes of urine or serum were added to BR buffer to give a total 
vo lume of 1 0.0 ml. When the vo lume of urine or serum increased, the background current 
increased rapidly, so to avoid the sample interferences di lut ion was carried out (9: 1 
buffer/sample mixture). In  this way the diluted sample produced a smooth curve without 
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any peak in the potent ial range from -0.4 V to - 1 . 5 V.  These di luted samples were used 
for oltamrnetry. 
2.2.  I nstru menta tion 
2.2. 1 .  Cyclic voltammetric measurements 
A Princeton ppl ied Research (P AR) model 264A polarographic and 
voltarnmetric ana lyzer, coupled with a PAR model 303A hanging mercury drop electrode 
(HMDE) were employed for cyc l ic vo ltammetric measurement . The conditions of 
measurement were hanging mercury drop electrode (HMDE) as a working e lectrode 
with area 0.052 cm2 versus Agi AgCI reference electrode and Pt wire counter electrode. 
Also, 1 00 mV/s scan rate, with variable deposit ion t ime and starting potential were used 
to invest igate the adsorbabi l ity of the tested drugs at the mercury electrode surface. The 
cyc l ic vo ltamrnograms were recorded on X- Y recorder RE 0 1 50 (PAR). 
2 .2 .2.  Differential pu lse stripping voltammetric measurements 
Different ial pulse stripping voltarnmetric (DPSV) measurements were carried out 
with a PAR model 264 vo ltarnmetric analyzer in conjuction with a PAR 303A HMDE 
and PAR 305 magnetic st irrer. In  DPSV the investigated drugs are preconcentrated into a 
hanging drop mercury e lectrode by stripping the deposited species back into solution by 
imposition of a potential step a pulse voltage ramp. The differential pulse mode is used 
because of its correction for the charging current and commercial availability. The 
amount of investigated drugs accumulated on the electrode surface in addition to the 
variables of  solut ion concentration and pH, is a lso affected by other variables such as 
deposit ion t ime accumulat ion potential and scan rate. I nstrument setting for differential 
pulse cathodic stripping vo ltammetry ( un less otherwise stated) were: scan rate 20 mV/s, 
pulse ampl itude 1 00 mY, pulsed appl ied at 0 .5  s intervals, deposition t ime 30-60 s (with 
stirring, unless otherwise stated). Voltammograms were recorded on an advanced X-Y 
recorder model RE 0 1 50 after automated deareation of the e lectro lysed so lution. 
2.2.3. Electrochemical cell 
A PAR cel l  equipped with hanging mercury drop (working e lectrode), Ag/AgCI 
(reference e lectrode) and Pt wire (counter electrode) were used for cycl ic and differential 
pulse cathodic stripping vo ltammetric measurements. The area of the hanging mercury 
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drop electrode was 5 .2 1 0-2 cm2 . N itrogen was bubbled through the so lut ion in the cel l  
for 1 6  min to remove oxygen and the corresponding vo ltammograms were recorded. 
Also nitrogen was bubbled through the so lution in the cel l  for 2-3 min after addit ion of 
the so lut ion of the tested compounds before recording the vo ltammetric curves. All  
measurement were performed at 20 ± 0.5 0c. 
2.3.  Optim i za tion of the experi menta l a nd i nstrume ntal pa ra mete rs 
2.3. 1 .  Influence of pH on DPSV determination of the investigated d rugs 
In  the vo ltammetric cel l, mix 2 ml o f  phosphate buffer at various pH (2- 1 1 )  with 8 
m!  water and then pass the purified nitrogen through the e lectrochemical cel l  for 1 6  min 
under st irred condit ions. Record the differential pulse adsorptive cathodic vo ltammetry of 
the background electrolyte at an accumulation potential of -0.4 V or -0.6 V vs. Ag/ AgCl,  
deposition t ime of 30 s,  20 mVs- 1 scan rate and pu lse ampl itude of 1 00 mY p p .  Under the 
experimental condit ions employed a so lut ion of 0.5 ml of the invest igated drug (4 x 1 0-4 
mollL or 1 x 1 0-3 mollL) was added and a stream o f  purified nitrogen was passed for 1 
min through the solut ion cel l  under st irred conditions. 
2.3.2. Influence of indifferent supporting electrolytes on the D PSV 
determ ination of the investigated d ru gs 
I n  separate experiments different supporting e lectrolytes (2 rnI) of phosphate 
buffer, Brittion-Robinson buffer and acetate buffer were mixed with 8 rnl of water in the 
e lectrochemical cel l .  The so lution in t he e lectrochemical cel l  was then purged with 
purified nitrogen for 1 6  min and the background vo ltammogram of each so lution at 
accumulat ion potential of -0.4 Y or -0.6 V vs. Ag/AgC� deposition t ime 30 s, 20 mYs- 1 
scan rate and 1 00 m V pp pulse amp l itude. Under the same experimental condit ions 
employed a so lution of 0.5 ml of tested drug (4 x 1 0-4 mollL or 1 x 1 0-3 mollL) was then 
p laced in the e lectrochemical cel l  and a stream of purified nitrogen was passed through 
the e lectrochemical cel l  under st irred condit ions. The vo ltammograms of the solutions 
were then measured at the above mentioned conditions. 
2.3.3. Influence of scan rate and pulse amplitude on DPSV determination of the 
investigated d rugs 
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In  the electrochemical ce l l  2 ml of  phosphate buffer, (PH 5 for NAL, pH 7 for crp 
and pH 1 1  for NOR) were mixed with 8 ml water. The solut ions were then purged with 
purified n itrogen for 1 6  min under stirred condit ions. The vo ltammogram of the 
background electrolyte was then recorded at variou scan rate ( 5-50 mVs- l ) and pulse 
ampl itude (25 - 1 00 mY). Following the same experimental cond it ions, a solution of 0.5 
ml of  the invest igated compounds (4 x 1 0-4 moVL or 1 x 1 0-3 moVL) was then introduced 
in the electrochemical ce l l  and a stream of purified nitrogen was passed for 1 min under 
st irred condit ions. Record the voltammogram of the solution at the same scan rate, pulse 
ampl itude, accumulat ion potent ial of -0.4 V or -0.6 V vs. Ag/ AgCI and deposit ion t ime of 
30 sec . 
2.3.4. Influence of accumu lation potential on the DPSV determination of the 
investigated drugs 
I n  the e lectrochemical cel l  mix 2 ml 0 f phosphate buffer, (PH 5 for N AL, pH 7 for 
CIP and pH 1 1  for NOR) with 8 ml water. Percolate purified nitrogen through the 
e lectrochemical cel l  for 1 6  min under stirred cond it ions. Record the voltammograrns of 
the background electrolyte at 30 s deposition time and various accumulation potential 
(from 0.0 to -0.6 V) vs. Ag/AgCI. Under the same experi mental cond it ions employed, a 
solution of 0.5 m1 of  the drugs under invest igat ion (4 x 1 0-4 moVL or 1 x 1 0-3 mollL) was 
then p laced in t he e lectrochemical cell and a stream of purified nitrogen was then passed 
through the electrochemical cel l  for 1 min under stirred conditions. Record the 
vo ltammograrns at 30 s, pulse ampl itude of 1 00 mY, 20 mVs- 1 scan rate at various 
accumulation potential. 
2 .3.5. Influence of deposition time on the DPSV determination of the investigated 
drugs 
Under the preVIOUS optimum experimental cond it ions of pulse amplitude, scan 
rate and accumulation potential mix  2 rnl of phosphate buffer, (PH 5 for NAL, pH 7 for 
CIP and pH 1 1  for NOR) with 8 rnl water in voltarnmetric cel l. Purified nitrogen gas was 
then purged through the solution  cell for 1 6  min u nder st irred cond it ions. Record the 
voltammogram of the background e lectrolyte at various depositions t imes (0-300 s) at t he 
opt imum scan rate and accumulat ion t ime. Repeat t he same experimental after p lacing 0.5 
ml of  the tested compounds (4 x 1 0-4 moVL or 1 x 1 0-3 moVL) in t he e lectrochemical cell 
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and passmg a stream of purified nitrogen for I mm through the cell under st irred 
condit ions. Record the vo ltarnrnograms of the so lution at each deposition t ime. 
2.3.6. Influence of divers ions on the OPSV determination of the investigated d ru gs 
The interference of  various ions, e.g. copper( I I ), lead( U ), zinc( I I ), cadmium( I I ), 
nickel( I I )  and chromium( I I I )  i ns at a 1 0 : 1 ( interferent : analyte) approximately exceed ing 
tho e normally found in bio logical fluids was crit ical ly invest igated on the DPSV 
detemlinat ion of the invest igated drugs. In the voltammetric cell 2 ml of Britton­
Robinson buffer at pH 5 for NAL or phosphate buffer at pH 7 for CI P or at pH 1 1  for 
NOR were mixed with 8 ml o f  water. To this so lution exact ly add 0 .5 ml of  the tested 
drug (4 x 1 0-4 mollL or 1 x 1 0-3 mollL) and record the voltammogrm after purging 
purified nitrogen for 1 6  min under st irred condit ion at the optimum condit ions of 
deposition t ime, pu lse ampl itude, accumulation potential and scan rate. Repeat the same 
experimental cond it ions in the presence of  each of  the added metal ion separately and 
record the vo ltarnrnograms. 
2.3.7. Application of DPSV in the determination of the investigated d rugs 
2.3.7. 1 .  Analysis of NAL in tablet, suspension, serum and urine 
I n  the voltammetric cel l, 2 ml of  Britton-Robinson buffer of  pH 5 was mixed with 
ml of 0.5 M NaNO) and 7 ml water. The cell so lution was then purged with dry 
nitrogen for 1 6  min under stirred condit ions and the voltarnrnogram o fthe background 
e lectrolyte was then measured at �.4 V vs. Ag/AgC I, deposit ion t ime o f 60 s, 20 mVs-J 
scan rate and 1 00 mV pp pulse amplitude. To this solut ion, 0.6 ml of  so lut ion sample of 
NAL tablet or suspension was spiked into the e lectrochemical cel l .  The so lution was then 
purged with dry nitrogen and the vo ltarnmogram for the unknown solution was then 
measured under the same experimental condit ions of the background e lectrolyte. The 
[mal drug concentration was then obtained from the mult i-step standard additions p lots 
using the Kaleida Graph computer program. Under the same above condit ions 2 ml of  
Britton-Robinson buffer of pH 5 was mixed with 1 ml o f  0 .5  M NaNO) and 1 ml o f  serum 
or urine then di luted to 1 0  ml with water for the detemlination of NAL in serum or in 
urine. This cell so lution was also purged with dry nitrogen for 1 6  min under stirred 
condit ions and the vo ltammogram o f  the background e lectrolyte was then recorded under 
these condit ions. The determination o fNAL concentration was obtained from the multi­
step standard addit ions p lots using the Kaleida Graph computer program. 
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2.3.7.2. Analy i of C I P  in tablet 
I n  the voltammetric cell, 2 ml of phosphate buffer of pH 7 was mixed with 1 m1 of 
0.5 M aNO) and 7 ml water. The cel l  so lut ion was then purged with dry nitrogen for 1 6  
min under st irred condit ions and the vo ltammogran1 of the background electrolyte was 
then measured at -0.4 V v . AglAgCl, deposition t ime o f 60 s, 20 mVs- 1 scan rate and 1 00 
mV pp pulse ampl itude. To this so lut ion, 0. 1 m1 of sample solution ofCIP  tablet was 
spiked into the e lectrochemical cel l .  The solut ion was then purged with dry nitrogen and 
the voltammogran1 for the unknown so lut ion was then measured under the same 
experimental condit ions of  the background electrolyte. The final drug concentration was 
obtained from the mult i-step standard addit ions plots using the Kaleida Graph computer 
progran1. 
2.3.7.3. Analysis of NOR in tablet 
2 ml of phosphate buffer of pH 1 1  was mixed with 1 ml of 0 .5  M NaCI04 and 7 
ml  water in the vo ltammetric cell .  The cell so lut ion was then purged with dry nitrogen for 
1 6  min under st irred condit ions and the vo ltammogram of  the background electrolyte was 
then measured at -D.6 V vs. AglAgCL deposition t ime o f 30 s, 20 mVs- 1 scan rate and 1 00 
mV pp pulse ampl itude. To this so lut ion, 0.05 ml o f  sample solution NOR tablet was 
spiked into the e lectrochemical cel l. The solut ion was then purged with dry nitrogen and 
the voltammogram for the unknown so lut ion was then measured under the same 
experimental conditions of  the background e lectrolyte_ The [mal drug concentration was 
obtained from the mult i-step standard addit ions p lots using the Kaleida Graph computer 
program. 
2.4.  Sol ubi li ty meas ure m ents 
An excess amount of  investigated drug was added into the aqueous solutions 
containing increasing amount of P-CD solution (0 - 9 x 1 0-3 M). The mixture was shaken 
in water bath for 2 h at 3 1 00K and then agitated for further 70 h at room temperature 
(25±O.5°C) unti l  the equil ibrium state was reached. The suspensions were filtered through 
filter paper (0.45 /-lm) and the concentration of invest igated drug in the fI ltrate was assayed 
spectrophotometrical ly at 257 run and 270 run for NAL and NOR, respectively. There was 
no interference from CD at this wavelength. All experiments were carried out at the 
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ambient temperature (25.0 ± 0.5  °C). The so lubi l ity values are the average of the three 
replicates. 
2.5. Spectrophotometric m eas u re m e n ts 
The ultravio let and visible absorption spectra were obtained using a Shimadzu 
UV-2 1 0 1  PC; UV-Vis canning spectrophotometer ( himadzu, Kyoto, Japan) using 
matched quartz cuvettes of 1 0  cm pathlength. 
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CHAPTER III 
Determination of Nalidixic acid and its 
interaction with DNA and Cyclodextrins 
D E T E R M I N AT I O N  O F  N A L I D I X I C  AC I D  A N D  I TS I NT E RACT I O N  
W I T H  D N A  A N D  C Y C L O D E XT R I NS 
3. 1 .  Cycl ic Volta m metric behavior of Adsorbed N A L  
The nature o f  the electrochemical process o f  NAL was stud ied by cyc l ic 
o ltammetry (CV). The cycl ic vo ltammetric behavior of 1 .9 x 1 0-5 M NAL at pH 5 .0  ( BR 
buffer) is represented in Fig. 3 . 1 ,  which shows two reduction processes, the flrst process 
( 1  C) being reversible fo l lowed by irreversible process (2C). The main process (2C) is 
due to the reduction of the carbonyl group (>C=O) on C4 to the 4-hydroxy product. The 
peak potential display a cathodic shift on increasing the scan rate (v) (Fig. 3 .2), thus 
reveal ing the irreversible nature of the second reduction process (2C) (Delahy, 1 953). 
Moreover the slope of the log ip vs. log v plot in the range 1 0-200 mV S- I was 0.75 1 (r 
=0.99 1 )  c lose to 1 ,  which is the expected slope for an ideal reduct ion of adsorbed 
(surface) species (Laviron, 1 980). So in this case the process appears to have an 
important adsorption component . 
This result indicates that the N AL molecules are strongly adsorbed and 
accumulated at the mercury e lectrode surface. The adsorption of NAL on the HMDE can, 
consequently, be used as an effective preconcentration step before quantitative 
measurements are undertaken. Owing to its better analytical characteristics, the 
vo ltammetric technique used in the stripping step was the differential pulse stripping 
voltammetry (DPSV). 
3.2. Differential  p u lse strippi ng volta m metry (DPSV) of NAL 
3.2. 1 .  Dependence of (DPSV) peak of NAL on pH 
The DPSV current of 1 .9 x 1 0-5 M NAL was recorded as a function of potential in 
phosphate buffer solut ions of varying pH (2-9) (F ig. 3 . 3 ). Reduction of NAL at the 
H MDE was found to be pH dependent. The recorded DPSV peaks at various pH values 
are mainly due to 2e-12W reduction of the pyridone moiety (C5I-LtNO) of NAL as 
discussed before (Fig. 3 . 1 ). I t  was also found that the peak potential is shifted to more 
negative values with increasing pH and the peak height decreases markedly at pH � 7.0. 
The reduction peak becomes broad and splitted into two consecutive smal l  overlapped 
peaks at pH � 7.0 (F ig. 3 . 3  curves 3 and 4). The reduction peak at ca. - 1 90 mV (PH 5 .0), 
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ha been reported pre iously for similar compounds ( I b rahim, 2000) and it was 
attributed to the reduction of Hg( I I )  bound to the adsorbed Hg( I I )-NAL film through the 
heterocyc l ic nitrogen atoms, N8.  Furthermore, the effect of buffer constituents on the 
ad orpt ive tripping re ponse was also studied in the presence of everal supporting 
bu f er electrolytes, e.g. acetate, phosphate and BR buffers. The best results with respect to 
enhancement, shape and reproducibi l ity were obtained in BR buffer so lution. Hence, BR 
buffer (pH =5 .0) has been recommended for a l l  DPSV measurements. 
3.2.2. Effect of anions of the supporting electrolytes on the DPSV peak of NAL 
The influence of various anions of an  ind ifferent supporting electrolytes ( such as 
03", sol", Cl04 ", r and Cr) on the DPSV peak of the adsorbed NAL film was 
invest igated (F ig. 3 .4) .  The result indicate that the cathodic reduct ion peak decreases in 
the order N03" � CI04" > solo > cr > I ". The mai n difference is connected with 
structural changes in the electrical double layer due to the spec ific adsorption of the 
anions of the supporting electrolyte. In this case the e lectrostatical ly attracted ions of the 
solvent repel the adsorbed mo lecu les from the e lectrode surface and decrease the forces 
of non-electrostatic adsorption of  N AL mo lecu les at a charged interface. On the other 
hand, a more sensit ive peak: was found in the presence ofN03", however in presence of 
hal ide anions (er or r) the height of  t he peak decreases markedly. This indicates that 
N03- exhibits the smallest tendency for specific adsorption anion and less e lectrostatic 
forces on the charged mercury surface. This reflects the rule of anions of indifferent 
supporting e lectrolytes on the degree of adsorption and accumulat ion of NAL film at the 
charged interface ( Ibrahim, 1 995). 
3.2.3. Effect of operational para meters on the DPSV peak of NAL 
In order to select the optimum operating condit ions for determination ofNAL at 
pH=5 .0, the effect of scan rate, starting potential ,  adsorption t ime and pulse ampl itude 
were careful ly investigated. 
(i) Effect of scan rate on the DPSV peak of NAL 
The DPSV of 1 .9x l O-5 M NAL was invest igated at different scan rates (v, mY S- I )  
at p H  5 and 1 00 m Y  pulse ampl itude (Fig. 3 . 5) .  I t  was found that ip value at 2 0  mY S- I is 
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more harp and suitable than at 5 or 1 0  mV S- I .  Therefore 20 mV s- t scan rate was 
e lected for the analyt ical determinat ion of NAL. 
( i i )  Effect of precoDcentration potentials on the DPSV peak of NAL 
The dependence of the height of the DPSV peak ofNAL on the preconcentration 
potential was tudied at pH 5.0 in the potential range from 0.0 V to - 1 .0  V (Fig. 3 .6). In 
thi potential range, the peak current proved to be independent of the accumulat ion 
potential. The latter behavior reflects that the NAL (pKa=5 .99) species accumulated on 
the mercury electrode surface in a neutral form. An accumulat ion potential of -D.4 V was 
chosen for the stripping analysis procedures. 
( i i i )  Effect of preconcentration time on the DPSV peak of NAL 
As expected, the extent of pre concentration is a function of the accumulation t ime 
(t , ec). Fig. 3 . 7  shows the dependence of accumulat ion t ime on the stripping 
vo ltarnmetric response of N AL.  The peak currents increase l inearly with increasing 
preconcentration t ime. It was a lso observed that when the accumulation t ime are 
increased saturation is reached. A pre-electro lysis t ime of 1 20 s was adopted for the 
stripping analysis ofNAL .  
( iv) Effect o f  pulse amplitude a n d  other instrumental parameters o n  the DPSV 
peak of NAL 
The effect of the pulse ampl itude on height of the DPSV peak was studied at pH 5 
(F ig. 3 .8) .  The dependency o f  t he peak height (ip, �) on the pulse amplitude (25- 1 00 
mY) indicates that the more sensitive reduction peak ofNAL was recorded at 1 00 mV 
pulse ampl itude. The peak currents ofNAL are p lotted against pulse amplitudes. The p lot 
is l inear up to ampl itude of 1 00 m V.  The analyt ical determination was performed at 1 00 
mV pulse amplitude. Other instrumental parameters, such as drop size (F ig.  3 . 9) and 
pulse repetition t ime ( Fig. 3 . 1 0), which direct ly affected the voltarnmetric response, were 
optimized. The selected working conditions were 5 .2 x 1 0-3 cm2 ( medium size, M) and 
0 .5  s pulse repetit ion t ime, respectively. 
3.2.4. Quantitative trace determination of NAL in the model samples 
According to the aforement ioned results, the optimum condit ions for the 
analytical determination of NAL by DPSV at H MDE are the fo l lowing: BR buffer 
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(PH=5 .0 in presence of N 3 ·), 1 00 mY pulse ampl itude, 20 mY S·I scan rate, 1 20 s 
accumulat ion t ime and -0.4 Y accumulation potent ial. Under these condit ions the 
re ponse of th peak height as a funct ion of NAL concentration is l inear ( Fig. 3 . 1 1 ) over 
the range 2.9 x 1 0-8 - 2 .5  X 1 0-5 M NAL. The regression coefficient square ( R2) and the 
detection l imit were found to be 0.998 and 0. 766 ng rnI- 1 ( 3 . 3  x 1 0-9 M),  respectively. The 
prec i Ion was determined from 5 repeated measurements of the reduction peak height of 
1 .0 1 0-7 M NAL. The percentage relative error was � 1 .2% and the percentage relat ive 
standard deviat ion (%RSD) was 5 .2%. 
3.2.5. I n terference study 
A systematic study was carried out to evaluate the potential effect of  coexist ing 
metal ions capable of forming complexes with NAL or deposit ing at the mercury 
electrode on the determination of NAL at 1 .9 x 1 0-5 M (4 .4 1 )lglrnl) level .  Serious 
interfering effects were observed in the presence of Cr( I l I )  and Co(Il), since the reduction 
potentials of both metal ions are very c lose to that of the tested compound. Tolerance was 
defined as the amount of  foreign spec ies that produced an error not exceeding ± 5% in the 
detennination of the analyte. Table 3 . 1  and Figures. 3 . 1 2  - 3 . 1 7  show the results obtained. 
3.3. A n a lytica l appl ication 
3.3. 1 .  Analysis of pharmaceutical samples 
A tablet of the commercial pharmaceutical Negram with a nal idixic acid label 
content of  500 mg was prepared according to the procedure previously described under 
experimental part (sections 2 . 1 . 7 and 2 .3 . 7) .  The proposed method was successfu l ly 
app lied to the assay o fNAL in commercial tablets and the results obtained are shown in 
Table 3 .2 and Fig. 3 . 1 8 . The amount ofNAL in Negram tablets in  the cel l  was determined 
by the standard additions method, to avoid matrix effects, at two different levels of  
concentration. The mean recoveries for the different concentrations were 99.0-99.2% with 
RSDs of 3 .9 1 and 3 . 7% (n = 5) .  
The DPSY determination of  NAL in Negram suspension also carried out by the 
standard addit ions method (Fig. 3 . 1 9) .  A mean value o f 25 .4  ± 0.42 )lg was obtained, in 
good agreement with the declared value of 25 )lg. The mean recovery was 1 0 1 .6% (Table 
3 .2) .  The RSD was 3 .32  (n = 5) for a significance level o f  0 .05.  The mean value of the 
contents in the Negram tablets or suspension is in good agreement with the reported 
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methods for similar compounds (Tamer, 1 990), so the proposed method is recommended 
for NAL determination in tablets or u pension. 
3.3.2. NAL determination in urine 
Appl icat ion of el ctroanalyt ical methods directly on analytes present in 
physio logical matrice such as urine or blood serum without any preliminary treatment 
are more intere ting. The determination of NAL in human urine and blood serum was 
chosen as a pract ical example. Adsorptive stripping vo ltarnmogram of a di luted urine 
sample (9 :  1 BR buffer/urine mixture) which no NAL had been added, is shown in (Fig. 
3 .20 curve 0). The influence of the concentration of NAL added to urine was studied. It 
was found that at - 1 .26 V, NAL displayed a concentrat ion-sensit ive peak height. A linear 
relationship between the peak current and the concentration o f  NAL in urine was 
obtained. Resu lts obtained for the determinat ion ofNAL in urine samples are presented in 
Table 3 . 3 .  Detection l imit of23 .2  ng mI- l ( 1 .0 x 1 0-7 M) NAL was calculated based on a 
signal-to-noise ratio of 3 .  The RSD was 4. 1 %. A c lear decrease in the s lope of the 
calibrat ion graph is observed, when comparing with those obtained for the NAL standard 
solutions, which indicates the existence of a matrix effect .  
3.3.3. NAL determination i n  seru m 
The proposed method was also successful ly  appl ied to the determination ofNAL 
in serum samples and the results obtained are shown in Table 3 .3 ,  F ig. 3 . 2 1  and Fig. 3 .22. 
In  this way, the d iluted serum sample (9. 5 :  0.5 B R  buffer/serum mixture) produced a 
smooth curve without any peak in the potential region of the second peak (2C). However, 
when the NAL was added to serum, a concentration-sensitive peak height was observed at 
- 1 .28 V .  The peak height under these condit ions varied l inearly with the concentration of 
NAL and the values of the regression coefficients ( R) are computed and assembled 
together with the straight l ine constant (Table 3 .3 ) .  Detection l imit of 20.2 ng ml- l (8 .7  x 
1 0-8 M) NAL was calculated based on a sIn = 3 .  The RSD was 3 . 2%. The percentage 
recovery o f  NAL was determined by comparing the peak currents of known drugs 
concentration in urine and serum with their equivalents in aqueous solution. Mean 
recoveries of the different NAL concentration in urine and serum were found to be 98.8 ± 
0.3% and 98.9 ± 0.4 1 %, respectively. 
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The stripping o ltammetric determinat ion of NAL ill pharmaceuticals human 
urine and serum was publ ished by u ( I brahim, 2002). 
3.4. Volta m m etric stud ies of the i nteraction of na l i d i xic acid with D N A  
The interaction of NAL with DNA was invest igated by cyc l ic vo ltammetry and 
differential pu lse stripping o ltammetry. These techniques are sensit ive electrochemical 
methods and p rmit the col lect ion of excel lent data at lower concentration of e lectroactive 
gue t .  
The changes in CY peak currents of NAL in the presence of  DNA are shown in 
F ig. 3 .23 .  The pure DNA is e lectrochemical ly inactive in the potent ial range from 0.0 Y 
to - 1 .4 Y (vs. Ag/AgCI) at the HMDE. The addition of  an excess of  ON A in NAL 
so lut ion caused the peak currents to d iminish considerably. The peak current decreased to 
about 67% of  that in the absence of ON A. In  terms of this result, it seems that binding of 
NAL to the large, s lowly diffusing DNA, causes the decrease in the peak current of the 
NAL ill the presence of an excess of ON A, which results in the considerable decrease in 
the apparent diffusion coefficient of the NAL-DNA adduct. 
The peak currents of the reduction wave at - 1 .20 V of NAL (PH 5 .0) in the 
absence and presence of excess DNA were separately examined as a funct ion of the scan 
rate at the HMDE. Experimental p lots of ipc vs v\12 for NAL and NAL-DNA adduct are 
shown in Fig. 3 .23C. The peak currents obtained for NAL and N AL-DNA adduct show 
l inear dependence on the square root o f  scan rate (v'/,) up to 500 mv s- ' , indicating 
diffu sional mass transport of the e lectroactive species to the HMDE surface at lower scan 
rate. Furthermore, the slope of the l inear of ipc versus v\12 without DNA ( l 0 .4 nAlmy 'l2 s­
II) was more than that with DNA (6.03 nAlmy 'l2 s-\I2) ,  suggesting the d iffusion coefficient 
of the free form o f N AL (D = 5 . 1 9  x 1 0� cm2 s- ' ) was larger than that of the complexed 
form ofNAL with 8 x 1 0-3 M DNA (D = 1 . 74 x 1 0� cm2 s- ' ) .  On the other hand, CY peak 
potentials were independent of scan rate, v, over the range 1 0-500 mV s- ' . 
Further evidence for the interaction of  NAL with DNA comes from the 
differential pulse stripping vo ltamrnetry (DPSV). The interaction ofNAL with DNA can 
be described using the fo l lowing equation: 
NAL + DNA �.=== •. NAL-DNA 
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Based on the variation ill the peak current (Fig. 3 .24), the formation constants of the 
comple formed between NAL and DNA were determined . For 1 : 1  complex the 
fo l lowing equat ion could be deduced based on Feog et al. , 1 997. 
l /CDNA = Kc ( I -N ( l -ilio) )  - Kc ------ - -------- ( 1 )  
wher , D A IS the concentration of  ON A, Kf is the apparent formation constant, io and i 
are the peak current without and with 0 A. A i the proportional constant . 
ccording to the decrease of peak currents with the concentrations of DNA (Fig. 
3 .24) and Eq.( l )  the fo l lowing equat ion was obtained: 
l ICD A= [ 1 .67 x 1 0  5 I ( l - ilio) ] - 1 .864 x 1 0  5 with a l inear correlation coefficient (R) of 
0.976, reveal ing that the binding complex of NAL mo lecule with DNA (per nucleotide 
phosphate) was a 1 :  1 association complex. The binding constant ofNAL to DNA was 
calcu lated from the y- intercept to be 1 . 84 X 1 0 5 M-I ,  as shown in Fig. 3 .24B. 
3.5. B i n d i ng of the N a l id ixic acid with cyclodextrins 
For studying the associat ion of NAL with CDs, the change in a physicochemical 
property o f  the drug (such as so lubi l ity, absorbance, and the e lectrochemical behavior) 
was fo l lowed as a funct ion of cyclodextrin concentration by fixing the pH ofthe 5%(v/v) 
methano l-water solution. 
3.5. 1 .  Solubility studies 
Fig. 3 .25  shows the phase solubi l ity d iagram of NAL in aqueous solut ion in 
presence of different concentrations of �-CD. The solubi l ity of NAL increased in an 
approximately l inear manner as a function o f  the �-CD concentrat ion. This would lead to 
the conc lusion that soluble complex having 1 :  1 stoichiometry was found with �-CD, i .e., 
AL-type so lubi l ity diagram according to H iguchi and Connors, 1 965. Also, it was 
assumed t hat the formation of  a complex with stoichiometry 1 :  1 because the straight l ine 
had a s lope less than unity (De I larduya et aL, 1 998). I n  aqueous solutions ofNAL-�-CO 
complex, the free drug molecules are in equil ibrium with the drug mo lecules entrapped 
within the cavity. Thus, on increasing the concentration o f  �-CD more NAL molecules 
wil l  transfer from the aqueous solution to the hydrophobic cavity of �-CO. Therefore, one 
can expect that more NAL dissolved in water in the presence of �-CD than that disso lved 
in absence of  it and consequently, the so lubil ity o fNAL increases with increasing the 
concentration o f  �-CD. 
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The apparent stabi l ity constant ( logK = 3) of the formed complex was calculated 
from the o lubility diagram according to equation (2) 
K = slope / So ( 1  - slope) --------------- (2) 
u mg the slope of the phase o lubi lity diagram and the determined NAL so lubi lity in 
water for o· The obtained olubi l ity of NAL (So) in aqueous solution is in a fair 
agreement with the literature values (Ross and Riley, 1 990; Staroscik and SuLkowska, 
1 97 1 ) . 
The Gibbs free energies of transfer of NAL from aqueous so lut ion to the cavity of  
P-CD (Table 3 . 4) have been calculated from the fo l lowing equation 
LltransGo = -RT In (S / So) -- ------------- (3) 
where and So are the solubi lit ies ofNAL in presence and absence of p-CD. As can be 
een from Table 3 .4, the LltransGo values are negative and increase negat ively with 
increasing P-CD concentration. This indicates that the transfer process is spontaneous and 
support the iew that P-CD is more favorable environment than water for NAL. 
Moreover, the interaction between NAL and P-CD increases with increasing P-CD 
content. 
3.5.2. Spectroscopic studies 
Complex formation between NAL and CDs was studied using the spectral shift 
method in 5%(v/v) methanol-water mixture at pH = 5 (phosphate buffer). The absorption 
spectra of  5 x 1 0-5 M NAL in phosphate buffer exhibited three dist inct absorption bands 
at 2 1 8, 257 and 323 nrn. Some important changes in the absorption spectra ofNAL at 
257 nm (Fig. 3 .26) were observed upon the addition of a-, and p-CD. As can be seen in 
Fig. 3 .26, for NAL-a-CD and NAL-P-CD systems, the addition of the host molecu le 
results in an increase in the absorbance intensity, but does not cause a shift in "'max. 
S imi lar attitude is obtained for a hepatoprotectant drug thioctic acid-p-CD system 
(Juquera and Aicart, 1 999), as wel l  as for anthracene, phenothiazine and thianthren-p­
CD systems (Dang et aL, 1 998). As a-CD or P-CD shows no absorption above 220 run, 
we can reasonably attribute these variations, primari ly, to the formation of the inclusion  
complexes ofNAL-CD systems. These c hanges in  the absorbance values are supposed to 
result from changes in the so lvent micro-environment upon inc lusion of the solute. The 
changes observed in molar absorbance values may result from the loss of hydrogen 
bonding accompanying the transfer of the guest molecule from the solut ion to the 
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cyc lodextrin ca ity. This is reasonable from the fact that there are no proton donating 
group inside the ca ity of the yclodextrin mo lecule. 
However, the maximum change in absorbance (Mmax ::::: 0.2) was so small thereby 
the as oc iat ion constant KcD-NAL could not be determined accurately by fitting the 
experimental data to the well known UV binding isotherm (Connors, 1 987). This feature 
indicates that UV spectroscopy is not ensit ive enough to study the CD-NAL system, or 
any other ystern, where the presence of CD does not result in a c lear change in the 
spectroscopic propertie of  the drug. Simi lar conc lusion is obtained for �-CD-thioctic acid 
ystem (Juquera and Aicart, 1 999), as well as for other CD-substrate systems ( Kano et 
a/. , 1 992; Cotta-Ramusino et a/. , 1 993). 
3.5.3. Voltammetric studies 
( i) Cyclic voltammetry 
The nature of the electrochemical process ofNAL in the absence and presence of 
various host molecules was investigated by cyc lic vo ltammetry (CV). As we discussed 
before the cyc l ic vo ltammogram of free NAL ( 1 .9 x 1 0-5 M) in BR buffer is in (Fig. 3 . 1 )  
shows two reduction processes. The first process ( 1  C) being reversible, fo l lowed by 
irreversible process (2C). The main process (2C) is found to be more concentration 
sensit ive. We are interested in the most sensit ive signal (2C) for fo l lowing studies and for 
titrations with cyclodextrins. The cyc lic vo ltammograms of NAL in the absence and 
presence of a-CD, as a representative example, was recorded as a function of potential in 
phosphate buffer of  varying pH (2-7), to elucidate the optimum pH for studying the 
interaction of  N AL with different hosts ( Fig. 3 .27 A-C). In  the presence of the host 
molecule the peak potentials as wel l  as the peak currents ofNAL are modified. As it is 
appeared in F ig .  3 .27, the peak current (2C) decreased to Ca. 53%, 70% and 43% (curve 2)  
of those in the absence of a-CD (curve 1 )  for pH 2, 5 and 7,  respectively. This behavior 
suggests that the neutral NAL species (PKa = 5 .99) are more strongly interacted with 
cyc lodextrins. On the other hand, the broading of the CV peak ( 1  C) in absence of a-CD 
(curve 1 Fig. 3 . 27) and its appearance as a needle- like peak in presence of a-CD (curve 2 
Fig. 3 .27), are probably due to the morphology of the adsorbed film on the HMDE surface.  
As shown previously ( Ibrahim, 1 995), the broad peak reflects a flat orientation ofthe 
adsorbed NAL species at the electrode surface; however, the needle-l ike peak points to a 
vertical ly oriented of the adsorbed NAL-a-CD complex. These results indicate that the 
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comple ation of the NAL mo lecule enhances the stacking interactions and hence would 
be e pected to fac i l itate the format ion of a perpendicularly stacked layer ofNAL-a-C D 
complex on the electrode urface. 
Furthermore, the effect of buffer const ituents on the binding affmity of NAL to 
o wa al 0 studied at pH 5 in the presence of several supporting buffer electrolytes, 
e .g . ,  acetate, phosphate, and BR buffers ( Fig. 3 .28) .  The best results with respect of 
shape and reproduc ibi l ity, as well as the enhancement of host-guest interact ion were 
obtained in phosphate buffer so lut ion. Hence, the phosphate buffer (pH 5) was 
considered optimum and used throughout the work of interaction of NAL with 
cyclodextrins. 
The effect of scan rate, v, on the NAL process (2C) at the HMDE, in absence and 
pre ence of host molecules was examined ( Fig. 3 .29). Experimental plots of ip vs. v "2 for 
NAL, AL-a-CD, and NAL-P-CD adducts show linear dependence on the square root of 
the scan rate, indicat ing diffusional mass transport of the e lectroactive species to the 
HMDE surface (Bard and Faulkner, 1 980). By l inear regression of the data, the 
fo l lowing equat ions are obtained : 
ip (nA) = 1 3 .6 + l OA y l l2 (R = 0.987) 
ip (nA) = -6.25 + 6.43 v lf2 ( R  = 0.999) 
ip (oA) = -3 .62 + 4 . 29 y ll2 ( R  = 0.999) - - - - - - - -------- (4) 
for NAL and NAL-P-CD and NAL-a-CD, respectively. Therefore, the slope of the l inear 
ip_v lf2 plot is d iminished markedly to about 55% and 44% in presence of P-CD and a-CD, 
respect ively, of that in the absence of host molecule. In terms of these results, the 
decrease of the peak currents in presence of various host molecules can be attributed to 
the decrease in the apparent d iffusion coefficients of NAL-host adducts. From these 
slopes, the diffusion coefficient, Dr, of the free NAL was found to be 5 . 1 9  x 1 0� cm2 S-I , 
whereas, Db = 1 .98 x 1 O� and l . 56 x 1 O� cm2 S-I for the bound NAL in presence of 1 . 7 x 
1 0-3 M P-CD and 1 .9 x l  0-3 M a-CD, respectively. These values are in good agreement 
with those previously reported for the reduction of other species due to the association 
with DNA (Carter et aL, 1 989) or with micel lar assembles (Kaifer and Bard, 1 985; 
McIntire et aL, 1 982). In princ iple, the formation of a substrate-micel le aggregate is 
expected to increase the effective rad ius of the substrate by a factor of about 4, which 
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explain the observed changes in diffusion coefficients (Kaifer and Bard, 1 985). The 
peak current could be a lso reduced if the host mo lecule caused an inc rea e in the viscosity 
of the so lut ion r ult ing in a decrease in the diffusion coefficient. But, no change in 
solut ion i cosity could be detected over the concentration range used for the host 
mo lecu les. Therefore, the decrea e of  the peal current detectable upon the addition of the 
ho t i obviously due to the lower diffusion coefficient of the bulky inc lusion complexes 
compared to that of the free NAL .  
( i i) Differential pulse stripping voltam metry 
Further evidence for the strong interaction of NAL with the asymmetric 
en ironment of CD cavity was obtained from DPSV. The recorded DPS voltarnrnograms 
of  5 x 1 0-{) M NAL in phosphate buffer (pH 5) exhibited two cathodic peaks at potential -
0. 1 90 and - l . 1 25 V corresponding to peaks 1 C and 2C obtained by CV. In  the presence 
of  different concentrations of  P-CD or a-CD, the so lution of NAL yields simi lar 
e lectrochemical behavior as the free guest, but the cathodic peak (2C) potentials as wel l  
as the peak currents are considerably influenced ( Fig. 3 .30). The cathodic peak potentials 
are s l ight ly shifted to the more negat ive potentials. This reveals that the NAL is more 
difficult to reduce in the presence of P-CD or a-CD as a result of entering hydrophobic 
cavity with lower po larity relat ive to the bulk solution. Also, the peak current is 
diminished due to the decrease of  the diffusion coefficients of  the host-guest associates 
compared to that of the free guest as discussed above. 
The decrease in peak current (2C) enable us to calculate the formation constant of 
the complexes formed between NAL and the studied host molecules to explain the degree 
of  the complexes formed. Therefore, the K values could be calculated from the fol lowing 
equation, as explained in  our previous work (Shehatta and Ibrah im, 200 1 ). 
1 1 
------- = ---------- + ---------------- ---------------- (5) 
K( 1 - C) [H]  
where ia and i are the peak currents of  the free NAL and that in presence of  CDs; [H] is 
the concentration of  C Ds and C is the proportional constant. According to this equation, 
on plotting (ia / ia - l) VS. 1 /[H] p lot, the ratio of the intercept to the s lope gives the value 
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of K. The plots in all AL-gue t ysterns are linear with good correlat ion coefficient (R 
� 0.99) indicating 1 :  1 complex i s  formed in  a l l  cases. The K values obtained by this 
approach, as well as the formation constant of NAL with y-CD previously reported 
( D u ran-Meras et al. ,  1 994; Celebi et al. ,  1 987), are showed in Table 3 . 5 .  There is a fair 
agreement within th experimental error, between the K values of NAL-�-CD obtained 
from vo ltammetric and so lubi lity techniques. 
3.5.4. Binding mode and mechanism of the inclusion complex 
Valero et al. ,  1 996, have calcu lated the dielectric constant of the cyclodextrin 
ca it ies from the spectral dependence of the so lvent polarity. They found that the 
cyc lodextrins cavit ies of a-CD �-CD, and y-CD have a smal ler polarity than the bulk 
water and the �-CD interior is the most hydrophobic of the three cavit ies studied. This 
indicate that the microenvironment of a substrate in �-CD is more hydrophobic than the 
corresponding value of a-CD and for y-CD.  All of these could reveal a tighter fi l l ing of 
this �-CD, i .e. ,  a greater penetrat ion of the drug into the �-CD cavity and consequent ly a 
greater hindrance of the entry of  water molecules. This is in consistent with the trend o f K  
values of NAL (Table 3 . 5 ). The binding constants l isted in Table 3 . 5  indicate that the 
interaction of NAL-�-CD is particularly strong due to the snug fit ofNAL into the �-CD 
cavity. But, the binding ofNAL to a-CD, with its smaller cavity, and y-CD, with its larger 
cavity, IS poorer. This highlights the importance of the size-fit relation between the host 
and the guest in detennining the strength of binding. Therefore, the remarkable 
enhancement in the association constant with decreasing the d ielectric constant of CD 
cavity support that the major contributing force fields is the hydrophobic interaction. 
The standard Gibbs free energy changes, �Go, for the binding ofNAL with the 
CDs were calculated from the well-known relationship: 
llGo = -RT 10 K --------------- (6) 
These values are negative (Table 3 . 5 )  revealing that the binding process IS 
favorable, consequently the transfer of NAL from an aqueous solut ion to CD cavity is 
spontaneous. Moreover, the changes of the Gibbs free energy corresponding to the 
association process are c lose or even of the same order of magnitude indicat ing same 
inclusion mechanism for entering NAL into both a-CD and �-CD cavities. 
In order to elucidate the structure of the inclusion complex and the group 
responsible of the inclusion into CD we involved the binding constants of smaller non-
5 1  
drug molecules formed by groups contained in AL. Thus, the K value ( 1 58 .5 )  of 
pyridine-a-CD comple 
compari on. 
as taken from literature ( Lewise and Hansen, 1 973) for 
Three different po ibi litie for NAL to enter into the CD cavity, as fo l lows: 
o 
HOOC 
(a) 
o 
�COOH 
A�IJl . . jJ H C N N 3 I 
(b) 
CH2 I CH3 
HOOC 
o 
(c) 
The orientation (a) may not be expected because it is considered that the highly 
hydrophil ic groups to be included in a relat ively hydrophobic cavity. Moreover these 
groups (C=O and --COOH) are more stabil ized by water molecules through the hydrogen 
bonds. 
I f  it is supposed t hat the complexation is due to the inc lusion of ethyl group at N l  
into the cavity of  a-CD (orientation b), then the expected free energy change should be 
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around 6 kJ / mo l. This is due to the change of the free energy for each methylene group 
included in a- D is around 3 kJ / mo l at 298. 1 5  K (Shebatta, 1 996; Ba tos et al., 1 990) . 
Ho ever. we obtained 1 4 .88  kJ / mol for NAL-a-CD complex indicating that this 
topo logy for entry of NAL into the a- D cavity is also exc luded. Moreover, the smaller 
ca it of a- D bind more tight ly with a linear alkyl group than that of �-CD (Sbebatta, 
1 996; Ba tos et aL, 1 990). However, the absorption spectra and the vo ltammetric studies 
as we ll as the K values show that the binding affmity of NAL is better of �-CD than that 
of a- D. Thus. the orientation (b) is not the favorable one 
Therefore, NAL is expected to take the orientation (c) in complexing with CDs. 
The ize of 2-methy l-pyridine group seems to fit the cavity size of CD. It was reported 
( Lewise and Hansen, 1 973) that the logarithm of the binding constant of pyridine with 
a-CD at 298. 1 5  K to be log K = 2.20, which is slight ly smal ler than that obtained for 
NAL-a-CD complex. Therefore, the inc lusion of NAL in the cavity proceeds in such a 
way that the methyl pyridine side penetrate into the cavity. Thus, the inclusion process in 
NAL can occur through the 2-methyl-pyridine side leaving the carboxyl group outside the 
hydrophilic cavity protruding into water. This orientation leads to fonnation of hydrogen 
bonds between the carboxyl group and the hydroxyl groups of �-CD resulting in 
enhancement of the stabil ity o f  N AL-�-CD complex. Also, the release of originally 
incorporated water molecules from the CD cavity is another important factor that can a lso 
contribute to the stabi lization ofNAL-CD complex. The high-enthalpy water molecules 
can form hydrogen bonds with the bulk water molecules. 
To test the reliabi l ity  of these hypotheses, we carried out the calculations on al l  
possible complexes originat ing from NAL with a-CD or �-CD taking into accounts the 
different modes of inclusion. The more favorable interaction energy is obtained for the 
topology (c) where the energy decreased by � 42 and 54 kcal for a-CD and �-CD, 
respectively. This reveals t hat the NAL-�-CD is more stable than NAL-a-CD. The 
energy-minimized conformation of the NAL-a-CD structure, as a representative example, 
is shown in Fig. 3 .3 1 .  The figure showed that the penetration of the drug through the 
wider rim and the drug penetrates through the axis of CD cavity along its depth. It was 
observed that the maximum width of the N AL molecule (5 .02 A) was less than the 
d iameter of �-CD (�7 A) faci l itating the molecule to penetrate into the �-CD cavity. But 
the length (7 .88 A) was more than the cavity depth (�7 A), thus the carboxyl ic group 
protruding out result ing in a fonnation of hydrogen bonds with the secondary OH group 
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located on the larger rim of  the p-cyc lodextrin. Therefore, the proposed structural formula 
of NAL-P-CD inelu ion complex is gi en (F ig. 3 . 32A). On the other hand, as the width 
of NAL i larger than the d iameter of a-CD (4 .5  A) ( Bender and Komiyama, 1 978), it 
hould not be able to fully penetrate into a-CD. In other words, only a part of the NAL 
mo le ule can be accommodated into the a-CD cavity, leaving the rest of the molecule 
protruding into water (Fig. 3 . 32B) .  This explains why the orientation of the adsorbed 
AL changed in presence of a-CD as discussed before in CV part. In  case of y-CD 
(diameter 8 .5  A) the NAL mo lecule is loosely packed in this large cavity, leading to weak 
interaction and consequent ly smal l  K value (Table 3 . 5) .  
Finall , the vo ltammetric study shows that the binding afflnity ofNAL is  much 
higher at pH 5 than the other studied pH values. This indicates that the CD cavit ies have a 
preferential affmity for the neutral acid form than the ionized ones. This can be explained 
as fo l lows: NAL (PKa = 5 .99) at pH 5 has the neutral form, whereas at pH 2 and pH 7, 
NAL has the cationic and anionic forms, respectively .  At pH 2, the NAL interacting with 
a It through N8 forming the cationic form and this renders the ful l  penetrat ion into the 
cavity .  A lso, at pH 7, NAL molecu le is in the ionized form as carboxylate. Thus, the 
requirement for solvation of the charged carboxylate group by water may prohibit the 2-
methyl group from ful ly penetrating the CD cavity .  Whereas, deeper penetration may be 
possible with the neutral carboxylic acid group. 
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Table 3 . 1 :  Change of the DP V peak current and potential of  1 .9x 1 0-5 M NAL in 
presence of interfering pecie ; supporting e lectrolyte, BR buffer with NaNO) (pH=5 .0) 
Potential  Conc. Change of Potential shift Tolerance 
interferent (M) signal ( %) (mY) level (llg/ml) 
CrO I I )  9.4x 1 0-5 +45 .9 -50 <0.052 
1 . 87x 1 0-4 +5 1 .0 -50 
eo( I I )  4 . 7  1 0� +28 .0  -37  <0.006 
9.3x 1 O� +33 .0  -37 
Zn( J I )  2 .8x 1 0-<> +4. 5  0 .0 �0. 1 83 
5 . 6x 1 0� + 1 4 .0 0 .0 
ed( U )  4 .7x 1 0� 0 .0  0 .0  <3 .93 
3 .5x  1 0-5 -5 .0  0 .0 
eu( I I )  9.4x 1 0-5 +3 . 7  0 .0 <28 .6 
4 .5x 1 0-1 +3 .7  0 .0  
Pb( I I )  9.4x 1 0-) 0 .0 +25 < 1 47. 1 
7 . 1 x  1 0-4 +8.3 +25 
Table 3 .2 :  Mean recoveries obtained for five determinations ofNAL in Negram tablets 
and suspension using DPSV. 
Sample NAL added NAL found RSD ( %) Recovery ( %) 
(llg) (}!g) 
Tablet 24 23 .8  3 . 70 99.2 
40 39.6 3 .9 1  99.0 
Suspension 25  25 .4 3 . 32  1 0 1 .6 
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Table 3 . 3 :  Analysis of  N AL  in pure, urine and blood serum using DPSV technique, B R  
buffer (pH  = 5 .0) .  
Sample Range of linea rity Linear  equation R Detection 
(M) limit (l\-Q 
Pu re 7.4 x 1 O-1S-2 .5x 1 0-) 1 (J.lA)=0. 707+0.057 C (J.lM) 0.998 3 .3x 1 0-'1 
U rine 
ample ( 1 )  1 . 3x 1 O-<>-3 .4x 1 0-5 I ( J.lA)=0.093+0.028 C (J.lM) 0.995 l .Ox 1 0-7 
ample (2) 7 .3 1 0-<> -3 .  9x 1 0-5 I (J.lA)=-0.083+0.03 1 C (J.lM) 0.996 1 .2x 1 0-7 
Seru m  
-
ample ( 1 )  2 .9x 1 O-<>-2. 7x 1 0-5 I (J.lA )=0. 1 66+0.044 C (J.lM) 0.995 9. 1 x  1 0-8 
ample (2) 1 .  9x 1 0-<>-3 .  9x 1 0-5 I (J.lA)=0.084+0.042 C (J.lM) 0.994 8 . 7x 1 0-8 
Sample (3 )  2 .9x 1 O-<>-4.4x 1 0-5 I ( J.lA)=0.020+0.04 1 C ( J.lM) 0.998 8 .9x 1 0-8 
Table 3 .4 :  Values of standard G ibbs energy of  transfer of nalid ixic acid from aqueous 
solut ion to the hydrophobic cavity of P-CD at 298. 1 5  K. 
1 03 [P-CDJ / M -�tr.DSGO I kJ mort 
1 1 . 72 
2 2 . 0 1  
3 2 . 72 
4 3 . 59 
5 3 . 73 
Table 3 . 5 :  The formation constant and standard Gibbs free energy of  the binding of 
nalidixic acid with cyclodextrins in  5%(v/v) methanol phosphate buffer (PH = 5)  at 298. 1 5  
K. 
H ost 
a-CD 
P-CD 
y-CD 
a (Duran-Meras et aL, 1994) 
b (Celebi et aL, 1 987) 
Log K _�Go I kJ mOrl 
2.60 1 4.88  
3 .20 1 8 .24 
2.45\ 1 .2 70 
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Fig.3. ! :  Cyc l ic voltammograms of 1 .9x  1 0-5 M NAL at pH 5 .0 (BR 
Buffer). Scan rate 1 00 mY S- l .  Peak 1 C  and 2C are e p lain d 
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Fig.3 .2 :  [A] Effect of the scan rate on the CV peak of 5x 1 0-6 1 L at 
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Fig.3.3 : Effect of pH on the DPSV peak of l .  9x 1 0-5 M AL. 
Scan rate 20 mV S- I ,  ta =30s and pulse ampl itude 1 00mV .  
Phosphate buffer: pH  ( 1 )  2 .0; (2) 5 .0; ( 3 )  7 . 0  and ( 4 )  9.0 . 
I nset : Variation of the peak height (2C) current as a function 
of pH.  
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Fig.3.4 :  Effect of anions on the DPSV peak of 1 .9x 1 0-5 M N AL. 
Scan rate 20 mV S- I , ta = 30 s,  pulse amplitude l OOmV and 
pH 5.0 (BR buffer) . ( 1 )  r; (2) N 03-; (3) solo; (4) C I04-
and (5 )  Cr. Es = -0.4 V (for each curve). 
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Fig.3.S :  Effect of scan rate on the DP V peak of 1 . 9x 1 O-5M AL 
pulse ampl itude 1 00mV, ta =30s and pH 5 .0  (phosphate). 
( 1 )  5 mV S- I ; (2) 1 0  mV S- I ; ( 3 )  20 mV S- I and (4) 50 mV -I  
I nset : Variation of the peak height current as a function of 
Scan rate (mV S- I ) . 
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Fig.3.6 :  Effect of pre concentration potential on the DP V peak 
of 1 .9x 1 0-5M NAL at pH 5 .0  (phosphate), pulse ampl itude 
1 00 mY, scan rate 20 mV S-I and ta ==30s. ( 1 )  Es = 0 V 
(2) Es == -0.2 V; (3) Es == -0.4 V ;  (4) Es == -0.6 V and 
(5) Es = -0.8 V. 
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Fig.3.7:  [A] Effect of adsorption t ime on the DP V pe
ak of 
1 . 8x 1 0-7 M NAL. Pulse ampl itude l OOmV, pH 5 .0  
(phosphate) and scan rate 20 mV S-
l . ( 1 )  Os; (2 )  50s; ( 3 )  1 00 ; 
(4) 1 50 s; (5)  200 s; (6) 250 s; (7) 300 s and (8)  350 
[B] Curve plot of peak height versus deposition t ime. 
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Fig.3.8 :  [A] Effect of pulse height on the DP Y peak of 1 .9x 1 0-5 1 
NAL. Scan rate 20 mY S- l , pH 5 .0 (phosphate) and ta =30 . 
( 1 )25 mY; (2) 50 mY and (3) 1 00 mY. 
[B ]  Curve p lot of peak height ver us pulse height (mY) .  
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Fig.3.9: Effect of drop size on the DP V peak of 1 .9x 1 O-5M AL. 
Scan rate 20 mV S- l ,  pH 5 .0  (phosphate),ta =30s and pulse 
amplitude 1 00 mY . ( 1 )  Smal l; (2) Medium and (3) Large. 
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Fig.3. 1 0 : [A] Effect of repetit ion drop t ime on the DPSV peak of 
1 .9x 1 O-5M AL. Scan rate 20 mV S- l ,  pH 5 .0 (phosphate), 
t3 =30s and pulse amplitude 1 00 mY. ( 1 )  1 s; (2) 0.5 s and 
(3) 0.2 s. 
[B] Curve p lot of peak height versus drop t ime. 
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Fig.3. 1 l :  [A] DPSV peak ofNAL for different co
ncentrations under the 
opt imum conditions in presence ofNaN03, pH 5.0
 
(BR buffer), ta = 1 20 s, scan rate 20 mV S- I and pulse. 
amplitude 1 00 mV ( 1 )  2 .9x 1 0-
& (2) 7 .4x 1 0-8 ; (3) 1 . 1 5x 1 0-
7 ; 
(4) 9.9x 1 0-7 ; (5 )  1 . 85x 1 0
-6; (6) 3 . 5x 1 0-6 ; (7) 5 .9x 1 0-
6 ; 
(8)  8 .97x 1 0-6 ; (9) 1 . 1 8x 1 0-
5 and ( 1 0) 1 .44 x 1 0-5
 M of AL 
[B] Calibration curve plot. 
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Fig.3. 1 2 :  OP V peak beha ior of 1 .9x 1 O.5M AL in pre ence ofZn( I l ) . 
Scan rate 20 mV S· I , pH 5 .0 (BR buffer) with a 03 • ta =30 
and pulse ampl itude 1 00 mY. ( 1 )  0; (2) 5 .6 x 1 0.{) and (3) 8.3 x 
1 0.{) M ofZn( I I ) . 
Fig.3 . 13 :  DPSV peak behavior of 1 .9x 1 0·5M NAL in presence of Co(II) .  
Scan rate 20 mV S·l , pH 5 .0 (BR buffer) with NaN03, ta =30s 
and pulse amplitude 1 00 mV . ( 1 )  0; (2) 4.7 x 1 0-6 and 
(3) 1 . 3 8  x 1 0.5 M ofCo(I I ). 
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Fig.3. 1 4 : DP V peak behavior of 1 .9x 1 0·5M AL in presence o f Pb( I l ) . 
can rate 20 mV S· I , pH 5 .0  ( BR buffer) with aNO), ta =30-
and pulse ampl itude 1 00 mY. ( 1 )  0; (2) 3 .67 x 1 04 and 
(3) 1 x 1 0.3 M of Pb( I I ) . 
Fig.3. 1S :  DPSV peak. behavior of I .  9x 1 0·5M NAL in presence of Cu( I I ) . 
Scan rate 20 mV S·l , pH 5 .0  (BR buffer) with NaN03, ta =30s 
and pulse ampl itude 1 00 mY. ( 1 )  0 ;  (2) 9.4 x 1 0.5 and 
(3) l . 8 x 1 0-4 M ofCu( I I ) .  
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Fig.3. 1 6 : DP Y peak behavior of 1 .9x 1 O-5M AL in pre ence of Cd( I J ) .  
Scan rate 20  mY S- l , pH 5 .0 (BR buffer) with aNO}, t a  =30 
and pu lse amp litude 1 00 mY. ( 1 )  0; (2) 1 . 8 x 1 0-5 and 
(3) 2.7 x 1 0-5 M of Cd(I J ) .  
Fig.3. 1 7: DPSY peak behavior of  1 . 9x 1 O-5M NAL in presence of. 
Cr(I I J)Scan rate 20 mY so l , pH 5 .0 (BR buffer) with NaNO}, 
ta =30s and pulse ampl itude 1 00 mY. ( 1 )  O� (2) 7 .5  x 1 O� and 
(3) 1 .46 x 1 0-5 M ofCr(I I I ) .  
[AJ  
_ 0 . 6 _ o. a  _ t  _ 1 . 2 
7 1  
_ 1 . 6  
E ( V ) 
[B ]  � �, --------------�--------. 
. - y =  1 2 1 16 · 35027x R · = 0 9934 
¢ 10" 0 5 1 0"' 1 1O'"i5 10--. 10� 10"':3 10"'J5 10� 
� 
Fig.3 . 1 8 : [A] Appl ication of  the standard addition method for 
determinat ion of AL in formulation ample (tablet ) .  
pH 5 .0 (BR buffer) with NaNO), t a  =60s, scan rate 20 
mY S-I and pulse amplitude 1 00 mY. ( 1 )  0.6 mJ of tablet 
solution; (2) 1 + 1 . 85x 1 0-<i; ( 3 )  1 + 6.2x 1 0-<i; (4) 1 + 
1 .0 1 x  1 0-5 ; (5) 1 + 1 . 8x 1 0-5 ; (6) 1 + 2 . 7x 1 0-5 and 
(7) 1 + 3 .4x 1 0-5 M ofNAL 
[B]  Calibration curve plot .  
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Fig.3. 1 9 : [A] Appl ication of the standard addition method for 
determination of NAL in formulation sample 
(suspension). ( 1 )  0.5 ml of su pension solution: 
(2) 1 + 1 .9x 1 0-<;; (3 )  1 + 6 .3x 1 0-<;; (4) 1 + 1 .03x t o-5 : 
( 5 )  1 + 1 .9x t o-5 ; (6) 1 + 2.7x t o-5 and ( 7) 1 + 3 . 5x  t o-5 M 
ofNAL. Other condit ions as in Fig.3 . 1 8 . 
[B] Calibrat ion curve plot .  
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Fig.3.20: [A] Concentration dependence of the DP V peak of AL in 
9 : 1 pH 5.0 / urine mixture. (0) background· ( 1 )  1 . 1 7x 1 0-' ; 
(2) l Ax 1 0-5 ; ( 3 )  1 . 8 x 1 0-5 ; (4) 2 .3x 1 0-5 ; (5)  2.8x 1 0-5 ; 
(6) 3 .2x 1 0-5 ; ( 7) 3 .6x 1 0-5 ; (8 )  4 . l x  1 0-5 and (9) 4 .7x 1 0-5 M 
ofNAL. Other condit ions as in Fig.3 . 1 8 . 
[B] Cal ibrat ion curve plot. 
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Fig.3.2 1 :  [A] Concentration dependence of the DP V peak ofN AL in 
9 .5 :0 .5  pH 5.0 / serum m ixture. (0) background; ( 1 )  7Ax 
1 0.Q; (2) 9.9x l O.Q; (3)  1 .2x 1 0-5 ; (4) 1 . 5x 1 0-5 ; (5) 1 . 7x 1 0-5 : 
(6) 1 .9x 1 0-5; (7) 2 .2x t o-5; (8) 2Ax t o-5 ; (9) 2 .9x 1 0-5 ; 
( 1 0) 3 .6x 1 0-5 and ( 1 1 )  3 .97 x 1 0-5 M of AL. Other 
Condit ions as in F ig .3 . l 8 . 
[B] Calibrat ion curve p lot. 
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Fig.3.22 :  [A] Concentration dependence of the DPSV peak
 of AL in 
9 .5 :0 .5  pH 5 .0 /  serum mixture. (0) background�( l )  8 . 3x  
1 0-6; (2 )  1 . 1 x  1 0-5 ; (3)  1 .6x 1 0-
5 ; (4 )  1 .9x 1 0-5 ; (5 )  2Ax 1 0-
5 . 
(6) 2 .6x 1 0-
5 ; (7) 3 x 1 0-5 ; (8) 3 . 5x 1 0-
5 ; (9) 4 x 1 0-5 and 
( l O) 4.4 x 1 0-5 M ofNAL .  Other cond itions as in Fig.3 . l 8 . 
[B ]  Calibration curve p lot. 
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Fig.3.23: [AJ Effect of the scan rate on the CV peak of 5x 1 0-6 M NAL 
In  the presence 8x 1 0-3 mg/ml of D A. At pH 5.0 
Phosphate (5% methano l) with NaN03 . ( 1 )  v = 1 0  mY S- I ;  
(2) v =20 mV S- I ;  (3) v =50 mV S- I ;  (4) v = 1 00 mY - I ; 
(5) v =200 mV S- I  and (6) v =500 mY S- I .  
[BJ Effect o f  scan rate o n  the C Y  peak o f  5 x  1 0-6 M NAL 
In  the absence of  DNA. Other cond it ions as in [AJ .  
[C] Curve plot of peak height current versus vl12 ( in the present 
and absent of  DNA) 
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Fig.3.24: [A] DPSV peak behavior of 5x 1 0.Q M AL in presence of 
DNA ( 1 )  0 ;  (2) 3 .96 x 1 0-4; (3) 7 . 8  x 1 0-4 ; (4) 1 . 1 7  x 1 0-3 : 
(5)  1 . 54 x 1 0-3 ; (6) 1 .9 x 1 0-3 ; (7) 2 .26 x 1 0-3 ; (8 )  2 .6  x 1 O-3 � 
(9) 2 .96 x 1 0-3 ; ( 1 0) 3 . 6  x 1 0-3 ; ( 1 1 )  5 . 2  x 1 0-3 ; and ( 1 2) 8 x 
1 0-3 0[ 0.04 mg/ml DNA Pulse amplitude 1 00 mY, pH 5 .0 
phosphate (5% methanol) with NaN03, scan rate = 20 
m V S- I and ta=30s. 
[B] Curve p lot of l lC versus l ie 1 -Cilio ))� 
1 0  
::; -� 8 u .. 
u 
)( � 6 
;;; 
c: 
a ?: 4 
:0 ::> "0 2 IJ) 
'0 
� 
0 
0.79 7 
0.39 6  
238  
• 
• 
• 
0 2 3 
1 0J Concentration of 
fA) 
4 3 2 
238 
78 
• 
4 5 
p -CD I M 
[B) 
254 
6 
2 70 A, run 
Fig. 3.25: Phase solubil ity diagram of AL in pho phate buf  r (pH = " ) 
I n  the presence of different �- 0 concentration . 
Fig.3.26: [A] UV-Vis spectra of 5 .0 x 1 0-5 M NAL in phosphate buffer 
(PH =5, 5% methano l) . ( 1 )  0; (2) I mM; (3) 5mM and 
(4) 6 mM of�-CD. 
(B] UV-Vis spectra of 5 .0 x 1 0-5 M NAL in phosphate buffer 
(PH =5, 5% metbanol) . ( 1 )  0; (2) 2mM; (3) l OmM and 
(4) 1 2  mM of a-CD. 
( A ) I C 
t + 
2 
C )  
- - - - - - - _ ../  
- - - -
- - ---
.... - - - - - - -
2C r\ 1 \  
: \ � I \ 
t I \ 1 I 2 ' -1 I I I I I I I I 
/ ./ 
/ 
I 
I 
I 
I 
I I I 
I 
J II 
--- - - - -
2 
1 
-.... - - - - - - -
- 0.8  
79 
./ 
,....- --
t I I 
/'_' J 
- 1 .6 E (  V )  
Fig.3.27:  Cyc l ic voltammograms for 1 .9 1 0-5 M NAL so lution in the 
absence ( 1 )  and in the presence of 5 x 1 0-3 M a-CD (2) at : 
(A) pH 2; (B) pH 5 and pH 7 phosphate buffer (5% methanol) 
at HMDE, scan rate 1 00 mV s -I . 
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Fig.3.28:  Cyclic voltammograms for 1 .9 x 1 0-5 M AL so lut ion in the 
absence ( 1 )  and in the presence of 5 x 1 0-3 M a-CD (2)  at : 
(a) pH 5 phosphate buffer; (b) pH 5 acetate buffer and (c) pH 5 
BR. Buffer (5% methanol) at HMDE, can rate 1 00 mY s - I . 
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Fig.3.29: [A] Effect of the scan rate on the CY peak of  5x 1 0-6 M L 
I n  the presence 1 .45x 1 0-3 M of �-CD. At pH 5 .0 
Phosphate ( 5% methano l) wi th  aN03. ( 1 )  v = 1 0  mY S- I ; 
(2) v =20 mY S· l ; ( 3 )  v =50 mY S· I ; (4) v = 1 00 mY S· I : 
(5 )  v =200 mY S· I and (6) v =500 mY S· I . 
[B ]  Effect of  scan rate on the CY peak o f 5x 1 0-6 M N AL 
I n  the presence of  1 .6 x 1 0.3 M of a-CD.  Other cond it ions 
as in [A] . 
[C] Effect of  scan rate of  the CV peak o f 5x 1 0-6 M NAL 
in t he absence of CDs. Other conditions as in [A] .  
[D]  Curve plot o f  peak height current versus v1f2 ( in the  present 
and absent of CDs). 
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Fig.3.30: [A] Different ial pulse stripping voltammograms for 5x 1 0-{) M 
NAL in phosphate buffer (pH = 5, 5% methano l) at 
HMDE. scan rate 20 mV S- I ,  ta =30 s, Es = -0.4 V and 
pulse ampl itude 1 00 mY . ( 1 )  0; (2) 9 .9x 1 0-5 ; ( 3 )  1 .96x 
1 0-4 ;  (4) 3 .85x 1 0-4 · ( 5 )  6 .66x 1 0-4 and (6) 8 .25x 1 0-4 M 
�-CD. 
[B ]  P lot of  l IC versus l /( 1 -(il io) ) .  
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Fig.3.3 1 :  Energy-minimized structure for AL-<l-CD complex.  
Fig.3.32 : Proposed structural fonnula ofNAL complexes with 
[A] �CD. 
[B] <l-CD. 
CHAPTER IV 
Determination of Norfloxacin and its 
interaction with 
DNA and Cyclodextrins 
DETERM INATION O F  NORFLOXACIN AND ITS INTERACTION 
WITH DNA AND CYCLODEXTRINS 
4. 1 .  Differential  pu lse stripp i ng voltammet ry of norfloxacin 
4. 1 . 1 . Dependence of (DPSV) peak of NOR on pH 
The DPSV voltammograrn of 4 . 76 X l O-s M NOR recorded as a function of 
potential i n  pho phate buffer solution of varying pH (5- 1 2) is repre ented in  Fig. 4 . 1 .  The 
recorded DPSV peaks at various pH values are main ly due to the reduction of CsH4NO 
group.  The DPSV peak i pH dependent, it sh ifts to more negat ive potentials wi th rise of 
pH. A wel l  defi ned peak i observed at pH 1 1 . This peak corre pond to the adsorpt ion 
and reduct ion of anionic species of NOR according to i ts pKa value (pKa J  = 6 .34 and pKa2 
= 8 .75) .  The optimum pH value 1 1 .0 was chosen for further tudies of thi drug. 
4. 1 .2. Effect of a nions of the support ing electrolytes on the DPSV peak of NOR 
The influence of various anions of  an  indifferent support ing electrolytes (such as 
N03-, solo, CI04 -, r and Cn on the DPSV peak of the adsorbed NOR fi lm was 
investigated (Fig. 4.2) .  The result indicates that the cathodic reduction peak decreases in  
the order Cl04 - � I - > cr > N03- > solo. The main d ifference is connected with 
structural changes in  the e lectrical double layer due to the specific adsorption of the 
anions of the support ing electrolyte. In this case the e lectrostatical ly  attracted ions of the 
solvent repel the adsorbed molecules from the electrode surface and decrease the forces 
of non-electrostatic adsorption of NOR molecules at a charged interface. On the other 
hand, a more sensit ive peak was found in the presence of CI04 - ,  however in the presence 
of sol- the height of the peak decreases markedly. This indicates that Cl04 - exhibits the 
smal lest tendency for specific adsorption anion and less electrostatic forces on the 
charged mercury surface. This reflects the rul e  of anions of indifferent supporting 
electrolytes on the degree of adsorption and accumul ation of NOR fi lm at the charged 
interface. Therefore, quantitative trace determination of NOR by DPSV was tested in 
presence of C I04 - ions. 
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4. 1 .3 Effect of operational parameters on the DPSV peak of NOR 
For determination of the opt imum condition for trace analysi of NOR, effect of 
many operat ional conditions on the DPSV behavior of NOR were examined at pH= 1 1 .0 ,  
uch a the effect of scan rate, start ing potential ,  adsorption time and pulse ampl i tude . 
( i )  Effect of can rate on the DPSV peak of NOR 
The DPS V vol tammogram of NOR at various scan rate are recorded at pH 1 1 .0 
( Fig .  4 .3 ) .  Scan rate of 20 mV S· l gave a better response compared to that of 1 0  mV · ) , 5 
mV · 1 or 5 0  mY . 1 , however at h igher scan rate than 20 mV S· I (e.g. 50  mV . 1 )  the 
w idth of the peak increa es and the sens i t iv i ty decreases . Hence a scan rate of 20 m V S· I 
" a  cho en for the tripping vol tammetry of the NOR. 
( i i)  Effect of p reconcentration potentials on the DPSV peak of NOR 
The dependence of the height of the DPSV peak of NOR on the preconcentration 
potential wa tudied at pH 1 1 .0 in the potent ial range from 0.0 V to -0.8 V (Fig. 4.4) . 
Max imum peak height was obtained, whichever scanning mode was used, i n  the 
preconcentrat ion potential range from -0. 1 V to -0.8 V. At adsorption potential values 
lower than -0. 1 Y ,  the cathodic current w i l l  obviously be lower and the stripping signal 
decreases. An accumulation potential of -0.6 Y was chosen for the stripping analysis 
procedures.  
(i i i)  Effect of preconcentration time on the DPSV peak of NOR 
A necessary prerequisite for the appl ication of cathodic  adsorpt ive stripping 
voltammetry is  that the adsorption equi l ibrium is attained at the HMDE before the 
reduction curren t  is measured. Fig. 4.5 shows the dependence of accumulat ion t ime on the 
stripping voltammetric response of NOR. At longer adsorption t ime equi l ibrium surface 
concentration i s  reached and the peak height becomes constant .  The ris ing part 
corresponds to d iffusion control led adsorption and the p lateau part represents the ful l  
coverage of the  e lectrode surface. Th is  indicates that the adsorption equi l ibrium is  
attained at  the HMDE before the reduction curren t  of NOR i s  measured. Therefore, a pre­
elec trolysis t ime of 30  sec was adopted for the stripping analysis  of the investigated drug. 
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( iv)  Effect of pu lse amplitude and other instrumental  parameters on the DPSV peak 
of N O R  
The effect o f  the pul e ampl i tude o n  height o f  the DPSV peak w a  studied at pH 
1 1  (Fig. 4.6) .  The dependency of the peak height ( ip , ).!A) on the pulse ampl i tude (25- 1 00 
mY) indicate that the more en i t ive reduction peak of NOR wa recorded at 1 00 mY 
pul e ampl i tude .  The peak current of NOR is plotted again t pulse ampli tudes . The plot 
i l i near up to ampl i tude of 1 00 mY. The analytical determination was performed at 1 00 
mY pul e ampl i tude. Other instrumental parameters, such as drop s ize and pulse 
repet i t ion t ime, which d i rect ly affected the voltammetric response, were opt imized (Figs. 
4.7, 4 .8) .  The selected working condit ions were 5.2 X 1 0-3 cm2 (Medium s ize,  M)  and 0 .5  
pu l  e repet i t ion t ime, respecti vely .  
4. 1 .4 .  Quantitative trace determination of NOR in  the model samples 
According to the aforementioned results the opt imum condit ions for the 
analytical determination of NOR by DPSY at HMDE are the fol lowing: phosphate buffer 
(pH= 1 1 .0 i n  presence of CI04-), 1 00 mY pulse ampl i tude, 20 mVs- 1 scan rate, 30 s 
accumulation t ime and -0.6 V accumulation potential . Under these condit ions the 
response of the peak height as a function of NOR concentrat ion i s  l inear over the range 
from 1 .47 x 1 0-7 M to 2.3 X 1 0-6 M NOR. The regression coefficient and the detection 
l i mi t  were found to be 0.997 and 1 . 597 ng mrl (5x 1 0-9 M), respect ively. The precis ion 
was determined from 5 repeated measurements of the reduct ion peak height of 5 x 1 0-7 M 
NOR. The percentage relative error was ca. 3 . 1 % and the percentage relat ive standard 
deviation (%RSD) was 4.2% (Fig. 4.9). 
4 . 1 .5.  I nterference study 
A systematic study was carried out to evaluate the potent ial effect of coexist ing 
metal ions capable of forming complexes with NOR or deposit ing at the mercury 
electrode on the determination of NOR at 4.76 x 1 0-sM.  Table 4. 1 and Figs. 4. 1 0  - 4 . 1 6  
show the resu l ts obtained. 
4.1 .6. Quantitative Determination of NOR in formulation sample 
NOR was determined in Noroxin tablets using the DPSV according to the 
experimental procedure mentioned above (sections 2. 1 .9 and 2.3 .7) .  A known volume of 
the Noroxin solution prepared above was spiked in to 1 0  ml aliquot of the base electrolyte 
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fol lowed by spikes of the standard NOR solution. The corresponding voltarnmograms 
have been recorded before and after each addit ion as indicated in Fig. 4 . 1 7 . Good 
recoverie have been obtained at various NOR concentrat ion leve ls .  The recoveries were 
c lo e to 1 00% i n  al l ba e e lectrolytes tested with a relat ive standard deviat ion of value 
I wer than 3 . 5 1 % .  
4.2. V o l t a m metric s t u d ies o f  the i n teraction o f  N O R  with DNA 
Typical CV behavior of NOR in the absence and presence of DNA are shown in 
Fig.  4. 1 8 . The cycl ic  vol tammogram of free NOR gives two cathodic peaks at -0.250 V 
and - 1 .25 V .  The econd one at - 1 .25 V i s  found to be reversible and more concentrat ion 
en i t i ve peak . Typical for al l quinolones, thi peak (- 1 .25 V) i s  the one-electron 
reduction tep of p iperaz i ne moiety (HAz) to the HAt radical according to the fol lowing 
react ion as propo ed previously for a s imi lar peak w i th DPP (Jaber and Lounici, 1 994), 
0 0 H 
F COO F -COO 
+ H .. +e , H 
I 
C 
I 
C2HS C2Hs 
� � H 
HAz HAZ 
However, the first peak (-0.250 V),  which appears at potential more posi t ive than 
-0 .40 V, could be ascribed to adsorpti ve process at the e lectrode surface as i t  has been 
proposed previously for the peaks observed within the same potential range i n  the 
differential pulse polarograms recorded within s imi lar pH ranges (Jaber and Loun ici, 
1994). We were interested in  the most sensitive piperazine singles for fol lowing studies 
and for t i tration with high molecular DNA solution . In the presence of DNA, the 
equil ibrium concentration of NOR decreases which resul ts in a decrease of peak current 
with a posit ive shift of the peak potential (ca. 50 mY). In this context, the cathodic peak 
current decreased to ca 37% (Fig. 4. 1 8  curve 2) of those in the absence of DNA. Under 
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the experimental conditions of Fig. 4 . 1 8 , pure DNA is electrochemical ly inactive in  the 
potential range of -D.2 V to - 1 .6 V at the HMDE. This was mainly due to the merging of 
cathod ic peak at low DNA concentrat ions with the background di charge (Palecek and 
Po tbieglova, 1 986). According to these observations, it  seems that the decreases of peak 
current of NOR after an addi t ion of exce s DNA are caused by the in tercalat ion of NOR 
to the bulky, slowly diffu ing DNA, which results in a con iderabJe decrease in the 
apparent di ffu ion coefficient .  
Current t i trat ions were performed by keeping the constant concentration of the 
drug whi le varying the concentrations of DNA using d ifferential pul e stripping 
voltammetry (DPSV) at pH 1 1  (Fig. 4 . 1 9) .  The interaction of NOR wi th DNA can be 
de cribed u ing the fol lowing equat ion : 
NOR+ DNA � NOR-DNA 
An equat ion for amperometric t i tration was described as previously (Eq .  1 ) . 
According to the decrease of peak currents wi th the concentrations of DNA and Eq. ( 1 )  
the fol lowing equation was obtained: 
l ICDNA= [2 .8 1 x 1 0  4 I ( l -ilio)] - 4.66 x 1 03 with a l inear correlation coefficient (r) of 
0.988, reveal ing that the binding complex of NOR molecule with DNA (per nucleotide 
phosphate) was a 1 :  1 association complex. The binding constant of NOR to DNA was 
calculated from the y-intercept to be 4 .66 x 1 0  3 M- l ,  as shown in Fig. 4 . 1 9B .  
4.3. Voltammetric studies of the interaction of NOR with Cyclodextrins 
Typical cyc l ic voltammetric (CV) behaviors of NOR in the absence and in the 
presence of CDs at pH 1 1 .0 (phosphate buffer) are shown in Figs . 4 .20 and 4.2 1 .  The 
cycl ic voltammetric behavior of pure NOR shows two cathodic peaks. The first cathodic 
peak, which appears at less negative potential, can be ass igned to adsorption process at 
the electrode surface, as explai ned before. The second peak (at ca.- 1 .25 V) the main 
reduction peak, was attributed to the reduction of piperazine moiety of NOR. 
The addition of P-CD or a-CD in  the NOR solution caused the peak currents to 
diminish.  This may be due to the binding of NOR to the large, slowly diffusing 
cyclodextrin causes the decrease i n  the peak current of the NOR in the presence of an 
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exce of �-CD or a-CD, which results in the considerable decrease 10 the apparent 
di ffu Ion coefficient of NOR-�-CD or NOR-a-CD adducts. 
Further evidence for the interaction of NOR with a-CD and �-CD comes from 
the different ial pul e tripping vol tammetry (DPS V).  In presence of di fferent 
concentrat ion of �-CD or a-CD, the peak current of NOR are strongly affected with 
mcrea ing concentration of p-CD or a-CD (Fig. 4 .22 and Fig. 4 .23)  reveal ing that an 
interaction ha occurred between NOR and CDs. 
Ba ed on the variation in the peak current, the formation constants of the 
complexe , formed between NOR and either a-CD or �-CD, were determined. For 1 :  1 
complex the fol lowing equation cou ld be deduced based on Feng et at., 1 997. 
l ICH = Kf [( 1 -A)/( l - ilio) ] -Kf ---------( 1 ) 
Based on the data extracted from Figs. 4 .22A and 4.23A the plots of Figs. 4 .22B and 
4 .23B are repre ented by the fol lowing equations using least squares method . 
l /Cp-cD = [ 302/( l - ilio)] + 396 
l ICa-CD = [234/( l - i/io) ] + 594 
with corre lation coefficients (R) � 0.995. This suggested that the inclusion complex of 
NOR with a-CD or P-CD was a 1 :  1 association complex . Thus, the formation constants 
(K),  which are usually  used to characterize the inclusion phenomena of CD system, were 
found to be 594 M-l and 396 M-l as calculated from the y-intercepts of Fig. 4.23 B and 
Fig. 4.22 B for a-CD-NOR and �-CD-NOR, respectively. a-CD binds NOR more 
strongly than �-CD as i ndicated from the large K and -L1G values (- 1 5 .84 and - 1 4.83 
kllmol for a-CD and p-CD, respectively). These resul ts indicate that the size of the 
cyclodextrin cavity plays an important role in the formation of the complex. On the basis 
of size ,  the cav i ty size of a-CD seems to be optimal for entrapment of the NOR molecule, 
whereas in  P-CD the binding leads to the formation of a more unstable complex . 
4.4. Solubility studies 
The NOR is known to have poor aqueous solubi l i ty, 0.28 mglml at 25 °C, 
(Mazuel, 1991). Fig. 4.24 shows the phase solubi l ity profi le representing the effects of 
i ncreasing concentration of P-CD on the apparent solubil ity of NOR in  aqueous solution . 
An increase i n  the solubi l i ty of the complex wi th respect to the free form was observed. 
In aqueous solution of NOR-P-CD complex, the free drug molecules are in equi l ibrium 
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with the drug molecules entrapped within the cavity. Thus, on increasing the 
concentration of P-CD more NOR molecule wi l l  transfer from the aqueous solution to 
the hydrophobic cavity of p-CD. Therefore, one can expect that more NOR dissolved in 
water in the presence of P-CD than dissolved in absence of it and consequently, the 
olubi l i ty of OR increases with increa ing the concentration of p-CD. A l inear plot was 
obtained and represented by the fol lowing equat ion : 
CNOR = 9 .06 X 1 0-4 + 0.2726 1 CP-CD R= 0.998 1 
Therefore, the solubi l i ty curve for NOR was classified as type AL, according to Higuchi 
and Connor class ification indicating the formation of 1 :  1 NOR-P-CD complex . The 
apparent stabi l i ty constant ( K  = 4 1 2  M- 1 ) of the formed complex was calculated from the 
olubi l i ty diagram according to the fol lowing equation :  
K = slope/So ( I -slope) 
usmg the slope of the phase solubil ity diagram and the determined NOR solubi l i ty in 
water (So). 
The Gibbs free energies of transfer of NOR from aqueous solution to the cavity of 
P-CD have been calculated from the fol lowing equation : 
L1tIanSG = -RT I n  (S/So) 
where S and So are the solubi l i ties of NOR in presence and absence of P-CD, 
respect ively. As can be seen from Table 4.2 the L1tIanSG values are negat ive and increase 
negat ively wi th  i nc reasing P-CD concentration . This indicates t hat the transfer process is 
spontaneous and supports the view that P-CD is more favorable environment for NOR 
than water. Moreover, the in teraction between NOR and P-CD increases with increasing 
P-CD content .  
Finally, there i s  a good agreement between K value obtained from voltammetric 
and solubi l i ty techniques. 
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Table 4 . 1 :  Change of the DPSV peak current and potential of 4.679 x 
1 0-5 M NOR in pre ence of interfering species; support ing electrolyte, 
pho phate buffer. 
Potential Cone. Change of Potential shift 
interferent (M) signal ( % )  (mV) 
Cr(TI I )  1 . 90x 1 0-) - 1 4 .90 +50.0 
1 . 86x 1 0-4 -20.56 +50.0 
Co(I l )  1 .42x 1 0-6 +69.77 -50.0 
2 .36x 1 0-6 +83 .72 -50 .0 
Zn( Il )  5 .70x 1 0-7 +44.77 0 .00 
2.80x 1 0-6 +94 .00 0 .00 
Cd(Il) 2.27x 1 0-) +26.00 +50.0 
4 .30x 1 0-5 +34.78  +50.0 
CU(II )  1 . 90x 1 0-) - 1 6 .25 0 .00 
1 .60x 1 0-3 -2 1 .25 +50.0 
Ni ( Il)  1 .90x 1 0-5 -27 . 3 5  + 1 2 . 5  
4 .74x 1 0-5 -25 .47 +50.0 
Pb(II) 2.77x 1 0-4 - 1 9. 86 0 .00 
8 .69x 1 0-4 -27 .39 + 1 2. 5  
Table 4 .2 :  Values o f  standard Gibbs energy of transfer o f  norfloxacin from aqueous 
solution to the hydrophobic cavity of P-CD at 298. 1 5  K. 
lOJ [f3-CD] / M 
-
�transGo / kJ mor1 
1 0_68 
2 1 . 1 4 
3 1 .62 
4 1 .94 
5 2 .22 
6 2 .59 
7 2 .70 
8 3 .03  
9 3 .29 
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Fig.4. 1 :  Effect of pH on the DPSV peak of4 . 76x 1 0-5 M OR. can 
rate 20 mV S- l ,  ta = 30 s and puLse ampl itude 1 00mV .  Phosphate 
buffer: pH ( 1 )  5 .0 ;  (2) 7 .0; (3 )  9 .0 ;  (4) 1 0.0;  ( 5 )  1 1  and (6) 1 2 .0. 
I nset :  Variat ion of the peak height current as a Funct ion of pH. 
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Fig.4 .2 :  Effect of anions on the DPSY peak of 4. 76x 1 0-5 M OR. 
Scan rate 20 mY S- l , t a  = 30 s ,  pulse amplitude l OOmY and 
pH 1 1 .0 (phosphate). ( 1 )  03-; (2) r; (3 )  cr;  (4) C I04-
and (5 )  SO/-. Es = -0.6 Y (for each curve). 
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FigA.3 : [A] Effect of scan rate on the DPSY peak o f 4 .76 1 0.5 M OR. 
pulse amp l itude 1 00mY, ta =30s and pH 1 1 .0 (phosphate) .  
( 1 )  5 mY S· l .  (2) 1 0  mY S· l ; (3) 20 mY S· l and (4) 50 m S· l . 
[B]  Curve plot of  peak height versus v (mY S· l ) .  
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FigAA: Effect of preconcentration potential on the DP V peak 
of 4 .76x 1 0.5 M NOR at pH 1 1 .0 (phosphate), pulse ampl itude 
1 00 mY, scan rate 20 mV 5· 1 and ta =30 . ( 1 )  -0 .2 V ;  (2) -0.4 
(3) -0.6 V and (4) -0.8 V.  
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FigA.5 :  Effect of adsorpt ion t ime on t he DP V peak of 1 .00 x 1 0-8 M 
NOR. Pulse amplitude 1 00mV, pH 1 1 .0 (phosphate) and scan 
rate 20 mV s - ' . ( I ) O s; (2) 30 s · (3 ) 60 s; (4) 90 s;  (5) 1 20 
and (6) 1 80 s . l nset :  Variat ion o f  the peak height current as a 
funct ion of adsorpt ion t ime. 
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Fig.4.6: Effect of pulse height on the DP V peak of4 . 76x 1 0-5 M OR. 
Scan rate 20 mV S- l ,  pH 1 l .0 (phosphate) and ta  = 30 s. 
( 1 )25 mY ; (2) 50 mV and (3) 1 00 mY. I nset :  Variat ion 
of  t he peak height current as a Funct ion of  pulse ampli tude ( mV).  
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Fig.4 .7 :  Effect of  drop size on the DP V peak of4 .76x 1 0-
5 1 OR. 
can rate 20 mV S- I , pH 1 1 .0 (phosphate) _ ta  =30 and pul e 
amplitude 1 00 mY . ( 1 )  Large; (2) Medium and (3 )  mal l .  
Fig.4.8: Effect of  repetit ion drop t ime on the DPSV peak: of  4 .76x 1 0-5 M 
NOR. Scan rate 20 mV S- I , pH 1 1 . 0  (phosphate), ta =30s and 
pulse ampl itude 1 00 mY. ( 1 )  0.2 s; (2) 0.5 s and (3)  I s. 
I nset : Variation of  the peak: height current as a function o f  drop 
Time. 
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FigA.9: [A] DP V peak o f  OR for different concentrat ions under the 
optimum condit ions in presence of NaCI04, pH 1 1 .0 
(phosphate) ta = 30 s, scan rate 20 mV S- I and pulse 
ampl itude 1 00 mY. ( 1 )  1 . 5x 1 O-7� (2) 2 .4x 1 0-7 ; ( 3 )  5 .2x 1 0-7 ; 
(4) 6.9x 1 0-7 ; (5 )  8 .7x 1 0-7; (6) 1 . 2x 1 0-6; (7)  1 . 5x 1 0� ; (8)  
1 .9x 1 0-6; (9) 2 .06x 1 0-6; ( 1 0) 2 .3x 1 0-6; ( 1 1 )  5 .4x 1 0� and 
( 1 2) 1 . 7 x 1 0-5 M of NOR. 
[B]  Calibrat ion curve p lot. 
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Fig.4. 1 0 : DPSV peak behavior of2 .86x 1 0·
sM OR in  presence of 
Zn(I I ) .  Scan rate 20 mV S·
l , pH 1 l .0 (phosphate), ta =30s 
and pulse ampl it ude 1 00 mY. ( 1 )  0; (2) 2 .97 x 1 0
-6 and 
(3) 5 .88 x 1 0-6 M of Zn( I I ) .  
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Fig.4. 1 1 :  DP V peak behavior of 2 .86x 1 0-5M NOR i n  presence of  
Co( I l ) . can rate 20  mV S- I , pH 1 l .0 (phosphate) ,  ta =30s 
and pulse amplitude 1 00 mY . ( 1 )  0; (2) 1 . 5 x l O� and 
(3)  4.9 x 1 0� M o f Co( I I ) .  
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FigA. 1 2 :  DPSY peak behavior of 2 . 86x 1 0-
sM OR i n  presence of 
Pb(I I ) . can rate 20 mY S-I , pH 1 1 .0 pho phate), ta =
30s 
and pulse amplitude 1 00 mY . ( 1 )  O �  (2) 4 .76 x 1 0
-4 and 
(3)  9 x 1 0-4 M of Pb(I l ) .  
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FigA. 1 3 : DPSV peak behavior of2 .86x l O-
sM OR i n  presence of 
Cu( I l ). Scan rate 20 mY S- I ,  pH 1 1 .0 (phosphate). ta =
30 
and pulse amplitude 1 00 mY. ( 1 )  0; (2) 4 .76 x
 1 0-1 and 
(3)  1 .76 x 1 0-3 M of Cu( I l ). 
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Fig.4. 1 4 : DPSV peak beha ior of2 .86
x l O-sM NOR in presence of 
Cd( I I ) .  Scan rate 20 mY S- I , pH 1 1 .0 (phosphate), 
ta =30 
and pulse amplitude 1 00 mY . ( 1 )  0; (2
) 2 .5  x 1 0-<; and 
(3) 2 .38 x 1 0-
5 M of Cd( I I ) . 
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Fig.4. 1 5 : DPSV peak behavior of2 .86x l O
-sM NOR in  presence of 
N i( I I ) .  Scan rate 20 mV S-
I , pH 1 1 .0  (phosphate) t 3  =305 
and pulse ampl itude 1 00 mY. ( 1 )  0 ;  (2) 1 .9
9 x 1 0-5 and 
(3) 4.975 x 1 0-5
 M ofNi( I I ) .  
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Fig.4. 1 6 : DPSV peak behavior of2.86x 1 O-5M OR in presence of 
Cr( I l l ). can rate 20 mV S- I , pH 1 1 .0 (phosphate), ta =30 
and pulse amplitude 1 00 mY. ( 1 )  0 ;  (2) 1 .99 x 1 0-5 and 
(3)  1 .96 x 1 0-4 M ofCr( I I I ) . 
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Fig.4. 1 7: [A] Appl ication of  the standard addition method for 
Determinat ion of NOR in formu lat ion sample (tablet). 
pH 1 1 .0 (phosphate) with aCI04, ta =30s, scan rate 
20 mY S- I and pulse ampl itude 1 00 mY. ( 1 )  0 .04 ml of 
tablet solut ion; (2) 1 + 4 .7x 1 0-7 ; (3) 1 + 9. 1 x  1 0-7 ; 
(4) 1 + 1 . 8x 1 0.{i; (5 )  1 + 3 . 6x 1 0-5 ; (6) 1 + 6 .8x 1 0-5 ; 
(7) 1 + 8 Ax 1 0-5; (8) 1 + l . l x  1 0-4 and (9) 1 + 1 .2x 1 0-4 M 
of NOR. 
[B] Calibration curve p lot. 
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 ence 
0[ 0. 1 67 mg/ml DNA. ( 1 ) I n  abs
ence of D A and (2) in 
Presence of DNA. can rate = 1
00 mV S- l ,  pH 1 1 .0 
(phosphate) with NaCI04, Es = 0 
V and Ef =- 1 .6 V .  
LA] 
- 0.6 - 0 8 - 1 -1- 2 -1 4 - 1 6 -2 E( V ) 
[B] 
2 10' 
1.8 1 0'  
1 .6 10' 
1.4 10' 
� 1.2 10' 
1 10' 
8 10' 
8 10' 
4 10' 
2 3 4 5 15 7 8 U(I-(NII 
1 09 
Fig.4. 1 9 : [A] DPSV peak behavior of 5 x 1 0-5 M NOR in presence of 
D A. ( 1 )  0; (2) 2 .64 x l O�; (3)  5 . 1 8  x 1 0�; (4) 6 .4 x l Oo{); 
(5) 7.6 x 1 00{)· (6) 8 . 8  x 1 O� · ( 7) 1 . 1  x 1 0-5 . (8 )  1 .2 x t o-5 ; 
(9) 1 . 5 x 1 0-5 1 . (1 0) 1 . 76 x 1 0-5 and ( 1 1 )  2 .24 1 0-5 M of  
DNA. Pulse ampl itude 1 00 mY, pH 1 1 .0 (phosphate) with 
NaCI04, Scan rate = 20 mV S-I and ta=30s. 
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Fig. 4.2 1 :  CV peak behavior of 5 x 1 O-5M NOR in absence and presence 
of 3 . 1 x 1 0-3 M of a-CD. ( 1 )  In absence of a-CD and (2) in 
presence of a -CD. Other conditions as in F ig. 4 . 1 8 . 
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Fig. 4.22:  [A] DPSV peak behavior of 5 x 1 0-5 M OR in presence 
of �-CD. ( 1 )  0; (2) 4.98 x 1 0-5 ; (3) 2.4 x 1 04; (4) 4 . 3  x l O-4 : 
(5 )  6. 1 2  x 1 04; (6) 9 . 5  x 1 0-4; (7) 1 .67 x 1 0-3 and (8) 2 . 3  ¥ 
1 0-3 M of p-CD. Other cond itions as in Fig. 4 . 1 9 . 
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(5) 1 .67 x 1 0-3 ; (6) 2 x 1 0-
3 ; (7) 2.6 x 1 0-3 and (8)  3 . 1 x 
1 0-3 M of a-CD. Other condit ions as in Fig. 4 . 1 9 .  
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CHAPTER V 
Determination of Ciprofloxacin and its 
interaction with 
DNA and Cyclodextrins 
DETERM INATION OF CIPROFLOXAC I N  AND ITS 
I NTERACTION WITH DNA AND CYCLODEXTRINS 
5. 1 .  Cycl ic  Voltam metric behav ior of Adsorbed CIP 
The nature of  the electrochemical proce s of  CIP was studied by cycl ic  
voltammetry (CV) at  the HMDE.  The cycl ic vol tammetric behavior of 5 x 1 0.5 M CIP at 
pH 7 .0  (pho phate buffer) is shown in (Fig. 5 . 1 ) . The dependency of the peak height ( ip, 
nA) of the cathodic peak on the scan rate (v = 20 - 500 mV S· I ) was also studied. We 
found that the lope of the log ip vs. log v plot in the range 20 - 500 m V S· I was 1 .07 (r  
=0.998), which is  the expected s lope for an ideal reduction of adsorbed (surface) species 
(Laviron, 1 980). So in this case the process appears to have an important adsorption 
component .  
This resul t  indicates that the CIP molecules are strongly adsorbed and 
accumulated at the mercury electrode surface. The adsorption of CIP on the HMDE can , 
consequent ly ,  be used as an effect ive preconcentration step before quantitat ive 
measurements are undertaken .  Owing to i ts better analytical characteristics, the 
voltammetric technique used in the stripping step was the differential pulse stripping 
voltammetry (DPSV).  
5.2. Differential pulse stripping voltammetry (DPSV) of CIP 
S.2. 1 .  Dependence of (DPSV) peak of CIP on pH 
The differential pulse s tripping voltammograms of CIP (4.76 X 1 0.5 M) are 
recorded over a wide pH range (Fig. 5 .2) i n  phosphate buffer solutions using differential 
pulse stripping voltammetry. As reported previously ,  CIP (at a concentration of 4 .76 X 
t o·5 M) gave rise to s ix  cathodic peaks in  alkal ine media. The main DPSV peak (at ca . .  -
l AO V) which was observed over the investigated pH range from 7 to 9 ,  is attributed to 
the reduction of piperazine moiety of the adsorbed CIP film .  This peak is strongly pH 
dependent and is shifted to more negative potentials with increas ing pH. For analytical 
purpose, a pH 7.0 was chosen , since it gave rise to the highest peak current together wi th 
good discrimination against the background electrolyte decay. 
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5.2.2. Effect of an ions of the supporting electrolytes on the DPSV peak of CIP 
The infl uence of variou an ion of an indifferent supporting electrolytes (such a 
N03', 0/', C I04', r and Cn on the DPSY peak of the adsorbed CIP fi lm was 
Inve tigated (Fig .  5 .3 ) .  A more en i t ive peak was obtained in the pre ence of N03 , 
however, the height of the peak decrea es in the presence of r ,  cr ,  SO/ ' or CI04'. This 
l Ildicate, that n i trate ion exhibi t  the lea t tendency for peci fic an ion ad orption and Ie 
electr tat ic ad orpt ion forces on the mercury surface. On the other hand, the s ignificant ly 
lower ad orpti i ty of CIP in the presence of pec ific adsorpt ion ( 1 ' ,  SO/' or CI04') i 
correlated to i t  en i ti v i ty to larger alterat ions of the ad orpt ion potential around the 
operat ive potential . Therefore, quanti tat ive trace determinat ion of CIP by DPS Y was 
te ted in pre ence of n i  trate ion . 
5.2.3. Effect of operational parameters on the DPSV peak of CIP 
In order to select the opt imum operat ing condi tions for determinat ion of  CIP at pH 
= 7 .0 , the effect of scan rate, adsorption potential , adsorption t ime and pul e ampl i tude 
were carefu l ly  investigated . 
( i )  Effect of scan rate on the DPSV peak of CIP 
The variation of peak height vs. the scan rate in  the range 5-50 mY S' I was studied 
for 4.76 X 1 0'5 M CIP solution at pH 7.0 .  At higher scan rate than 20 mY S' I the width of 
the peak increases and at slower scan rate than 20 m V S' I the peak height decreases. A 
scan rate of 20 m V S' I was chosen for the stripping analys is  procedures (Fig. 5 .4) .  
( i i )  Effect of preconcentration potentials on the DPSV peak of CIP 
The effect of the adsorption potential was fol lowed at pH 7 .0  between 0.0 Y and -
0 .8  Y for CIP (Fig.  5 .5 ) .  The optimum accumulation potential was obtained at -D.4 Y. 
The peak height decreased markedly with shifting the potential to more negative values 
than -DA V.  Therefore, the deposition potential was adopted at -D.4 V for the stripping 
analysis experiments. 
( i i i )  Effect of preconcentration time on the DPSV peak of CIP 
As expected, the extent of preconcentration is  a function of the accumulation time 
(ts, sec) .  Fig.  5 .6 shows the dependence of accumulation time on the stripping 
voltammetric response of CIP. The peak currents i ncrease l inearly with increasing 
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preconcentrat ion time. At longer ad orption time an equi l ibrium surface concentration i 
reached and the peak height become con tant. A pre-electrolysis t ime of 60 wa 
adopted for the tripping analysi of CIP.  
( iv )  Effect of pu lse ampli tude and other instrumental parameters on the DPSV peak 
of C I P  
The effect o f  the pul e ampli tude on height of the DPSY peak was studied at pH 7 
(Fig. 5 .7) .  The dependency of the peak height ( ip, J..lA) on the pulse ampl i tude (25 - 1 00 
mY) indicate that the more sensit ive reduction peak of CIP was recorded at 1 00 mY 
pul e ampl i tude . The peak of CIP i plotted against pulse ampli tude. The plot i l i near up 
to ampli tude of 1 00 mY. The analytical determination was performed at 1 00 mY pul e 
ampl i tude . Other in  trumental parameters, such as drop size and pul e repet it ion t ime 
which d i rectly affected the voltammetric response , were opt imized (Fig .  5 . 8  and Fig.  5 .9) . 
The elected working condi tions were 5 .2  X 1 0'3 cm2 (Medium s ize, M) and 0 .5  s pulse 
repeti t ion t ime, respectively .  
5.2.4 Quantitative trace determination of CIP in  the model samples 
The appl icabi l i ty of the DPSV technique as analytical method for trace 
determination of CIP was tested as a function of the depolarizer concentration (Fig. 5 . 1 0) .  
The optimum conditions were found to be phosphate buffer (pH = 7.0 in  presence of 
N03'), 100 mV pulse amplitude, 20 mV S' I scan rate, 60 s accumulation time and -0.4 V 
accumulation potential . Under these conditions the response of the peak height as a 
function of CIP concentration is l i near over the range 1 .5 x 1 0,8 M - 1 .2 x 1 0'7 M .  The 
regression coefficient and the detection l imi t  were found to be 0.996 and 1 .988 ng mr l (6 
x 1 0'9 M) ,  respectively.  The precision was determined from 5 repeated measurements of 
the reduction peak height of 5 x 1 0'7 M CIP. The percentage relat ive error was ca. 3 . 1 % 
and the percentage relat ive standard deviation (%RSD) was 4 .2%.  
5.2.5. I nterference study 
A systematic study was carried out to evaluate the potential effect of coexist ing 
metal ions capable  of forming complexes with CIP or depositing at the mercury electrode 
on the determination of CIP at 4.76 x 1 0'5 M .  Table 5. 1 and Figs. 5 . 1 1  - 5 . 1 7  show the 
resul ts obtained. 
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5.2.6. Quantitative determination of CIP in  pharmaceuticals 
Ciprofloxacin wa determined in Bactiflox-250 tablet u i ng the DPSV according 
to the e peri mental procedure mentioned in chapter 2. There is  no need for any extraction 
procedure before vol tammetric analysi , and the standard addit ions technique wa applied 
l the pharmaceutical product . A known volume of the Bacti flox-250 solution prepared 
prevlOu Iy wa piked into 1 0  ml of the buffer olution (pH 7.0) fol lowed by spikes of the 
tandard CIP  olution . The corresponding vol tammogram have been recorded before and 
after each addit ion a indicated in Fig. 5 . 1 8 . The graph i l i near with a correlation 
coeffic ient of 0 .997 . In the piked amples containing 9 .8  x 1 0-6 M of CIP, 1 .029 x 1 0-5 M 
of C IP wa found with a re lat ive standard deviat ion of 3 .2% (for 5 determi nation) .  An 
average recovery of 1 05% was obtained for the spiked samples. 
The re u l t  obtained here show that the proposed DPSY method is  fa t ,  sensit ive 
and better u i ted than conventional methods, l ike spectrophotometry or chromatography, 
which often requ i re a concentrat ion step in order to improve the detection l imit ,  result ing 
al o in ample destruction . Al l  the e features make DPSV an attractive analytical 
approach for this c lass of drugs. 
5.3. Voltammetric studies of the interaction of CIP with DNA 
The e lectrochemical behavior of the reduction of CIP at HMDE prompted us to 
use the voltammetric method to trace the in teraction of CIP with asymmetric environment 
of the DNA. Typical cycl ic voltammetric behaviors of CIP in the absence and in the 
presence of DNA are shown in Fig. 5 . 1 9 . Working with the HMDE, the adsorbed CIP 
compound and i ts reduction products exhibit  complicated voltammograms. Under the 
conditions of Fig. 5 . 1 9  the complications caused by adsorption layers and the chemical 
spl i t t ing reaction have l itt le effect .  In the presence of DNA (Fig.  5 . 1 9A), the peak currents 
decreased and the cathodic peak potential s l ightly shifted (20 mY) in a negati ve direction 
but the anodic peak potent ial did not change. The reason for the decrease of peak current 
was that the apparen t  diffusion coefficient (D) decreased and also the apparent 
concentrations of the e lec troact ive species decreased (Carter et al., 1989). The decrease 
in the peak currents can be attributed to decrease in D value for CIP species in presence 
of the host molecule. This is supported by the decrease in the slope of the l inear ip - v"2 
plots accompani ed by the addit ion of host molecules. The slope of the l inear plot of ip 
versus vl/2 wi thout DNA (38 . 5 nNmyl12 S-Y.l) was more than that w ith DNA (3 1 .5 
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nNmy I/2 S,Yz), suggest ing the diffusion coefficient of the free form of C IP (D = 5 .69 x 
1 0,6 cm2 , I ) was larger than that of the complexed form CIP-DNA (D = 3 . 8  x 1 0'6 cm2 s' 
I ). Further evidence for the formation of a new adduct of CIP with DNA is given by the 
di sappearance of the three mal l peaks in the CY, denoted a l (cathodic peak), a2 and a3 
(anodic p ak ) located at ca.-0.45 Y ,  -0 .3  Y and -0 . 1 0  Y, respectively (Fig. 5 . l 9B) .  The 
peak are een only i n  the ab ence of DNA, and appear to reflect capaci t ive change as 
re-orIentat ion proces occurs .  Thi indicating the complexation of CIP molecule 
enhance the tacking i nteraction and hence wou ld be expected to fac i l itate the formation 
of a perpendicularly stacked layer of C IP-DNA complex on the electrode urface. S i mi lar 
behaV IOr was obtai ned previou Iy ( I brahim, 1 995). 
Further evidence for the interaction of CIP with DNA comes from the di fferential 
pul e tripping voltammetry (DPSY) .  In presence of di fferent concentrat ions of DNA the 
peak potential and the peak currents of C IP are influenced (Fig. 5 .20). Moreover, the 
experimental data of decrease of DPSV peak current with DNA corresponded wel 1 to 
Eq.( I ) . According to experimental data (at pH 7 .0), the fol 1owing equation was obtained : 
l ICONA= [2 .44 x 1 0 5 / ( I - ilio) ] -3 .6439 x 1 0  5 with R = 0.979, reveal ing that the binding 
complex of C IP molecule with DNA was a 1 :  1 association complex.  The binding constant 
of CIP to DNA was calculated from the y-intercept to be 3 .6439 x 1 05 M ' I , as shown in 
Fig. 5 .20. 
5.4. Voltammetric studies of the interaction of CIP with Cyclodextrins 
The i nc lusion phenomena of ClP-CD complex were i nvestigated by cycl ic 
voltammetry and d ifferential pulse cathodic stripping vol tammetry which are sensi tive 
electrochemical methods and permit the col lection of excel len t  data at low concentration 
of electro act ive guest. Typical cycl ic voltammetric (CV) behaviors of CIP in the absence 
and in the presence of C Ds at pH 7 .0  (phosphate buffer) are shown i n  Fig. 5 .2 1 .  The 
cyclic voltammetric behavior of pure CIP shows two cathodic peaks. The first cathodic 
peak, which appears at l ess negative potential ,  can be assigned to the reduction of Hg-CIP 
complex (Shehatta and Ibrahim, 200 1 ;  Ibrahim, 2000). The second peak (at ca.- I .4 V) 
the main reduction peak, was attributed to the reduction of piperazine moiety of CIP. 
The addition of P-CD or a-CD in the CIP solution caused the peak currents to 
diminish. This may be due to the binding of CIP to the l arge, slowly diffusing 
cyclodextrin w hich causes the decrease in  the peak current of the CIP in the presence of 
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an excess of P-CD or a-CD, and consequently results in the considerable decrease in the 
apparent di ffu ion coefficient of C IP-P-CD or CIP-a-CD adducts .  This is emphasized 
from the decrease in  lope of the l i near ip_v l 12 plots (R � 0.995), where the slope values 
(Fig. 5 .2 1 D) are 43 .8 ,  40.5 and 37 .5 nAimy l/2 S·y, in absence and presence of a -CD and 
p-CD, re pect i vely .  From these value , the d iffusion coeffic ient (Dr) of the free CIP was 
found to be 7 .4 x 1 0.6 cm2 . 1 ,  whereas Db = 6 .3  X 1 0.6 and 5 .4 x 1 0.6 cm2 · 1  for the bound 
CIP in the pre ence of 3 . 33  x 1 0.3 M of a-CD and p-CD, respecti vely .  
It i noteworthy that the current could also be d imin ished i f  the hosts caused an 
l ncrea e i n  the olut ion v isco i ty wi th a corresponding decrease in  the diffusion 
coeffic ient . However, no change in  solut ion v iscosity could be det.ected over the range 
7.4 x 1 0-4 and 3 . 5  x 1 0.3 mM CDs. 
Further evidence for the i nteraction of C IP with a-CD and P-CDs comes from the 
di fferent ial pulse stripping voltammetry (DPS V).  In presence of d ifferent concentrations 
of p-CD, the peak currents of the first and the second peaks of C IP are trongly affected 
wi th i ncreas ing concentration of P-CD (Fig. 5 .22) reveal ing that an interaction has 
occurred between CIP and p-CD. Whereas, i n  the presence of different  concentrations of 
a-CD, the cathodic peak potentials as wel l  as the peak currents of C IP are influenced (Fig. 
5 .23) .  The cathodic peak potent ials of the first and the second peaks shifted to more 
posit ive potent ial ,  indicating that the reduction of CIP molecule is enhanced when i t  
enters the a-CD cavity, a cavity with lower polarity. On the other hand, the current of  the 
first peak increases, whereas the current of the second peak decreases with increasing 
concentration of a-CD or P-CD i ndicat ing that an interaction has occurred between CIP 
and a-CD or p-CD. 
Based on the variation In the peak current, the fonnation constants of the 
complexes, fonned between CIP and either a-CD or P-CD, were determined. For 1 :  1 
complex the fol lowing equation could be deduced. 
log ( l ICco) = 10gK + log [IH.a / (Ia- IH.a)] ----------(7) 
Applying this  equation to the data extracted from Figs .  5 .22A and 5 .23A the fol lowing 
two equation are obtained applying the least squares method by plotting log ( l ICco) 
versus log [ IH-a / (Ia- IH-a)] (Figs. 5 .22B and S .23B). 
l IC�-co = 2.03 + 0.662 log [IH-G / (Ia- IH-G)] 
l ICa-co = 1 .94 + 1 .43 log [IH-G I (Ia- IH-G)] 
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with correlat ion coefficients (R) z 0.97. This revealed that the inc lusion complex ofCIP 
with a-CD or P-CD was a 1 :  1 association complex and the format ion constants (K) were 
87 M-1 and 1 07 M-t , as calcu lated from the y-intercepts of F ig. 5 .23 B and Fig. 5 .22 B for 
a D and p-CD, respect ively. 
P-CD binds C IP  more strongly than a-CD as ind icated from the large K and -L'lG 
values (- 1 1 .07 and -1 1 . 59 IU/mo l for a-CD and P-CD respectively). These results 
indicate that the size of the cyc lodextrin cavity plays an important role in the formation of 
the complex. On the basis of size, the cavity size of P-CD seems to be optimal for 
entrapment of the C IP  molecule, whereas in a-CD the binding leads to the formation of a 
more unstable complex. Further evidence for the formation of a better fit between the C IP  
and large P-CD cavity i s  given by the disappearance of  the three smal l  peaks i n  the CV, 
denoted at (cathodic peak), a2 and a3 (anodic peaks) located at ca. -0.45 V, -0.3 V and -
0. 1 0  V, respect ively ( Fig. 5 .2 1 ) . In case ofa-CD, the peak a t  d isappeared, whereas both 
a2 and a3 decreased. 
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Table 5 . 1 :  hange of the DP V peak current and potential of 2 . 86 x 1 0'5 M 
cr p in presence of interfering spec ies; supporting e lectro lyte, phosphate 
buffer. 
Peak 1 Peak 2 
Potent ial Conc .  Current Current Potential 
interferent ( M) Change (%) Change Shift ( mv) 
(%) 
Cr( I l l) 4. 74x 1 0'5 -23 . 70 -- --
9.43x 1 0'5 -40.20 -- --
Co( I l )  1 .40x 1 0.{) - 1 0 .20 +22. 3  +50 .00 
3 .30x 1 0-6 -23 . 1 0  +64. 7  +68 . 75 
Zn( I I )  2 .27x 1 0.{) + 1 46.4 +9.80 + 1 8 . 75 
6. 20x 1 0-6 +22 1 . 7 + 1 6 .2 +25 .00 
ed( I I )  2 . 37x 1 0.{) 0 .000 + 1 .70 0 .000 
9 . 35x 1 0-6 + 1 6.40 +20.9 0 .000 
Cu( I I )  1 .90x 1 0') -23 .60 -3 . 70 0 .000 
1 . 8 7x 1 0-4 -33 . 30 +25 .2  -25 .00 
N i( l l )  4 . 70x 1 0'5 - 1 9.40 + 1 6. 7  -25 .00 
7 .60x 1 0'5 -27.80 +27 .2 -37 . 50  
Pb(I I )*  8 . 70x 1 0-4 +33 .30  + 1 2 .4 +68 .75  
1 .60x 1 0,3 +53 .60 + 1 3 . 7  +75 .00 
*New peak at - 1 . 0 1 25 V 
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Fig.S .2 :  Effect of pH on the DP V peak of 4 .76 1 0-5 M ClP .  c an  
rate 20 mV S- I ,  ta = 30 s and pul e ampl itude 1 00mV . Ph phate 
buffer: pH ( 1 )  5 .0 ;  (2) 7 .0 and (3)  9.0 . Inset :  Variation f the 
peak height current as a Function of pH.  
Fig.5.3: Effect of anions on the DPSV peak of 4 .76x 1 0-5 M ClP .  
Scan rate 20 mV S-I ,  ta = 30  s ,  pulse amplitude 1 00mV and 
pH 7 .0 (Phosphate). ( 1 )  cr; (2) CI04- ;  (3)  N03-; (4) r 
and (5) SO/-. Es = -0.4 V (for each curve). 
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Fig.sA: Effect of scan rate on the DP V peak of 4.76x 1 0-
pulse ampl itude 1 00mY, ta =30s and pH 7.0 phosphate) .  
( 1 )  5 mV S- I ; (2)  1 0  mV S- l ; ( 3 )  20 mY - I  and (4) 50 m - I  
I nset : Variat ion of the peak height current as a Funct ion  of can 
rate, v. 
Fig.s.s: Effect of preconcentration potential o n  the DPSY peak 
of 4.76x 1 0-5 M eIP at pH 7.0 (phosphate), pulse amplitude 
1 00 mY, scan rate 20 mV S-l and ta =30s. ( 1 )  0 V; (2) -0.2 V;  
( 3 )  -0.4 V; (4) -0.6  Y and (5)  -0.8 Y.  
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Fig.5.6: [A] Effect of adsorption
 t ime on the OP V peak of 4 .76x \
0- 1 
ClP .  Pulse ampl itude 1 00m , pH 7
.0 (pho phate) and can 
rate 20 mV 5-1 . ( 1 )  Os; (2) 30s; (3) 60s' (4) 90
s and (5 )  1 20 . 
[B ]  Variation of the peak height cur
rent as a Function of 
adsorption time (peak 1 ) . 
[C] Variation of the peak height curr
ent as a Function of 
adsorption time (peak2) .  
Fig.5.7: [A] Effect of pulse height on the DPS
V peak of 4.76x 1 0-
5 M 
ClP .Scan rate 20 mV S- I ,  pH 7 .0 (phosphate) and t
a = 30 s. 
( 1 )  25 mV (2) 50 mV (3)  1 00 mY. 
[B] Variation of the peak height current as a Functio
n of 
pulse height (peak 1 ) . 
[C] Variation of the peak height current as a Function o
f 
pulse height (peak 2). 
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Fig.5.8:  Effect of drop size on the DPSY peak of 4 .76x 1 0-5 M C IP .  
Scan rate 20  mY S- l , pH 7 .0  (phosphate), t a  = 30 s and pulse 
ampl itude 1 00 mY. ( 1 )  Small ;  (2) Medium and (3) Large. 
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Fig.5.9:  Effect of repetit ion drop time on the DP V peak of 
4.76x 1 0.5 M elP .  Scan rate 20 mV S· l ,  pH 7.0 (phosphate). 
ta =30s and pulse amplitude 1 00 mV. ( 1 )  0.2 s' (2) 0.5 s 
and (3)  I s. I nset : Variat ion of the peak height current as a 
funct ion of drop time (peak 2) .  
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Fig.S. 1 0 : [A] DPSV peak of C IP  for different concentrations under the 
optimum condit ions in presence ofNaNO}, pH 7.0 
(phosphate), ta = 60 s, scan rate 20 mV S- I and pulse 
amplitude 1 00 mY . ( 1 )  1 .9x 1 O-{)� (2) 2 .7x 1 0-{); (3 )  1 . 1 8 '  1 0-5; 
(4) 2 . 5x 1 0-5 ; (5)  4.6x 1 0-5; (6) 7 . 8x 1 0-5 and (7) 1 . 1 x  1 0-4 M. 
[8]  Calibrat ion curve plot. 
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Fig.S. l I :  DPSY peak behavior of2 .86x 1 O-5M C lP  in presence of  
Co(l l ) .  Scan rate 20 mV S- l ,  pH 7 .0  (phosphate), t a  =30s 
and pulse ampl itude 1 00 mY . ( 1 )  0 ;  (2) 1 . 5 xl 0-<> and 
(3) 3 . 5  x l  0-<> M ofCo( I I ) .  
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Fig.5. 1 2 :  DPSV peak behavior of2 . 86x 1 O-5M erp  in presence of 
Pb( I I) .  Scan rate 20 mV S-I , pH 7.0 (phosphate) ta =30 
and pulse amplitude 1 00 mY . ( 1 )  0; (2) 9. 1 x 1 0-4 and 
(3) 1 .67 x l O-3 M of Pb( I I ) . 
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Fig.S. B: DPSV peak behavior of2 .86x 1 O-
5M C lP  in presence of 
Cue I l ) .  Scan rate 20 mV S- 1 pH 7 .0 (phosphate), ta =30s 
and pulse ampl itude 1 00 mY. ( 1 )  0 ;  (2) 1 .99 x l O-
5 and 
(3) 1 .96 x l  0-4 M ofCu( I l ) . 
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Fig.5. 1 4 :  DPSV peak behavior of2 . 86x 1 O·
5M CIP in presence of 
Cd( I I ) .  Scan rate 20 mV S·
l , pH 7.0 (phosphate), ta ==30s 
and pulse amplitude 1 00 mY. ( 1 )  0; (2) 2
.5 x 1 0-O and 
(3)  9 .8 x 1 0-O M of Cd( I I ) . 
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Fig.S . l S :  DPSV peak behavior of2 . 86x 1 0-
5M CIP  in presence of  
N i( I I ) .  Scan rate 20 mV S- I ,  pH 7 .0 (phosphate), ta =30s 
and pulse amplitude 1 00 mY . ( 1 )  0 ;  (2) 4.9 1 0-
5 and 
(3)  7.9 x l O-5 M ofNi( I I ) . 
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Fig.5. 1 6 :  DPSY peak behavior of 2. 86x I O,sM CIP  in pre ence of 
Cr( I I I ) . Scan rate 20 mY S- l ,  pH 7 .0 (phosphate), ta  =30s 
and pulse ampl itude 1 00 mY. ( 1 ) 0; (2) 4 .9 x l O-5 and 
(3) 9.9 x l O-5 M ofCr( I I I ). 
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Fig.5. l 7 : DPSY peak behavior of 2 . 86x 1 O-
sM e IP  in presence of 
Zn( I I ) . Scan rate 20 m Y  S- l ,  pH 7 .0 (phosphate), t a  =30 
and pulse ampl itude 1 00 mY . ( 1 )  0 ;  (2)  2 .4 x l O
-Q and 
(3) 6 .5 x l  0-<> M of Zn( I I ) .  
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Fig.S. 1 8 : [AJ Applicat ion of the standard addit ion met
hod for 
determination of C IP  in formulat ion sample (tablet) .  
pH 7 .0 (phosphate) with aN03. t a  =605, scan rate 20 
mV 5- 1 and pulse amplitude 1 00 mY . ( 1 )  0 . 1 ml of tablet 
solut ion; (2) 1 + 9 .8x 1 0
�; (3) 1 + 1 .9x 1 0-5 ; (4) 1 + 3 .9  
x 1 0-5 ; (5) 1 + 5 .6x 1 0-
5 ; (6) 1 + 7 .3x 1 0-5 ; (7 )  1 + 9x 1 0-
5 
(8) 1 + 1 . 1 x  1 04 and (9) 1 + 1 .2x 1 0
4 M ofCIP .  
[B ]  Calibration curve plot. 
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Fig.5. 1 9 :  [A] Effect of the scan rate on the C
V peak of 5x 1 0-
5 M CIP  
In  the presence 0 .2  mg/ml DNA. At  
pH 7 .0 (phosphate) 
with NaN03. ( 1 )  v =500 mV S
- I ; (2) v =200 mV S-
I : 
(3) v = 1 00 mV - 1 ; (4) v =50 mV S
- I and (5 )  v =20 mV S
- 1 . 
[BJ Effect of the scan rate on the CV 
peak of 5x 1 0-
5 M C IP  
without DNA. Other conditions as i n  [A] .  
[C] Curve plot o f  peak height current 
versus v1f2 (in the present 
and absent of DNA) 
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Fig.5.20 :  [A] DP V peak behavior of 5x 
1 0-5 M CIP in presence of 
D A. ( 1 )  0 ;  (2) 1 . 33x 1 0
-6; (3 )  2 .6x 1 0
-6; (4) 6 .4x 1 0
-6 : 
(5 )  8 .8x 1 0-6 ; (6) 1 . 1 x  1 0-
5 ; (7) 1 . 3x 1 0.
5 and (8)  � .2x 1 0-
5 M 
DNA. Pulse ampl itude 1 00 mY, pH 7 .0  (ph
o phate) \vith 
NaN03, Scan rate = 20 mV so
l and ta=30s. 
[8] P lot of l lC versus 1 /( l -(iI�)) .  
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Fig. 5.2 1 :  [A] Effect of the scan rate on the CV pea
k of 5x 1 0-5 M eIP 
I n  the presence 3 .33  x 1 0-
3 M of �-CD. At pH 7.0 
Pho phate with a 03. ( 1 )  v = 500 mV S-
l ; 
(2) v = 200 mV S-
I
; (3)  v = 1 00 mV S-
I ; (4) \' = 50 m S-
l ; 
and (5)  v = 20 mV S- l . 
[B ]  Effect of scan rate on the CV peak of 5x 1 0-
5 M C IP  
I n  the presence of 3 . 33  x 1 0-
3 M of  a-CD. Other cond it ions 
as in [A] . 
[C] Effect of scan rate of the CV peak of 5x 1 0-
5 M CIP 
in the absence of CDs. Other conditions as in [ A] .  
[D] Plot o f  peak height current versus v
lf2 (in the present 
and absent of CDs) . 
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Fig. 5.22 : [A] DPSV peak behavior of 5 x 1 0-5 M CIP in pre ence 
of �-CD. ( 1 )  0; (2) 7.4 x I O-4; (3 )  1 . 1 5  x 1 0-3 ; (4) 1 . 87x I O-J ; 
(5) 2. 1 87 x 1 0-3 M of �-CD. Other condit ion as In 
Fig. 5 .20. 
[B] P lot of log I /[CD] versus log I H-G lIo-I H-G · 
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Fig. 5.23: DPSV peak behavior of 5 x 1 0-5 M CIP in presence 
of a-C�. ( 1 )  0; (2) 4.76 x 1 0-4 ; (3)  l . 3 x 1 0-3 ; (4) l . 67x l O-3 : 
( 5 )  2 .59 x 1 0-3 M of a-C�. Other conditions as in 
Fig. 5 .20. I nset :  Curve plot of log l I[CO] versu 
log I H-G IIG-I H-G · 
CHAPTER VI 
Conclusion 
CONCLUSION 
The re ults obtained here obviously how that the tudied cyclodextrins enhanced 
the aqueou solubi l ity of fluroquino lone ant imicrobial drugs. Therefore, it expected that 
the formulat ion of  fluroquinolone as a microencapsulate with CDs may enhance its 
aqueous olubil it and show a better bioavai lability. Such drug-CD inclusion complex 
may he lp to avoid the undesirable side effects which the administration of the drug alone 
may provoke. thus improving its therapeutic usefulness. Also, there is a hope that the 
fluroqinolone content of medic ines may be reduced, and the side effects wil l  lessen, i .e .  
the therapeutical risk wil l  be smal ler, whi le the pharmacological effect wi l l  increase 
consequent ly, the quantity o f  medicine residues wi l l  be smal ler. In addit ion, the use of 
CD i of utmost economical importance. 
The extensive deve lopments of pharmaceut ical field requITe more ngorous 
methods for the control and enhance the bioavai labi l ity o f  drugs. The e lectrochemical 
methods such as cathodic stripping vo ltammetry have become increasingly important in 
the determination of compounds of pharmaceut ical interest because it gives more 
accurate, more sensit ive simpler, quicker and automatical ly operated procedures. I ts  
appl icat ion is based on the abi l ity o f  substance being determined to accumulate at the 
e lectrode surface during a waiting t ime at a potential which anodic current flows. 
The bio logical importance ofNAL, NOR and eIP has stimulated our considerable 
interest in stripping analysis of these drugs. The aforementioned results of cyclic 
voltammetry indicate the adsorption of these compounds. This phenomenon can be 
exploited for the e lectro analytical determination of the investigated drugs with the aid of 
differential pulse stripping vo ltammetry (DPSV). Various considerat ion of the 
experimental variables and the processes which take place on the hanging mercury drop 
e lectrode are also taken into consideration. It has been found that the determination of 
these drugs depends on various parameters, e .g . ,  pH, concentration of drug, adsorption 
time, adsorption potential, scan rate and pulse amplitude. The influence of these 
parameters on the shape and the peak height of cathodic stripping peak during the 
negative scan of potential has been determined. The drugs under investigation can be 
determined with the aid of DPSV at concentration of the order of rnagnitude 1 0-9 M. The 
applicabi l ity of the proposed method to the determination of these drugs in 
pharmaceutical samples was also described. To avoid matrix effect the amount of drug in 
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tablets in the cel l  was determined by the standard addit ions method. The mean recoveries 
for the different concentration were 90 - 1 05%. 
The propo ed method was also successfully appl ied to the determinat ion of these 
drug in human urine and b lood serum without any pre liminary treatment . The percentage 
recoverie of the in est igated drugs were calculated by comparing the peak currents of 
known drug concentration in urine or serum with their equ ivalents in aqueous solut ion. 
Mean reco erie of the different drug concentrations in urine and serum were found to be 
98.0 and 1 06%, respective ly. Addit ional ly, numerous pharmacokinetic studies have 
shown reduced bioavai labi l ity of quino lones after simultaneous administration of metal 
ions containing preparations. 0, a systematic study was carried out to evaluate the 
potential effect of coexisting metal ions capable of forming complexes with the drugs 
under investigation or depositing at the mercury e lectrode on the determination of these 
drugs . 
The DNA-binding studies are important for the rational design and construction of 
new and more efficient drugs targeted to DNA. These are extremely useful in 
understanding the DNA sequence recognition by drugs as wel l  as by proteins. In addition, 
the common feature in their structures, which characterizes both CD and DNA, are that 
they have a hydrophi l ic coat and a hydrophobic core. The hydrophilic groups (OH in CDs 
and P04-3 in DNA) of these macromolecu les are oriented to the exterior creating sites 
available for intercalative (hydrophobic) interactions. So, the voltammetric methods were 
used to probe the interaction (electrostatic or intercalative) ofNAL, NOR or CIP with calf 
thymus DNA at the HMDE. The changes in the cycl ic voltarnmetric behavior of these 
drugs in an aqueous medium on addition of DNA have been used to probe the interaction 
between these spec ies. The binding constant of the NAL-DNA, NOR-DNA and CIP­
DNA interactions were also obtained by a t itration of these drugs with nucleotide 
phosphate using differential pulse stripping vo ltammetry (DPSV). The binding constants 
for these adduct indicated that these drugs have a high affmity for DNA. Therefore, the 
results we obtained here may open to us many new doors to understanding and 
developing the mechanism action of drugs in l iving body which wil l result in saving 
money, t ime and effort .  
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Ab tract 
The qumolone antibacterial agent nalidIxic acid (NA L) was stud ied by cycl Ic  voltammetry (CY) and cathod Ic 
adsorptIve stnppmg voltammetry (CASY). A sensitive method is described for the determmation of NAL in I ts pure 
form. dosage forms and biological fl uids. Controlled adsorptive accumulation of N A L  on a hanging mercury drop 
electrode provides the basis for the direct stripping measurement of that compound in the nanomolar concentration 
level. DifTerent  variables were studied and optimized. The proposed method depends upon the voltammetric activity 
of NAL in Bri t ton- Robinson buffer, whereby a well-defined cathodic peak is produced at pH 5.0 in presence of 
N O ), .  The calibration graph to determine N A L  was l inear in the range 7.4 x 1 0  - R_2 .5  x 1 0 - 5 M by CASY. CAS 
voltammetry has been proved to be advantageous over a l iquid chromatographic (LC) technique, allowing to 
detection limit signal to noise ratio, (s/n = 3) of 0.766 ng ml - I  (3.3 x 10 -9 M )  N A L  to be reached . The relative 
standard deviation (n = 5) was 5.2% at concentration level of 1 .0 x 1 0 - 7 M N A L .  The degree of interference from 
coexisting metal ions on the CASY signal for NAL was evaluated. The method was applied to two different 
commercial pharmaceutical products (Negram tablets and suspension) with very good recoveries. It  was also shown 
that the method was s uccessfully applied to the determination of N A L  in human urine and blood serum. Mean 
recoveries were 98.8 ± 0.3 and 98.9 ± 0.41%, respectively. 0 2002 Elsevier Science B . Y .  All rights reserved . 
KeYlmrds: Nahdlxic acid; Adsorptive stripping voltammetry; Urine; Serum; Pharmaceutical analysis 
1 .  Introduction 
Quinolone antibacterials have aroused mucb 
interest because of their potency and efficacy. The 
first analogue of this class of synthetic agents used 
clinically was nalidixic acid for treatment of uri ­
nary tract infections [ 1 ) . I t  is more active against 
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gram-negative t ban gram-positive organisms 
tbrougb inbibit ion of tbeir DNA gyrase (2). 
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Recently, tbe chronic toxicity and carcinogenicity 
of AL were evaluated [3] .  The major metabolite 
of nalIdixic acid is the 7-hyd roxymethyl nalid ixic 
acid which exhibits at least in vitro antibacterial 
activity nearly Identical in  pectrum and potency 
to that of the parent compound [4]. The overall 
conversion of nalidixic acid to 7-hyd roxymethyl 
nalid ixIc acid had also been reported by McCb­
esney [4] to be normally about 32%. The exten­
sive development of tbe pharmaceutical field 
requires more rigorous analytical methods for tbe 
control of d rugs. Measurements of  low levels of 
A L  commonly rely  on spectroscopy [5] or chro­
matography [6 ,7 ] .  H P LC is the most frequently 
applied technique to the determination of NAL 
whether in dosage forms and biological fluids 
[8 - I I ] .  In recent years , modern electroanalytical 
techniq ues, especial ly adsorptive stri pping 
voltammetry, are becoming increasingly impor­
tant in the determination of compounds of phar­
maceutical in terest [ 1 2 - 1 7] .  The adsorptive 
s tripping proced ures are faster, easier, cheaper 
and more sensit ive tban spectrometric and LC 
methods and tbat tbe experimental methodology 
is less ted ious .  M oreover, they can be successful ly 
employed for the analysis of  materials in compli ­
cated systems (e .g .  tablets, urine ,  serum and 
so on). 
The basic d . c. polarographic behaviour of 
NAL at the DME was firs t  studied by Staro­
sak et al. [ 1 8 ] .  A difTerential pulse polaro­
graphic method for tbe determination of NAL 
and i ts metaboli te, the  7-bydroxymetbyl deriva­
tive, in  urine was reported [ 1 9] .  Tbe l imit  of 
quantification of tbis method ( 1 0 - 5- 1 0 - 6  M )  is 
higb. No report has been publ ished on tbe ad­
sorptive stripping voltammetric analysis of NAL 
in  urine, serum and i n  pharmaceutical formula­
tions. 
Tbe aim of this  study was to develop a method 
for tbe determination of low levels of NAL by 
catbodic adsorptive stripping voltam metry 
(CASy) and to apply i t  to pharmaceutical formu­
lations. This  s tudy also describes the applicabil i ty 
of the method to biological materials such as 
human urine and blood serum. 
2. E pcrirncntal 
2. 1 .  Instrumental /on 
A PAR M odel 303 H M DE was used in con­
junction with a PAR Model 264A polarographic 
analyzer/stripping voltammetry and X-Y recorder 
Model REO l S I  for cathodic adsorptive stripping 
voltammetric (CASY) and cyclic voltammetric 
(CV) measurements. The cel l was maintained at 
22 ± 0 .5  0c. An Ag/AgCl saturated KCl refer­
ence electrode and a Pt wire auxil iary electrode 
were used . A PAR M odel 305 st irrer were also 
used for CAS voltammetry. The pH was mea­
sured using a Radiometer model M64 digital pH ­
meter. 
H igh Performance Liquid Chromatography 
(H PLC) ana lyses were performed on a Waters­
All iance 2690, ( Waters Inc . ,  USA). Waters UV­
Vis-486 was employed for the detection at 257 
nm. Analytes were chromatographed on Nova­
Pak C I S  reversed-phase packed columns ( 1 50 x 
3 .9  mm). The cbromatograpby was carried out at 
40 °C with a mobile phase consisting of acetoni­
trile and 1 .2% glacial acetic acid (35 :65 ,  v/v). The 
flow rate was of 1 .0 ml  min - I .  After equil ibrat­
ing tbe chromatographic system, samples were 
injected into the system and tbeir  respective chro­
matograms recorded. A Waters M il lennium 32 
chromatographic manager workstation was used 
to record chromatograms and calculate peak 
beights or areas of NAL.  
2.2. Chemicals and reagents 
Nalidixic acid ( l -ethyl- I ,4-dibydro-7-methyl -4-
oxo- I ,8 -napbthyridine-3-carboxylic acid) was ob­
tained from Sigma and was used witbout further 
purification. Stock solutions were prepared by 
dissolving the d rug in I :  I etbanol/water mixture. 
The supporting electrolyte was B ritton - Robinson 
(BR)  buffer brought to a constant ionic s trength 
0.5 kM (or 1 . 5 k M ,  SO� - )  by the addit ion of 
NaX (X = CI - , CIO; , NO; , SO� - )  and adj usted 
to the desired p H .  Aceta te or phosphate butTer 
also served as a supporting electrolyte. Al l  metal 
salts (purchased from BDH) are in nitrate form. 
Twice-disti l led water was used to prepare the 
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solutions. H uman urine and blood serum sample 
were used shortly after collect ion. 
2. 3. Voltammetnc measurements 
A 1 0.0 ml of BR buffer was placed in a polaro­
graphic cell and de-oxygenated by passing ni trogen 
for 1 6  min.  The voltammetric response was ob­
tained using a pulse repetit ion time of 0.5 s ,  within 
an amplitude of 1 00 mV and a scan rate of 20 mV 
s - 1 (or 1 00 m V  s - I for eV). For catbodic stripping 
experiments a preconcentration potential of - 0.4 
Y was applied for a selected period of time (unless 
othenvise stated), fol lowed by a 1 5  s rest and a 
d ifferent ial-pulse voltammetric scan in the negative 
poten tial direct ion. For mult i -s tep standard addi­
t IOns method d ifferent add it ives of  tbe standard 
drug solutIOn were added fol lowed by recording the 
voltam mogram.  
2.4. Tahlet and suspension treatment 
Five tablets of Negram.  eacb containing 500 mg 
of nalidixic acid. were powdered and tbe amounts 
corresponding to 1 00 mg ofNAL were weigbed and 
finally d issolved in  ethanol during 1 5  min. The 
excipient was separated by filtration and the precip­
i tate washed three times wi th ethanol .  The solution 
and washing ethanol were transferred quantita­
tively into a calibrated flask and di luted to a final 
volume of 250 ml ( 1 :  I ethanol/water mixture). One 
mil l i l i tre of  this solution was di luted to 1 0.0 ml witb 
etbanol to obtain the suitable final concentration. 
An aliquot of  this solution was added to 1 0.0  ml 
of  BR buffer (pH 5 .0) and the vol tammogram was 
recorded fol lowing tbe vol tammetric procedure. 
One mil l i l i tre of Negram suspension, claimed to 
contain 250 mg N A L  per 5 .0 ml suspension solu­
tion, was dissolved i n  1 00 mI l :  I ethanol/water 
mixture. A smal l  amount of non-dissolving excipi­
ents settled at the bottom of the flask. One mil l i l i tre 
of tbe clear supernatant was transferred to a 1 0.0 
ml volumetric flask and di luted to mark witb 
etbanol . A 50 III portion was added to the voltam­
metric cell containing supporting e lectrolyte (BR 
buffer, pH 5 .0) and  tbe  voltammogram was 
recorded . The s tandard additions metbod was then 
applied. adding successive al iquots of 1 00 III of 
1 x 10 - 4 M NAL solution. The concentrations of 
the NAL in the investigated samples were calcu­
la ted from tbe mult i -step standard additions plots 
using tbe KALElDA GRAPl l computer program. 
2. 5. Urine and serum treatment 
Different vol umes of urine or serum were added 
to B R  buffer at pH 5 .0 to give a total volume of 
1 0 .0 ml. Wben tbe volume of urine or serum 
increased , tbe background current increased 
rapid ly. so to avoid the sample interferences di lu­
tion was carried out (9: 1 buffer/sample mixture). In 
this way tbe d i lu ted sample prod uced a smooth 
curve without any peak i ll the potential range from 
- 0.40 to - 1 . 5 V. This di l uted samples were used 
for voltammetry. Because tbe general reduction 
pattern of tbe major  metabolite of nalidixic acid 
(7-byd roxymetbyl nalid ixic acid) resembles that of 
the parent acid [ 1 9] .  tbe proposed met bod cannot 
able to differentiate between tbe paren t drug and 
tbe metabolite; i .e .  tbe sum of both nalidixic acid 
and 7-hyd roxymetbyl nalid ixic acid can be deter­
mme. 
3. Results and discussion 
3. 1.  Effect of pH and the nature of the electrode 
process 
The eASY current  of N A L  ( 1 .9 x 1 0 - 5  M) was 
recorded as a function of potent ial  in phospbate 
buffer solutions of  varying pH (2-9) ( Fig. 1 ). 
Reduction of N A L  a t  tbe H M D E  was found to be 
pH dependent. The recorded eASY peaks (Figs .  1 
and 2e) at various pH values are mainly due to tbe 
red uction of the carbonyl group ( :>  e=o) on e4 to 
the 4-bydroxy product [ 1 8 ] .  I t  was also found tbat 
tbe peak potential is shifted to more negative values 
witb increasing pH and tbe peak height decreases 
markedly at pH � 7.0 .  The red uction peak be­
comes broad and spli tted into two consecutive 
small overlapped peaks at pH � 7.0 (Fig. I ) .  Tbe 
reduction peak (Figs. I and l C) at ca. - 1 90 mY 
(pH 5 .0), bas been reported previously for similar 
compounds [20] and i t  was attributed to tbe reduc­
tion of Hg( J I )  bound to tbe adsorbed H g( I I )-NAL 
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film through the hetero yclic nit rogen atoms, N8.  
A plot  of EpIc v . pH (from 2 to 9) was a st raight 
l ine wi th  a s lope of 0.07 V, howing that two 
hydrogen ions were invol ed in the electrode pro­
cess.  Furthermore, the etTect of buffe r con­
stituents on the adsorpt Ive tr ipping response was 
also studied in the presence of several supporting 
buffer electrolytes, e.g.  acetate, phosphate and BR 
butTers. The best results with respect to enhance­
ment ,  shape and reprod ucibility were obtained in 
B R  buffer solution. Hence, B R  buffer (pH 5 .0) 
< 1 .2 
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has been recommended for al l  CASV measure­
ments. 
Tbe nat ure of the electrocbemical process of 
AL was also studied by cyclic voltammetry 
(CV). The cyclic voltammetric behaviour of 1 .9 x 
1 0  - 5 M NAL at pH 5 .0 ( B R  buffer) is sbown in 
Fig. 2 ,  which sbows two red uction processes, the 
fi rst process ( l  C) being reversible, fol lowed by 
irreversible process (2C).  Tbe main process (2C) 
is due to a 2e - j2H + red uction of tbe pyridone 
moiety (C5H4NO) of NAL as discussed above 
! 
r\ I ( 2 C )  
I I 2 I I r I 
I 
r \ 
I I 10•2 )' A  I I 
I \ 
I \ 
I \ 
I \ \ r \ 
I 
I 
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- 0.2 - 1 .8 E(  V )  
Fig. 1 .  Effect of pH on the eASY peak of 1 .9 x L O - s  M NAL. Scan rate 20 mY S - I , I. = 30 s and pulse amplitude 1 00  mY. 
Phosphate buffer. pH ( I )  2.0. ( 2 )  5.0; ( 3) 7.0; and (4) 9 .0 . Inset ' variation of the peak height (2C) current as a function of pH. 
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Fig. 3 Peak height dependence of t he CASY peak (2C) on the 
accwnulation tune: (a) ( 1 .0 x 1 0 - 7  M NAL) and accwnula­
lion potential; ( b) ( 1 .9 x 1 O - }  M NAL). BR buffer pH 5 .0. 
Other condition} as  in Fig. I . 
(Figs .  I and 2C). The peak potentials display a 
cathodic shift on increasing the scan rate ( v )  ( inset 
of  Fig. 2), thus revealing the irreversible nature of 
the second red uction process (2C) [2 1 ] .  Moreover, 
the slope of the log ip vs. log v plot in the range 
1 0 - 200 mY S - 1 was 0 .75 1 (r = 0.99 1 ) , close to I ,  
which is the expected slope for an ideal reduction 
of surface species [22] .  So in this case, the process 
appears to have an important adsorption compo­
nent. The adsorption of NAL on the H M D E  can , 
con equent1y, be used as an elTective preconcen­
tration s tep before quantitat ive measurements are 
undertaken.  
3. 2. Eifect of accumulatIOn time and 
accumulation potential 
As expected, the extent  of preconcen tration is a 
function of the accumulation t ime OJ. Fig. 3a 
shows the dependence of accumulation time on 
the stripping voltam metric response of AL.  The 
peak currents increase l inearly with increasing 
preconcentrat ion time. It was also observed that 
when the accumula tion t ime are i ncreased satura­
tion is reached . A preelectrolysis time of 1 20 s was 
adopted for the stri pping analysis of N AL.  
The effect of  the accumulation potential (EJ 
was fol lowed at p H  5.0 between 0.0 and - 1 .0 Y 
for NAL (Fig. 3 b) .  I n  this potential range, the 
peak current p roved to be independent of the 
accumulation potential .  The latter behaviour 
reflects that the N A L  (pKa = 5 .9 [23]) species ac­
cumulated on the mercury electrode surface in a 
neutral form . 
3.3. EiJecl 0/ the anions 0/ the supporling 
electrolyte 
The influence of va rious anions of an indiffer­
ent supporting electrolyte (such as NO) , SO� - , 
Cl04 , r - and C l - ) on the CASY peak of the 
adsorbed N A L  film was investigated . The results 
indicate that the cathodic red uction peak de­
creases in  the order NO) � Cl04 > SO� - > Cl­
> 1- . The main  d ifference i s  connected with 
s tructural changes in the electrical double layer 
due to the specific  adsorption of the anions of the 
supporting electrolyte .  In this case the electrostat­
ical ly attracted i ons of  the solvent repel the ad­
sorbed molecules from the electrode surface and 
decrease the forces of  non-electrostatic adsorption 
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of A L  molecules at a charged interface. On the 
other hand, a more ensitive peak was found in  
the presence of O} , however in presence of 
balide anions ( 1 - or 1 - )  the heigbt of the peak 
decreases markedly. This ind icates that NO} ex­
hibits the smallest tendency for specific ad orption 
anion and less electro tatic forces on tbe cbarged 
mercury surface. This reflects the rule of anions of 
indifferent supporting electrolyte on the degree of 
adsorption and accumulation of AL fi lm at tbe 
charged interface [24].  
Several instrumental parameters, such as drop 
s ize, scan rate and pulse amplitude, which directly 
affect the voltammetric response, were optimized . 
The chosen working condi tions were 1 .2 x 1 0 - 1  
cm2, 20 m V  s - t and 1 00 mY, respectively. The 
stripping currents were not mod ified when varying 
the rest period. The chosen value, 1 5  s ,  is suffi­
cient to allow the formation of a uniform concen -
Table I 
tration of the analyte in the mercury d rop and to 
ensure that the subsequent stripping step is per­
formed in a quiescent solution . 
3. 4. Quantitative trace deterrnination of NA L 
3. 4. 1 .  CA S V  
According t o  the aforementioned results ,  the 
optimum condit ions for the analytical determina­
tion of N A L  by eASY at H M DE are the fol low­
ing: BR buffer (pH 5.0 in  presence of NO} ), 1 00 
mY pulse ampl i tude, 20 mY s - t scan rate, 1 20 s 
accumulation t ime and - 0.4 Y accum ulation po­
ten tial .  U nder these condi tions the response of the 
peak height as a function of NAL concentration 
is l inear over the range 2.5 x 1 0 - 5 - 7 .4 x 1 0 - 8  M 
NAL with regression coefflcient (r ) of 0.998.  The 
l imit  of quanti tat ion,  defined as tbe lowest con­
centration, which can be accurately and rel iably 
Change of the CASY peak current and potential of 1 .9 x 1 0 - 5  M NAL In presence of interfenng species; supporting electrolyte, BR 
buffer with NaND) (pH 5.0) 
Potential interferent Concentration (�1) Change of signal (0/..) Potential sluft ( mY) Tolerance level (J.lg rul - I ) 
Cr(III) 9 .4 x I 0 - 5  + 45.9 - 50 < 0.052 
1 .8 7  x I O - �  + 5 1 .2 - 50 
Co{II) 4.7 x 1 0 - ·  + 28.0 - 3 7 < 0.006 
9.3 x 1 0 -" + 33.0 - 37 
Zn(II) 2 . 8  x 1 0 -6 + 4. 5  0.0 � 0 . 1 8 3  
5 .6  x 1 0 - ·  + 1 4.0 0.0 
Cd(lI) 4.7 X 1 0 -6 0.0 0.0 < 3 .93 
3 .5 x 1 0 - 5  - 5.0 0.0 
Cu(1I) 9.4 X 1 0 - 5  + 3. 7  0 . 0  < 28.6 
4 .5  x I O - �  + 3. 7  0 .0 
Pb(1r) 9 .4  x 1 0 - 5  0 .0 + 25 < 1 47 . 1 
7 . l x I O - �  + 8. 3  + 25 
Table 2 
Mean recoveries obtamed for five determinations of NAL in Negram tablets a nd suspensIOn using CASY and HPLC 
Sample Metbod NAL added (J.lg) NAL found ( J.lg) RSD (',t,,) Recovery (0/..) 
Tablets CASY 24.00 23 .80 3 . 70 99.2 
40.00 39.60 3 . 9 1  99.0 
H PLC 20.00 20.38 4. 1 0  1 0 1 .9 
4 1 .20 42.24 5 . 2 1  1 02 . 5  
SuspensIOn CASY 25.00 25.40 3 . 32 1 0 1 .6 
H PLC 24.50 25. 1 0  4.7 1  1 02.4 
M S Ihrahlm el at Tatanla 56 (2002) 4 71 - 4 79 477 
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Fig. 4. Concentration dependence of the CASV peak of NAL 
in 9' 1 pH 5.0/urine lUlxture: ( 1 )  background; (2)  4.3; (3) I I ; (4) 
I S, (5) 2 1 ; (6) 28; (7) 34; and (8) 47 �M NAL. BR buffer (in 
presence of NO; ) and I. = 1 20 s. For other conditions see 
voltammetric procedure 
quantitated , was found to be 0. 766 ng ml - '  
(3 .3  x 1 0  - 9 M).  The p recision was determined 
from five repeated measurements of the reduction 
peak height of 1 .0 x 10 - 7  M NAL.  The percent­
age relative error was ca. 1 .2% and the percentage 
relative standard deviation (RSD%) was 5 .2%. I t  
was found that the  detection l imit of this method 
(3 . 3  x 1 0  - 9 M) is lower than that of previously 
reported methods [ 1 9] .  
3. 4.2. HPL C 
The NAL chromatogram exhibited one wel l -re­
solved peak with a retention time of 3.4 min 
under the experimental condition used (data not 
shown). Quantitative analysis of NAL by HPLC 
showed three orders of magnitude (ca . 10 - 4 _ 
1 0 - 7 M) linear analytical range (r 2 = 0.999) and a 
l imit of quantitation of 23.22 ng ml - I ( 1 .0 x 
1 0  - 7 M )  with a signal-to-noise ratio of ca . 5 
calculated from the relative standard deviation 
value for peak areas. This results indicate that the 
application of CAS vol tammetry for trace deter­
mination of N A L  is extremely sensit ive (Table 3) 
than H P LC.  The H PLC was also appl ied to the 
assay of N A L  in human urine, blood serum and 
pharmaceuticals (see be low). 
3. 5. In terference study 
Most of the t ransitional metals are present in 
very low concentrations in ivo and their environ­
ment can be considerably al tered when a thera­
peutica lly effective dose of drug is administered. I t  
has  been observed tha t  the formation of  a com­
plex between the metal ions and the d rug has a 
remarkable effect on the activity of the drug [25) .  
Additionally, n umerous pharmacokinetic studies 
have shown reduced bioavilabil i ty of quinolones 
after s imultaneous admini stration of metal ions 
containing preparations [26 - 28] .  So, a systematic 
study was carried out  to evaluate the potential 
effect of coexist ing metal ions capable of forming 
complexes with N A L  or deposi ting at the mercury 
electrode on the determination of NAL at 1 .9 x 
1 0  - 5 M (4 . 4 1  �g ml - 1 )  level .  Serious interfering 
effects were observed in the presence of Cr( I I I )  
and  Co( I I ), s ince the reduction potentials of both 
metal ions are very close to that of the tested 
compound. Tolerance was defined as the amount 
of foreign species that prod uced an error not 
exceedi ng ± 5% in  the determination of the ana­
lyte. Table 1 shows the results obtained. 
3. 6. A nalytical application 
3. 6. 1.  A nalysis oj pharmaceutical samples 
A tablet of the commercial pharmaceutical Ne­
gram with a nal idixic acid label content of 500 mg 
was prepared according to the procedure previ-
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ously described under Section 2 .4. The proposed 
method was successful ly applied LO the assay of 
AL in com mercial tablets and the results ob­
tamed are shown in Table 2. The amount of A L  
In egram tablets in the cel l  was determi ned by 
the standard additions method , to avoid matrix 
effects, at two different levels of concentration . 
The mean recoveries for the different concentra­
tions were 99.0- 99.2% with RSDs of 3 . 9 1  and 
3 .7°'0 (n = 5) .  
The eASY determination of NAL in Negram 
suspension was also carried out by the standard 
add itions method. A mean value of 25 .40 ± 0.42 
Ilg was obtained , in  good agreement with the 
declared value of 25 Ilg. The mean recovery was 
1 0 1 . 6% (Table 2). The RSD was 3 . 32 (n = 5) for a 
sign ificance level of 0.05.  The mean value of the 
contents in the egram tablets or suspension is in 
good agreement with the reported mcthods for 
s imi lar compounds [29], so the proposed method 
is recommended for NAL determination in tablets 
or suspension. These resul ts were also compared 
with those obtained from an independent method 
Table 3 
based on chromatographic determination ( H P LC) 
(Table 2). As can be observed there is a good 
agreement between both methods. This is indica­
tive of non-intcrference of the other ingredients 
and the excipients present in the formulations. 
3. 6. 2. NA L determination in urine 
Applications of e lectroanalytical methods di­
rectly on analytes present in  physiological ma­
trices such as urine or blood serum without any 
preliminary t reatment are more interesting. The 
determination of NAL in human urine and blood 
serum was chosen as a practical example. Adsorp­
tive stripping voltammogram of a di luted urine 
sample (9: I BR buffer/urine mixture) to which no 
NAL had been added, is shown in Fig. 4 (curve 
marked as I ). The influence of the concentration 
of AL added to urine was studied . It was found 
that at - 1 .26 V;  NAL displayed a concentration­
sensitive peak height. A linear relationship be­
tween the peak current and the concentration of 
NAL in  urine was obtained . Results obtained for 
the determi nation of NAL in urine samples are 
AnalysIs of NAL In pure, unne and blood serum using eASY techntque, B R  buffer (pH S O) 
Sample Range of IIneanty ( M )  Linear equation R Detection lunit ( M )  
Pure 7.4 x 1 0 - 8-2.5  x 1 0 - 5  ' (�) = 0. 1 5 6 + 0.054C (11M) 0.998 3.3 x I O - �  
Urine 
Sample ( I )  1 . 3  x 1 0 - °-3.4 x 1 0 - 5  I (�) = 0.093 + 0.028C (11M) 0.995 1 .0 x 1 0 - 7  
Sample (2) 7.3 x 1 0 - 6-3.9 x 1 0 - 5  , (�) = - 0.083 + 0.03 1 C (11�) 0.996 1 . 2  x 1 0 - 7  
Serum 
Sample ( I )  2.9 x 1 0 - 6-2 .7  x 1 0 - 5  I ( �) = 0. 166 + 0.D44C (11 M )  0.995 9. l x l O - 8  
Sample (2)  1 .9 x 1 0 - °-3.9 x 1 0 - 5  , (l!A) = 0.084 + 0.042C (11 M )  0.994 8.7 x 1 0 - 8  
Sample (3) 2.9 x 1 0 -0-4.4 x 1 0 - 5  ' (�) = 0.020 +0.04 I C  (11M) 0.998 8 .9 x 1 0 - 8  
Table 4 
Mean recoveries obtained for three determinations of NAL In urine and blood serum uSing H PLC techmque 
Sample NAL added (M) NAL found (M) RSD (%) Recovery (0;'.) 
Unne 1 .0 x 1 0 - 0  9.45 X 1 0 - 7  5 . 2 1  94.5 
5.0 x 1 0 - 6  4 . 75 X 1 0 - 1>  4 .72 95.0 
1 .0 x 1 0 - 5  9 .62 x I 0 - 6  5.33 96.2 
Serum I O x l O - 6  9.57 x 1 0 - 1  4.82 95.7 
5 .0  x 1 0 - 6  4.85 x l O - '  5 . 1 4  96.6 
1 .0 x 1 0 - 5  9.66 x 1 0 - 1>  5 .42 96.6 
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presented tn Table 3. Detection l imit of 23 .2  ng 
ml I ( 1 .0 10 - 7 M) AL was calculated based 
on a si n = 3. Tbe RSD wa 4. 1 %. A clear de­
crease in tbe s lope of the calibration grapb is 
observed, wben omparing with those obtained 
for the A L  standard solutions, whicb indicates 
the existen e of a matrix effect . 
3. 6. 3. NA L determination In serum 
The proposed method was also successfully 
applied to tbe determination of NAL in serum 
samples and the resul ts obtained are shown in 
Table 3. In this way the di luted serum sample 
(9' 1 BR buffer/serum mixture) prod uced a 
smooth curve witbout any peak in tbe potential 
region of tbe second peak (2C) was observed 
(data not shown). H owever, wben tbe A L  is 
added to serum, a concentration-sensitive peak 
beight was observed at - 1 .28 V .  Tbe peak 
beight under tbese varied l inearly witb the con­
cen tration of NAL and tbe values of tbe regres­
sion coefficients (r) are computed and assembled 
togetber witb tbe straight line constants (Table 
3). Detection l imit  of 20.2 ng ml - I (8 .7 x 1 0 - 8  
M )  N A L  was calculated based on a sin = 3 .  Tbe 
RSD was 3 . 2%. Tbe percentage recovery of 
NAL was determined by comparing tbe peak 
currents of k nown drug concentration in  urine 
and serum witb tbeir equivalents in aqueous so­
lution. Mean recoveries of tbe different NAL 
concentrations in  urine and serum were found 
to be 98.8 ± 0.3 and 98 .9  ± 0 .4 1%, respectively. 
On tbe otber band, results obtained for tbe 
H PLC determination of NAL in  urine and 
serum samples are presented in Table 4. Tbis 
results indicate tbat, for urine and serum sam­
ples tbe average recoveries ranging from 94 .5  to 
96.2 and 95 .7 to 97.0%, respectively, depending 
on tbe concentration level used . As can be ob­
served, the most satisfactory recoveries were ob­
tained witb tbe use of tbe proposed metbod 
(CASy). The less tban 1 00% recovery of N A L  
could possibly b e  d u e  to the interaction o f  tbe 
drug with tbe unne or serum matrix, as men­
tioned before. 
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